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ABSTRACT 
 
 
De Novo Initiated RNA Synthesis by the Hepatitis C Virus RNA-dependent RNA  
 
Polymerase. (May 2010) 
 
Sreedhar Reddy Chinnaswamy, B.V.Sc. & A.H., University of Agricultural Sciences, 
 
Bangalore; M.V.Sc., Indian Veterinary Research Institute; MS, New Mexico State  
 
University at Las Cruces.  
 
Co-Chairs of Advisory Committee,       Dr. Cheng C. Kao 
                                                                     Dr. Ryland F. Young 
 
 
      Hepatitis C Virus (HCV) is a positive-strand RNA virus that has infected more than 
3% of the world population. Chronic infections by the virus lead to cirrhosis and 
hepatocellular carcinoma. HCV is currently the leading cause for liver transplantation in 
the US. The nonstructural protein NS5B of HCV is the RNA-dependent RNA 
polymerase (RdRp) that replicates the viral RNA on host derived membranous structures.                
        Structurally NS5B has the characteristic fingers, thumb and palm domains seen in 
all polymerase proteins. However, extensive interactions between the fingers and thumb 
domains completely encircle the active site of NS5B as seen in solved X-ray diffraction 
crystal structures. These interactions are primarily mediated by a short (35 residues) 
flexible loop called the ∆1 loop. NS5B produced from heterologous systems can initiate 
RNA synthesis by a de novo initiation mechanism from 3’ends of RNA templates or can 
also extend from 3’ ends of primers that are annealed stably to a template RNA in 
biochemical assays. The closed conformation of NS5B as per X-ray crystal structures 
can only accommodate a ssRNA but not a dsRNA, hence necessitating a conformational 
 
 
 
iv 
change between de novo initiation and elongation. The details of these conformational 
changes are not known and will prove to be important to design potent polymerase 
inhibitors. The study performed for this dissertation focused on the conformational 
requirements of NS5B during de novo initiation and primer extension (or elongation). 
Biochemical assays utilizing template RNAs that can lead to both de novo initiation and 
primer extension products were utilized, and a systematic mutational analysis of the 
template channel of the RdRp was performed. Mutants W397A and H428A were 
identified that showed only primer extension but no de novo initiation. Structural 
analysis of NS5B suggested that these residues were important contact points in the ∆1 
loop and thumb domain interactions. A deletion mutant, m26-30 with a five amino acid 
deletion at the apex of the ∆1 loop also failed in de novo initiation but not primer 
extension reactions. Biophysical and gel shift assays showed that m26-30 was in a more 
open conformation than the WT enzyme. Furthermore, oligomerization of NS5B was 
demonstrated and its role in RNA synthesis was examined. It was found that the de novo 
initiation competent conformation of NS5B is maintained by oligomeric contacts 
between individual subunits, likely by stabilizing the ∆1 loop and thumb domain 
interactions. Mutations disrupting the ∆1 loop and thumb domain interactions as well as 
those in the allosteric GTP binding site induced conformational changes in the protein 
partially explaining the defect in de novo initiation activity in enzymes carrying those 
mutations. These results not only contribute to the overall mechanism of RNA synthesis 
in viral RdRps but also open new avenues for developing HCV polymerase inhibitors. 
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1 
CHAPTER I 
 
INTRODUCTION*  
 
         Hepatitis C virus (HCV) was first identified as the causative agent of non-A non-B 
viral hepatitis in the late 1970’s. It was estimated in the year 2000 that HCV had infected 
over 170 million people worldwide (1). Infection can be through injection drug use, 
contaminated blood transfusion, needle pricks and also unprotected sex. A majority of 
the acute infections lead to chronic conditions characterized by cirrhosis and 
hepatocellular carcinoma (2). HCV is the leading cause for liver transplantation in the 
US. A humoral immune response is raised by the host in acute infections, but does not 
lead to elimination of the virus in 80% of cases and results in chronic infection. Men are 
about twice less likely to clear the virus during the acute phase of infection than women 
(3). It is also common that HCV can cause an acute infection more than once in the same 
individual, due to the virus changing its antigenic properties frequently because of an 
error prone RNA polymerase that can readily incorporate mutations into the genome 
(referred to as quasispecies)  (4). The molecular clone of the virus was isolated in 1989 
by Michael Houghton’s Lab at Chiron Corporation (5). Subsequent to this discovery, 
significant progress has been made in understanding HCV biology (6), although a 
vaccine for prevention and a safe and potent drug for treatment of HCV infections 
This dissertation follows the style of Biochemistry. 
*Fig. 3 in this chapter is reprinted in part with permission from “Replication of hepatitis C 
virus” by Moradpour, D., Penin, F., and Rice, C. M. (2007). Nature Reviews Microbiolgy. 5, 
453-463. Copyright [2009] by Nature Publishing Group.  
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is not yet available. This chapter provides an introduction to HCV; briefly reviews the 
problems encountered in HCV research; introduces the RNA polymerase of HCV with 
an emphasis on its structure and function; discusses the mechanism of RNA synthesis in 
different viral RdRps and concludes with a discussion on the scope of the research that is 
the basis for this dissertation. 
 
LIFE CYCLE AND GENOME ORGANIZATION OF HCV 
         HCV is an enveloped positive-strand RNA virus that belongs to the family 
Flaviviridae, which includes other human viruses like Dengue virus and West Nile virus. 
To our knowledge, HCV can successfully infect only humans and chimpanzees. Unlike 
the other members of the family which involve complex life cycles with arthropod 
vectors as intermediate hosts, HCV does not have insect or other known intermediate 
hosts (Fig. 1).  HCV infects hepatocytes  but can infect other cell types like lymphocytes 
and astrocytes in the brain by a receptor mediated endocytosis pathway involving mainly 
the CD81 receptor and Claudin-1 receptors (7). The RNA genome of HCV is ~9.6 kb in 
length and encodes a polyprotein that is cleaved by host and viral proteases into 
structural and non-structural components (Fig. 2). The 5’ and 3’ UTRs of the HCV 
genome are highly structured. The 5’ UTR contains an internal ribosome entry site 
(IRES) that recruits host ribosomes to translate the viral genome. The 5’ UTR, 3’ UTR 
and even the coding region have important cis-acting replication elements needed to 
initiate genomic RNA synthesis (8).  
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Figure 1: HCV life cycle in an infected cell.  Virus binding to receptors and receptor 
mediated endocytosis a); uncoating of the viral structural proteins and release of 
genomic RNA (red line) b); translation of viral polyprotein and cleavage into its 
individual components  c); assembly of viral replication complexes (RC) on 
‘membranous webs’ which are composed of host derived membranes and proteins; and 
production of negative strand RNA (blue line) and positive-strand RNA (red line) d); 
assembly of new virus particles e); maturation of virus particles f); new virus particles 
exit the cells by budding g); This figure is adapted from reference (7). The nucleus is in 
blue and ER membranes are shown as dark lines while the ‘membranous web’ structures 
are shown as brown oval structures. The translated viral proteins are in different shapes 
and colors on the putative ER structures. The receptors that bind and internalize HCV 
are shown as dark straight lines with blunt or round ends on the plasma membrane. HCV 
is shown as an icosahedral particle (a clear explanation for the arrangement of the capsid 
including the triangulation number is not available largely due to an inability to produce 
and assemble sufficient amounts of the capsids in vitro) encapsidating the genome (red). 
The icosahedron is made of core protein (purple lines) while the E1 and E2 (see below) 
surround the core protein and are shown as blue spheres and a yellow layer.  
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Figure 2: HCV polyprotein cleavage. The positive-sense RNA is schematically depicted 
on the top with the size of the genome indicated. The internal ribosome entry site (IRES) 
is depicted as a purple box in the 5’ UTR. A schematic of the arrangements of the 
mature HCV proteins is shown below the RNA. The polyprotein coding sequence is 
shown in green and yellow blocks (green for structural proteins and yellow for non-
structural proteins). The green inverted triangles represent cleavage by the host signal 
peptidases. The core protein is further processed at its C-terminus by the ER signal 
peptide peptidase (brown arrow). The NS2 protease separates itself from NS3 and the 
remaining polyprotein by autoproteolysis (yellow inverted triangle). The remaining 
polyprotein is cleaved by NS3 protease by using NS4A as the cofactor (blue inverted 
triangles). The putative functions of the individual proteins are indicated below each 
protein. RC-replication complex. 
 
 
 
 
 
~ 9.6 kb 
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The core, E1 and E2 proteins form the structural components of the HCV virion and are 
processed by endoplasmic reticulum (ER) proteases. The core protein surrounds the viral 
genome forming the nucleocapsid and has a basic N-terminus and a hydrophobic C-
terminus (9). E1 and E2 are glycosylated proteins and have important immunogenic 
regions including the hypervariable region (HVR) in E2 which is responsible for 
immune evasion (10). E1 and E2 spike the nucleocapsid throughout the surface and are 
responsible for membrane fusion and viral entry (11). p7 is a ~60 amino acid protein that 
is required for viral replication in vivo and has ion channel activity (12).  
       The nonstructural proteins NS2, NS3, NS4A, NS4B, NS5A and NS5B are processed 
by NS2 protease and NS3-4A protease (Fig. 3). NS2 is an autoprotease that cleaves the 
NS2-3 junction. There is evidence to suggest that NS2 is active as a dimer (13), and 
recent evidence implicates NS2 in virus assembly (14). NS3 is a bifunctional enzyme 
with a serine protease activity at its N-terminus and an ATP dependent helicase activity 
at the C-terminus. The protease activity cleaves the nonstructural proteins from NS3 to 
NS5B in the polyprotein sequence by using NS4A as a cofactor. NS3-4A also cleaves 
the adaptor proteins that function in innate immunity signaling and helps the virus evade 
host immune responses (15). NS4B is a membrane-associated protein and is needed to 
form ‘membranous webs’, the sites of HCV replication complexes (RC) in the 
endoplasmic reticulum (ER) (16). These structures are unique to HCV infected cells 
which are made of ER derived membranes and are defined as tight structures made of 
tiny vesicles in a membranous matrix or sponge-like inclusion bodies (16). NS5A is an  
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Figure 3: The HCV proteins and their membrane association. This figure is reproduced 
with permission from reference (7). The known structures of the proteins are depicted as 
ribbon diagrams while the unsolved structures are shown as grey spheres and 
transmembrane domains are shown as helices buried in the membrane. The semi-circular 
arrow denotes NS2 autoproteolytic cleavage. The straight arrows indicate NS3 cleavage 
regions.  Almost all the HCV proteins have at least one transmembrane domain or a 
membrane associated amphipathic helix. The core protein has two amphipathic helices 
and a C-terminal signal peptide (green). The scissors indicate cleavage by ER associated 
signal peptidases. (Signal peptide peptidase cleavage is shown by the scissor on the 
cytosolic side). The glycosylation of the envelope proteins E1 and E2 heterodimers are 
shown as green spots. The p7 protein has an extended and a short transmembrane 
domain. The NS2 dimer (catalytic domains are shown as blue and pink ribbons) is 
tethered to the membrane at their N-terminal hydrophobic domains (13). The NS3 
protease domain is shown in blue and its catalytic residues are shown as purple spheres. 
The amphipathic helix in NS3 protease is in green and the N-terminal transmembrane 
domain and NS3 associated domain of NS4A are in gold. NS3 helicase is shown 
connected to the protease domain and its three domains are colored orange, blue and 
grey. The NS4B structure is not available and is shown as a membrane protein with a 
cytosolic C-terminal domain. The dimerized domain I of NS5A are shown as ice blue 
and magenta ribbons while the N-terminal amphipathic helix is shown as orange and 
blue ribbons. Domains II and III of NS5A are shown as grey ovals. NS5B C-terminal 
transmembrane domain is in magenta and the thumb, palm and fingers domain are in 
green, orange and blue. The detailed description of the specifics in generating this figure 
is found in reference (7) and the references therein. 
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RNA binding protein that exists in a phosphorylated form in cells, is known to suppress 
anti-viral immunity (17), and may have a role in modulating the dependence of HCV on 
cyclophilins (18). NS5B is the RNA-dependent RNA polymerase (RdRp) that 
synthesizes viral RNA in the RC. The RC also contains other viral nonstructural proteins 
as well as host proteins and is associated with ‘lipid rafts’ (19), and ‘lipid droplets’ (20) 
in HCV infected cells. Lipid rafts and lipid droplets are specialized membrane 
microdomains that are detergent-resistant, with the latter showing a characteristic 
staining with oil red O stain. It has also been noted that a large portion of the HCV NS 
proteins do not participate in replication of the viral genome (21), suggesting that some 
of them may have additional functions like interactions with host factors and modulating 
the host environment. NS5B is known to bind and down-regulate the abundance of the 
master tumor suppressor Retinoblastoma protein (pRb) (22).  
 
PROBLEMS IN HCV RESEARCH      
         A prophylactic vaccine and effective therapeutic options are not yet available for 
HCV, despite determination of the HCV sequence 20 years ago and extensive research 
efforts. This speaks of how intractable HCV has been both in the clinic and in the 
laboratory. HCV exists as a quasispecies, due to an error prone RNA polymerase that 
lacks proof-reading activity, making targeted therapies difficult (23). There are also six 
HCV genotypes (named as genotypes 1 to 6) and several subtypes in each genotype 
(named as a, b, c, etc) that respond differently or not at all to the standard therapy of 
pegylated interferon and ribavirin. As mentioned above, HCV can modulate the immune 
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responses from the host. Altogether these features of HCV have made it refractory to 
vaccine development (24-26).  
Two additional challenges had plagued the early phase of HCV research. Firstly 
there is no natural, small animal model for studies of the infection and pathologies.  
Indeed, even infected chimpanzees exhibit only minimal pathologies, unlike 
humans(27) . Second, prior to 2005, HCV could not efficiently infect cultured cells. 
Therefore, studies of HCV in the laboratory were limited to infecting chimpanzees and 
working on recombinant portions of the HCV genome.   
A breakthrough came in 1999, when Lohmann et al., developed the subgenomic 
replicon system for HCV (28). Subgenomic replicons are viral mini-genomes that lack 
the genes encoding structural proteins but have genes encoding fully functional 
nonstructural proteins that can replicate RNA in cell culture and can express reporter 
genes (28).  Mutations in NS5A, NS3 and NS4B were necessary for the replicons to 
multiply in cells to sufficient levels (named as replication enhancing mutations or 
REMs)  (29). These adaptive mutations also helped the full-length viral genome to 
replicate in cells but they failed to produce infectious viral particles (30).  Nonetheless, 
these replicons taught us important features about HCV replication and served as the 
initial systems for the identification of HCV inhibitors.   
Studies of HCV replicons revealed an important interaction with the innate 
immunity system.  A subgenomic replicon system was initially established in the human 
hepatoma cell line (Huh-7) for the genotype 1b virus (con 1 isolate). Curing the Huh-7 
cells with interferon has led to cell lines like Huh-7.5 that allowed HCV replicons to 
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replicate to higher levels. Characterization of the Huh-7.5 cells led to the identification 
of a defect in the innate immunity receptor, RIG-I (31), that allowed more efficient HCV 
subgenomic replication. REMs were later identified in the NS3 and NS5A region of 
genotype 1a HCV that supported subgenomic replication in Huh-7.5 cells (31).  
A major breakthrough in HCV research was the isolation of a genotype 2a HCV 
strain that caused fulminant hepatitis in a Japanese patient (named JFH1) and the 
subsequent establishment of cell culture infections using this strain (32-33). JFH1 could 
successfully infect Huh-7.5 cells and multiply without the need for REMs. The JFH1 
isolate opened the door for researchers to study the complete cycle of the HCV infection, 
especially viral entry. A feature of the JFH1 virus, however, is that it was not pathogenic 
in chimpanzees (34), and the prevalence of the 1a and 1b HCV infection in the western 
world precluded 2a from serving as a vaccine strain. In studies on HCV RNA replication, 
the subgenomic replicon system, along with NS5B protein expressed from heterologous 
systems, remains to be extensively used to understand the mechanism of RNA synthesis 
and also to develop inhibitors targeting NS5B.  
 
NS5B, THE RNA-DEPENDENT RNA POLYMERASE OF HCV  
      NS5B is the key enzyme for HCV replication and is the focus of this dissertation 
project. Like other polymerases, NS5B has the characteristic divalent metal binding 
motif, GDD that contains two consecutive aspartates in the palm domain consistent with 
the notion that all polymerases use the two-metal ion mechanism of catalysis (35). The 
591-amino acids NS5B protein has a hydrophobic C-terminal tail (21 amino acids) 
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needed to tether the protein on to the membranes (Fig. 3). These residues are dispensable 
for enzymatic activity but needed for viral replication in cells (36-37). NS5B lacking the 
C-terminal hydrophobic 21 amino acids (referred as ∆21) or 55 amino acids (referred as 
∆55) is widely used in biochemical assays both for mechanism studies and inhibitor 
studies (36, 38-42). No significant differences between the enzyme kinetics of the full-
length versus ∆21 enzymes were observed (36, 43). ∆21 however, is several fold more 
active than the full-length protein in both de novo initiation and primer extension assays. 
This may be due to efficient template binding and turnover since the KM for the different 
NTPs were the same for both proteins (43).   
       HCV NS5B was initially identified based on homology with the RdRps of other 
viruses with positive-strand RNA genomes (44).  The first report on the enzymatic 
activity of HCV NS5B was published in 1996 by Behrens et al. (45). In this report 
baculovirus expressed HCV RdRp was characterized to have a primer extension activity 
with heterologous RNA templates. The primer in this RNA was formed by a ‘looping-
back’ of the 3’ end of the template RNA. Lohmann et al., (46) demonstrated that a 
recombinant NS5B was able to copy the full-length HCV positive-strand genomic RNA 
by a ‘copy-back’ synthesis from the 3’ end of the template. Although these works 
established the polymerase activity of HCV RdRp, the mechanism of initiation on the 
natural viral genomic templates remained unclear. The reported ‘loop-back’ primer 
extension activity does not represent a mechanism relevant to HCV RNA replication and 
the ‘loop-back’ structure is present at the 3’ end of plus-strand  but not minus-strand  
HCV genomic RNA (47-48). During this time a related RdRp from the Bovine Viral 
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Diarrhea Virus (BVDV) was reported to initiate RNA synthesis by a de novo mechanism, 
suggesting the possibility that a similar mechanism existed for HCV RdRp (49).  De 
novo initiation was soon demonstrated with recombinant HCV NS5B using both short 
synthetic RNA templates as well as from the full-length and truncated positive-strand 
HCV genomic RNA (50-53).  Kao et al., showed that a stable secondary structure is 
needed at the 3’ end of the template RNA for efficient de novo RNA synthesis (50). GTP 
and ATP, but not UTP or CTP, were preferred as the initiation nucleotides (40, 53-54) in 
de novo initiation RNA synthesis. High levels of GTP but not other NTPs were found to 
stimulate de novo initiation (55). A low affinity GTP-binding site was later identified in 
NS5B, suggesting that GTP may act at this allosteric site to stimulate de novo initiation 
(38). 
            Three groups independently solved the X-ray diffraction crystal structures of the 
C-terminally truncated versions of NS5B in the year 1999 (56-58). NS5B was shown to 
have a thumb, fingers and the palm domains similar to all the other known polymerases 
(Fig. 4) (59). The palm domain has the conserved GDD residues that coordinate the 
divalent metal ions and carry out the nucleotidyl transfer reaction. Several crystal 
structures of NS5B in complex with inhibitors, NTPs and also with a short 5-nt ssRNA 
have been reported but, thus far, no structural information is available for the ternary 
complexes involved in initiation and elongation (60-64).  
A unique feature of the HCV RdRp and that of related viral RdRps (65-66), is 
that the thumb and the fingers domains are bridged by two loops called the ∆1 loop and  
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Figure 4: NS5B is crystallized in the closed conformation. Surface representation of the 
crystal structure of HCV NS5B ∆35 (PDB ID 1QUV). (A) The front view of the 
polymerase showing the encircled active site (yellow). (B) Front view of NS5B and the 
∆1 loop is shown as a ribbon in cyan. Helix A in the ∆1 loop is the short helix at the tip 
of the loop that holds the thumb domain mainly by hydrophobic contacts. ∆2 loop is 
shown as a ribbon in magenta. The side chains of the two loops are in purple. (C) A cut 
away representation of the polymerase exposing the template channel (the tunnel 
running from the top towards the active site depicted in yellow). The channel is only 
wide enough to accommodate a ssRNA (the thick line is shown to indicate that the width 
of the channel at its widest point is less than 10Å distance). GDD in the active site is 
colored yellow. (D) Top view of NS5B showing the β loop as a blue ribbon. T: thumb 
domain, F: fingers domain, and P: palm domain.  
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∆2 loop (also referred as finger-loops) (Fig. 4). These two loops are responsible for the 
closed conformation of the enzyme that results in a complete encircling of the active site 
from the front side (front side is viewed with the thumb domain at the left and fingers 
domain at the right side of the viewer in Fig. 4). The back side is covered by another 
loop designated as the β loop which forms part of the template channel and the β loop 
extends towards the metal coordinating residues in the active site (Fig. 4). This 
encircling of the active site will result in a well defined but narrow template channel that 
can accommodate a ssRNA but not a dsRNA (Fig. 4C) (63).   
Since the ternary complex of the RdRp involved in elongation will contain 
dsRNA, the closed structure solved by X-ray crystallography should transition to the 
more open one during elongation stage of RNA synthesis. It was initially proposed that 
the β loop is used by the polymerase for this transition (57). In fact, a study showed that 
a deletion of eight residues in the β loop allowed productive elongation from dsRNA 
templates whereas the WT enzyme was not able to perform primer extension (67). 
However, if the β loop is pushed out of the template channel to accommodate the 
dsRNA a large rotation of the thumb domain is thought to be necessary (56, 64).  
       The model in which the unique closed conformation of the enzyme was proposed to 
be engaged in de novo initiation was based on work on the ternary structure of the RdRp 
from phage φ6 (see below) (68).  Furthermore, mutations that disrupted the ∆1 loop and 
thumb domain interactions, and thereby altered the closed conformation of the enzyme 
were detrimental for RNA synthesis (69). Therefore, it was speculated that this 
interaction is stable during the catalytic cycle of polymerization and that it may be used 
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for the ‘clamping movement’ of the polymerase on the RNA template during elongation 
(69). If true, this mechanism would be unique to HCV and related viral RdRps that have 
a ∆1 loop like structure since there is no precedent for a bridging interaction between the 
thumb and fingers domains during elongation RNA synthesis of other polymerases (59, 
70). The ∆1 loop in HCV NS5B (Fig. 4B) contains 35 residues and is largely a coil 
structure except for the region that contacts the thumb domain where a small helix (helix 
A) fits into a pocket defined by amino acids H428, I432, W397, A396 and several other 
hydrophobic residues.         
  RNA synthesis in the HCV RdRp can be divided into at least four sequential 
stages in vitro: 1) Assembly of productive initiation complexes (de novo initiation or 
primer extension complexes); 2) Nucleotidyl transfer to synthesize the first or first few 
phosphodiester bonds; 3) Processive elongation; and 4) Termination of RNA synthesis. 
The first two steps are collectively called initiation events and are the rate limiting steps 
in the polymerase reaction. Different conformations of the RdRp are thought to be 
involved in de novo initiation and primer extension/elongation due to large differences 
observed in the KM values for the NTPs involved in these two phases of RNA synthesis 
(71) (Fig. 5). In vitro, the RdRp can also switch templates before termination, although 
the relevance of this activity in HCV replication has not been reported. Under certain 
conditions, the HCV and other viral RdRps can also add non-templated nucleotides to 
the 3’ terminus of the template (39, 72). While this activity can be relevant in the repair 
of deleted ends of the RNA, its biological relevance to HCV infection remains to be 
demonstrated. In vivo however, de novo initiation is the relevant mechanism of HCV  
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Figure 5: RNA synthesis mechanisms in NS5B. De novo initiation versus primer 
extension/elongation in NS5B. De novo initiation involves the recognition of the 3’ end of the 
template RNA (red) by NS5B and initiation of RNA synthesis without the need for a primer. De 
novo initiation has two steps: Initiation (involves the synthesis of a primer of 5-6 nt, shown as 
green) and Elongation. Initiation is thought to be rate limiting. By contrast Primer 
extension/Elongation involves extension of a primer (black) along the length of a template (red) 
from a preformed primer-template RNA complex akin to the elongation step in de novo initiation. 
The newly extended RNA is shown as green. The KM values shown are obtained from Ferrari et 
al.(71) 
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replication and it is likely that the 3’ end of the RNA threads into the closed 
conformation of the polymerase with assistance from other viral nonstructural proteins 
like NS3. This process may involve changes in the ∆1 loop and thumb domain 
interactions within a monomeric NS5B for a better gripping of the template in the active 
site. A higher order structure of NS5B can stabilize the ∆1 loop and thumb domain 
interactions to selectively stimulate de novo initiation as several reports have shown that 
NS5B can oligomerize both in vitro and in vivo (73-76). Prior to the start of this 
dissertation project, the closed conformation of NS5B was proposed to be needed for de 
novo initiated RNA synthesis while a more open one may be suitable for assembly of 
primer extension complexes and also when the polymerase is engaged in elongation (56-
57). In 2006, Ranjith-Kumar et al., showed that the HCV RdRp was able to direct de 
novo initiated RNA synthesis from a circularized template (77).  Since a circularized 
RNA cannot thread a terminus into the active site, this observation suggests that the 
HCV polymerase could undergo a transition from the closed to an open conformation 
before template recognition (Fig. 6).   
 
MECHANISM OF RNA-DEPENDENT RNA SYNTHESIS  
     Although the HCV RdRp is a relatively recent addition to the list of viral RdRps, it 
has proved to be a good model system especially to study de novo initiation RNA 
synthesis. The ease of obtaining an active enzyme in a recombinant form and its lack of 
template specificity are some of the reasons for the HCV RdRp to be used as a model  
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Figure 6: A closed to open transition is needed by the HCV RdRp (NS5B) to assemble 
the initiation complex on a circular template. The closed structure of NS5B is shown as a 
cartoon with the three domains: thumb, fingers and palm shown in different shades of 
grey and marked T, F and P respectively. The red star represents the active site located 
in the palm domain. The ∆1 loop connecting the fingers and thumb domains is in blue. 
The RNA (linear or circular) is shown as a thick black line. A linear RNA can thread its 
3’ terminus into the template channel to reach the active site to initiate RNA synthesis. A 
circular RNA can also direct de novo initiation by the HCV RdRp.  Since a circular 
RNA cannot thread a terminus into the active site, this result clearly demonstrates that 
the closed polymerase structure that predominates in the crystal structure can change to 
an open conformation. What facilitates the close to open conformation is a central 
question for this dissertation project. 
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RdRp for structural and biochemical analyses. However, much of our initial 
understanding of the RdRps came from viral replicases (Replicases are RdRps that are  
complexed with other viral and host derived proteins. The entire complex is responsible 
for template recognition and RNA synthesis, although the RdRp is the catalytic subunit) 
from many RNA viruses infecting both prokaryotes and eukaryotes (78).  RNA synthesis 
in general by the RdRps is accomplished by two major mechanisms: de novo initiation  
or primer-dependent RNA synthesis. In the latter class the primers can be small viral 
encoded peptides as in the case of the Picornaviridae family of viruses or the primer 
may be derived from the capped 5’ end of a host mRNA (cap-snatching) or the 3’ end of 
the template RNA looping back on itself to act as a short primer for the RdRp to extend. 
Some negative stranded segmented RNA viruses like the influenza viruses use both de 
novo initiation and a cap-snatching mediated primer- dependent mechanism of RNA 
synthesis in their life cycles (79). In the RdRps that initiate RNA synthesis by a de novo 
mechanism a short primer is synthesized in a process called abortive cycling. The 
polymerization begins by the generation of a short oligonucleotide (~5-6 nucleotides) 
and then due to a critical conformational change from initiation to elongation in the 
RdRp, RNA synthesis is aborted. The primers so generated are extended during the 
elongation phase of RNA synthesis.  
         The Qβ replicase. Qβ (Leviviridae family) is a single-stranded positive-sense RNA 
bacteriophage whose replicase has served as an important model system for studies on 
viral RdRps especially before the advent of recombinant DNA technology which made 
available the individual polymerase proteins of different viruses for biochemical studies. 
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The Qβ replicase normally amplifies the ~ 4.2 kb RNA genome of the E. coli infecting 
bacteriophage Qβ by a de novo initiation mechanism.  RNA synthesis can approach rates 
of 29 nt/sec (80-81) in comparison to ~3 nt/sec observed for the HCV RdRp (67).  
The Qβ replicase contains four different subunits that total ~215 kDa in mass. 
The RdRp subunit is encoded in the phage genome whereas the other three are host 
encoded proteins viz E.coli ribosomal S1 protein and the translation elongation factors 
Tu and Ts. An additional protein called ‘host factor’ HF, is needed for Qβ RNA 
replication in phage infected cells and also to amplify Qβ RNA in vitro. The role of the 
translation elongation factors seems to be structural since their protein biosynthesis 
specific functions, aminoacyl tRNA binding and GTP binding are dispensable for Qβ 
replication (82). The translation elongation factors are not required during elongation but 
are absolutely needed for initiation and furthermore they can retain their function in the 
Qβ replicase even after trypsinization (83). It is known that EF Tu and EF Ts function as 
a complex in the replicase since kirromycin, an antibiotic that prevents their association, 
inhibits Qβ replicase (83). Furthermore, both elongation factors derived from a different 
bacterial species, C. crescentus can replace their E. coli counterparts in the Qβ replicase 
and still be functional.  
The role of S1 seems to be to enforce tighter binding between the replicase and 
Qβ RNA. However, the RNA helix unwinding activity of S1 that is needed in the 
ribosomes during protein biosynthesis is dispensable for Qβ replication (84). The S1 
protein is also not needed for copying non-Qβ RNA templates (85). S1 can bind to two 
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distinct sites in the Qβ RNA (the M and S sites) which is important for replication of the 
RNA. The role of S1 in protein biosynthesis is to assist in the mRNA binding to the 30S 
ribosome. Both these roles of S1  (i.e. in Qβ replication and protein biosynthesis) may 
therefore appear to be related but S1 from C. crescentus or B. subtilis cannot substitute 
the E. coli S1 in the Qβ replicase whereas it can readily substitute the E. coli S1 involved 
in translation (83). HF is also needed for initiation but not elongation by the Qβ replicase 
and its role may be in binding to the 3’ end of Qβ RNA during initiation. Interestingly 
the function of HF can be completely substituted by the divalent cation manganese in 
RNA synthesis assays in vitro (83). 
       An intriguing aspect of Qβ replicase is its high selectivity in amplifying only some 
RNA templates including the ~4.2 kb genome of the Qβ phage and some select RNAs 
that are  < 250 bases long that arose from recombination events between the phage and E. 
coli RNAs (86). The amplification is exponential since the parent template RNA and the 
newly synthesized copy of the template RNA are both templates for subsequent rounds 
of replication. Although it has remained elusive as to what specifies RNAs for 
exponential amplification by the Qβ replicase, some general rules have been identified: 
A 5’ leader stem loop structure and a free 3’ region in the template; A 5’ GGG sequence 
and a 3’ CCCA sequence (The replicase adds the 3’ terminal A to the product strand in a 
non-templated fashion and is not copied while synthesizing the complementary strand); 
and a stable secondary structure in the body of the template RNA (86).  These simple 
rules are sufficient to allow the replicase to discriminate between the replicable RNAs 
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and the innumerable number of host RNAs that the replicase would encounter in the 
infected E. coli cell. 
          The requirement of high concentrations of the initiating nucleotide GTP is thought 
to confer some template specificity as different templates require varying GTP 
concentrations for successful initiation (87). A high concentration of GTP for initiation 
is also a feature of the HCV RdRp (55). Also similar to the requirements of the HCV 
RdRp, the divalent cation manganese can decreases the concentration of GTP required 
for initiation on legitimate templates by the Qβ replicase, presumably by interacting with 
the phosphates of the GTP (87-88). The specificity in template selection seems to arise at 
the initiation stage rather than the template binding stage as presence of short 
oligonucleotide primers at the 3’ ends can convert many RNAs to legitimate Qβ 
templates (89). The replicase binds with high affinity to an internal site in the Qβ 
genome about 1500 bases upstream of the 3’ terminus and the long range interactions 
between this site and the 3’ terminus is important for replication (90). However the 
replicable minus-strand RNA does not have a specific binding site for the replicase (91) 
suggesting that the initiation of the plus versus minus-strand  RNAs have distinct 
requirements. As mentioned, the S1 protein and the HF protein assist in exposing the 3’ 
termini of the plus-strand  RNA genome for template loading into the active site of the 
catalytic subunit of the replicase (92). These two proteins partially could be responsible 
for the template specificity of the Qβ replicase. However a mere presence of these two 
proteins will not make any RNA molecule a legitimate Qβ template for amplification 
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suggesting complex interactions between the replicase subunits and RNA and also 
within the RNA molecule.  
       The ability for exponential amplification of legitimate RNA templates by the Qβ 
replicase suggests that there is a mechanism to ensure the single-strandedness of the 
nascent RNA molecule, so that it is available for the next round of RNA synthesis. There 
should be a ‘plow-like’ structure near the active site of the enzyme that will help to keep 
the nascent RNA from annealing to the template strand. In case of the HCV RdRp, the 
nascent RNA remains base-paired with the template RNA at least in vitro (93) and in 
vivo, a dedicated protein such as the NS3 helicase may be responsible for unwinding 
dsRNA. In contrast to the Qβ replicase, the nascent RNA remains double stranded in a 
related RdRp from the dsRNA bacteriophage φ6 (94). Therefore, the Qβ replicase is 
unique in its ability to prevent the annealing of the nascent and the template RNA once 
they exit the polymerase active site when a legitimate template is being replicated. 
However, all legitimate templates need not necessarily be ‘replicable’ i.e. amplifiable 
which in turn means that the nascent RNA remains base-paired with the template RNA 
with some of the templates of Qβ replicase.  
Ugarov et al., have characterized the Qβ templates as legitimate and illegitimate 
based on several criteria (86). The replicase bound to legitimate templates requires high 
concentrations of GTP for initiation and such complexes are stable as determined by 
their resistance to aurintricarboxylic acid (ATA), a chemical agent that prevents RNA-
protein interactions. In contrast the replicase bound to illegitimate templates does not 
need high concentrations of GTP for initiation, can recognize and extend a ‘loop-back’ 
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RNA akin to primer extension and such template-replicase complexes are sensitive to 
ATA. Based on these results they hypothesized that upon binding to a legitimate 
template the Qβ replicase undergoes a conformational change to a ‘closed’ structure and 
this ensures the formation of a stable initiation complex. This conformational change 
does not take place upon recognition of an illegitimate template and the replicase will 
stay in an ‘open’ conformation which makes the replication complex ATA sensitive. 
This model posits that different conformations are present in the Qβ replicase which can 
recognize different templates and perform de novo initiation, and the conformations can 
depend on the nature of template. However no clear differences in the template 
characteristics were evident and therefore it was not clear how the replicase would 
become ‘closed’ or ‘open’, and as a result show different ATA sensitivities based solely 
on template criteria.  
In a follow-up study, Ugarov and Chetverin (95) have shown that functional 
circularity is a defining criteria for a legitimate template. The 5’ end and 3’ portion of 
the template molecule must interact (the 5’ and 3’ ends need not be covalently 
connected: i.e., they need to be functionally circular) to form a legitimate template that 
can form an ATA resistant elongation complex with the Qβ replicase. Point mutations in 
the 5’ end of a legitimate template can make the elongation complex unstable and 
conversely mutations which establish 5-3’ base-pairing within a template molecule can 
give rise to a more stable elongation complex. These results suggested that the functional 
circularization along with conformational changes in the replicase is important in 
determining the legitimacy of a template. This also can explain how the nascent RNA 
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product of Qβ replicase retains its single-stranded nature since the nascent RNAs will 
need to compete with the intramolecular interactions at the terminal portions of the 
template. Atomic resolution structure of the Qb RdRp remains to be determined and this 
along with elucidation of the replicase structure as a whole should further advance the 
field of RNA-dependent RNA synthesis.   
     The φ6 RdRp.  The polymerase from the φ6 phage has also served as a model RdRp.  
φ6 is a dsRNA virus from the family Cystoviridae. The φ6 RdRp is a single polypeptide 
chain and copies the genomic RNA by a de novo initiation mechanism. The replication 
of the genomic RNA occurs within the capsid structure in which an RdRp is pre-
packaged. The RdRp from φ6 was co-crystallized with a five nucleotide RNA from the 
3’ end of the plus-strand genomic RNA and GTP was soaked into the crystals revealing 
the first structure of the quaternary complex of an RdRp consisting of all of the 
components needed for initiation (68). In this landmark report, it was seen that the RdRp 
is in a closed conformation with the finger-loops bridging the fingers and thumb 
domains and the 3’ end of the template initially overshoots in the polymerase active site 
but in presence of GTP, it reverses and forms the initiation complex. This led to the 
speculation that the closed conformation may be the de novo initiation-competent 
conformation in all other viral RdRps. However, a dsRNA could not be modeled into the 
structure as steric clashes arose with the C-terminal domain (an observation also made 
for the HCV RdRp (57)), and it is not clear how a dsRNA is accommodated within the 
template channel during elongation in this RdRp as is the case with the HCV RdRp (68). 
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The C-terminal domain was proposed to act like a platform for the assembly of the 
initiation complex.  
The φ6 phage has to replicate a dsRNA without the need for a helicase activity; 
initiation in this case should also involve melting the 3’ end of the template from the 5’ 
end of the non-template for assembly of the initiation complex (96). However the 
specific structure(s) that contribute to this event in the RdRp is not clear. The φ6 RdRp 
also initiates by utilizing GTP as the initiating nucleotide and it prefers a stretch of Cs at 
the 3’ end of the template (97). Similar to the HCV RdRp the φ6 RdRp can also perform 
efficient primer extension that does not depend on high concentrations of GTP.         
      The BVDV is used as a surrogate system for studying HCV replication and its RdRp 
is also structurally and functionally well characterized (49, 65).  The BVDV RdRp was 
crystallized in different conformational states in two different crystal forms (65). The 
finger-loop region was present in different states in five different monomers further 
providing evidence that this region in the RdRp is highly flexible. A second GTP 
binding site close to the active  site within the palm domain was identified in the BVDV 
RdRp, (98) in contrast to the reported allosteric GTP binding site in the thumb domain of 
the HCV RdRp (38). Studies on the dengue viral RdRp have shown evidence for the 
hypothesis that different conformations of the RdRp are responsible for de novo 
initiation and primer extension (99). In a study by Ackermann et al., a higher 
temperature selectively inhibited de novo initiation while not affecting primer extension 
reactions, suggesting a thermal regulation of RdRp conformation (99). However, this 
effect was not observed for the HCV RdRp (88).  
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The polioviral RdRp is another well studied polymerase (100). The polioviral 
RdRp is a primer dependent enzyme and uses a viral encoded protein primer for 
initiation (101). Structurally this RdRp and the related RdRps from the rabbit 
hemorrhagic disease virus (RHDV) and foot and mouth disease virus (FMDV) are 
characterized by a relatively large entrance to the template channel as they lack the β 
loop structure that covers the back of the HCV RdRp (102-103) (Fig. 4D). This large 
cavity at the entrance of the channel is needed to accommodate a dsRNA or the protein 
primer for elongation by the RdRp.  
        The majority of RdRps encountered in RNA viruses however begin RNA synthesis 
by a de novo initiation mechanism (78). In RdRps that initiate by a de novo mechanism a 
common feature is that the initiating nucleotide (referred to as NTPi) is a purine 
nucleotide. An initiation complex comprises the divalent cation-bound RdRp and the 
template RNA with its 3’ end in the active site of the enzyme, base-paired to the NTPi 
and NTPi + 1 nucleotide (Fig. 7). GTP is the NTPi in the HCV RdRp initiation complex 
comprising the minus-strand RNA template. GTP bound to the initiation site (NTPi  
site) and in the appropriate orientation initiates the reaction by a nucleophilic attack from 
its hydroxyl group on the phosphodiester bond between the α and the β phosphate of the 
NTPi+1 nucleotide. The divalent cations lower the pKa of the hydroxyl group of GTP to 
cause its deprotonation (104) and initiate the nucleophilic attack. The divalent metals 
also facilitate the release of the pyrophosphate from the active site while protonation of 
the pyrophosphate is mediated by an active site amino acid (105). Magnesium is the 
metal ion that is thought to be required by polymerases for nucleotidyl transfer in vivo,  
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Figure 7: De novo initiation complex in an RdRp. Template RNA (thick black line) 
positions itself in the divalent cation metal-bound active site of the RdRp (yellow) such 
that the 3’ end is base paired to the ultimate and penultimate nucleotides (NTPi and 
NTPi+1 respectively). The NTPi is usually GTP, which initiates the RNA synthesis 
reaction with its 3’ OH group attacking the phosphodiester bond between the α and β 
phosphate group of NTPi+1. (The three RdRp domains: thumb, fingers and palm are 
shown as T, F and P in different shades of grey). The NTP tunnel is a positively charged 
cavity at the junction of the thumb and palm domains. It is thought to feed NTPs into the 
active site (yellow) during catalysis. 
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while manganese has been reported to substitute for magnesium in in vitro biochemical 
assays involving RdRps (88, 106). In HCV NS5B, manganese selectively stimulates de  
novo initiation (88). Manganese was recently shown for the φ6 RdRp to structurally 
affect the active site by making it more flexible (107). This flexibility may increase the  
efficiency of NTPi utilization during initiation in RdRps. Presence of manganese 
however is known to decrease the fidelity of RdRps (106) and may even be used by 
viruses to enforce mutations in their genomes, that will allow them to exist as 
quasispecies.  
 
SCOPE OF THE STUDY 
     The focus of this study is primarily on the de novo initiation RNA synthesis by the 
HCV RNA polymerase.  This is the likely mechanism used by the HCV NS5B to initiate 
genomic RNA synthesis in infected cells. Several studies have shown that NS5B purified 
from recombinant sources can efficiently de novo initiate from the 3’ ends of ssRNA. 
Consistent with this, the KM values for NTPs during initiation are about ten thousand 
fold higher during initiation than during elongation (71), supporting the notion that 
different conformations of NS5B participate in de novo initiation and primer extension. 
However, the mechanistic and structural details of these steps, especially the mechanism 
of transition from de novo initiation to elongation by NS5B has remained elusive. The 
Kao laboratory had been dedicated to understanding the interaction between the RdRp, 
the template and the nascent RNA involving de novo initiation RNA synthesis by the 
HCV NS5B (78). Significant progress has been made in terms of defining the template, 
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NTP and metal ion requirements by NS5B during de novo initiation (40, 50, 88). 
Importantly the demonstration that the polymerase could transition from the closed to 
open conformation before initiation (77) laid the foundation for the present work.  The 
NS5B protein has also been reported to function as oligomers (74-76) and how 
oligomerization affects de novo initiation RNA synthesis was not clear.  
The work conceptualized and performed for this dissertation seeks to build on the 
current understanding of the mechanism of de novo initiation by HCV NS5B, and the 
associated conformational requirements in the enzyme. The results from the current 
study should help us better understand the mechanism of action (MOA) of the HCV 
NS5B inhibitors that block initiation stage of RNA synthesis. Chapter II summarizes the 
current knowledge concerning the inhibitors of NS5B, with emphasis on their MOA. 
Defining the structural element in the RdRp that regulates de novo initiation and 
elongation by the HCV RdRp is the focus of Chapter III, and this work was published in 
the Journal of Biological Chemistry in 2008. The role of NS5B oligomerization in de 
novo initiation was also investigated, and is presented in Chapter IV. The manuscript 
involving this work is in review at the Journal of Virology. Chapter V deals with the 
different conformational states in a monomeric NS5B, and a discussion of its relevance 
in inhibitor studies.  This manuscript was recently accepted for publication in Virus 
Adaptation and Treatment. In appendix I the effect of mutations in NS5B that prevent its 
interaction with the tumor suppressor Retinoblastoma (pRb) protein is presented.  This 
collaborative work has been published in the Journal of Virology in 2009.  In appendix 
II, the effect of mutations in NS5B that conferred Cyclosporine A (CsA) resistance to 
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HCV in infected cells, on the in vitro RdRp activity is examined and this work was 
published in the journal Hepatology in 2009. In appendix III, the results of the screening 
of a nucleoside mimic compound library from a commercial source for binding and 
inhibition of NS5B are presented. 
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CHAPTER II 
HCV NS5B INHIBITORS 
 
          There is an urgent need to develop potent drugs against HCV as the conventional 
therapy, a combination of pegylated IFN and ribavirin, is associated with severe side 
effects and also not effective in 50% of the patients. HCV causes a progressive disease 
typically over a 20-30 years span, but shows a sustained viremia from the acute infection 
stage onwards. Therefore drugs that can block the virus replication are needed to control 
the disease. HCV is not cytopathic, but the major damage to the liver is brought on by 
the immune system, which suggests that an alternative strategy to control the disease is 
to modulate the immune system. However, such advanced therapies are not yet available 
for liver diseases and controlling the virus replication in the host is the currently 
available option.   
          The Hepatitis C virus polymerase is the key enzyme for the replication of the 
HCV genome and has been the target of numerous inhibitor studies (reviewed in (108)). 
The rationale for targeting the HCV polymerase is based on the paradigm of established 
therapies that target the polymerases encoded by other viruses like the human 
immunodeficiency virus (HIV), hepatitis B virus, and herpes viruses (109). Many of the 
HCV NS5B inhibitors have been identified from screening proprietary compound 
libraries either in vitro or in cell-based assays rather than being developed based on 
rational structure-based design.  Thus, the effective compounds provide an unbiased 
means to assess how structure influences function.  In addition, studies to probe the 
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mechanism of RNA synthesis by HCV NS5B such as the one undertaken for this 
dissertation should complement drug discovery efforts. As proof of concept, the results 
presented in Chapter III help us to better understand the MOA of the benzimidazole and 
indole class of drugs that were previously identified to inhibit HCV NS5B.  This chapter 
reviews, and seeks to summarize recent knowledge on the inhibitors of HCV NS5B and 
in that context attempts to gain a better understanding of the mechanism of RNA 
synthesis. 
The inhibitors of HCV NS5B can be broadly classified into four classes based on 
their chemical composition and/or mode of action. The first class consists of nucleoside 
or nucleotide analogs that act as competitors of NTPs during RNA synthesis. This class 
also includes the purine analog ribavirin, the only FDA approved small molecule drug 
for the treatment of HCV, although it exerts its action by multiple mechanisms (see 
below). The second class consists of non-nucleoside inhibitors that allosterically target 
the NS5B, and the majority of them inhibit the initiation stage of RNA synthesis. Other 
inhibitors which have a distinct MOA than the inhibitors from the first two classes are 
presented in the third class. A fourth and rapidly emerging class consist of compounds 
that target cellular proteins needed for HCV polymerase function. This class may be 
advantageous in that the virus cannot rapidly evolve resistance to the inhibitors.  
 
NUCLEOSIDE INHIBITORS (NI) 
          Nucleoside or nucleotide mimics are usually designed to cause premature chain 
termination during viral nucleic acid synthesis. Phosphorylation of the nucleoside 
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prodrugs to their triphosphorylated forms is required for inhibitory activity. Several 
nucleoside analogs have been studied in vitro, with the recombinant NS5B protein and in 
cells expressing HCV subgenomic replicons, and also in animal models.  A number of 
these compounds have progressed to clinical trials and can act in synergy with the 
interferon-ribavirin combination therapies (108).  
A simple 2’ ribose modification of cytidine (2’-O-methyl) and adenosine (2’- C-
methyl) (Fig. 8) nucleosides will result in potent inhibitors of HCV subgenomic 
replicons acting as ‘non-obligate’ chain terminators of RNA synthesis by NS5B (non-
obligate chain terminators have an intact ribose 3’OH group for elongation but they can 
induce structural constraints in the active site to lead to chain termination) (110).  A 
resistant mutation S282T in the NS5B region was identified for the 2’ ribose modified 
nucleoside analogs (111). Biochemical characterization revealed that the resistance was 
due to reduced affinity to the compound and also due to an increased ability by the 
mutant polymerase to incorporate the nucleotide analog during elongation.  
            Migliaccio et al., reported good oral bioavailability and synergistic inhibitory 
activity of 2’-C-methyl guanosine (2’-C-mG) and interferons (111). However, a 7-deaza 
modified 2’-C-mG suffered from poor cell penetration and inefficient phosphorylation 
by cellular kinases whereas a 7-deaza modification of 2’-C-methyl-adenosine resulted in 
a compound with improved pharmacokinetic properties and low toxicity than its 
unmodified form (112). MK0608 (7-deaza-2’-C-methyladenosine) has an EC50 of 0.25 
µM in replicons and has showed promising results in animal studies (113).  
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Figure 8: The structures of (A) 2′-C-methyladenosine and (B) 2′-O-methylcytidine. 
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       Other modifications including halogenation have improved the potency of 2’ ribose 
modified nucleoside analogs. PSI-6130 (2;-deoxy-2’fluoro-2’-C-methylcytidine) (and  
R7128, a prodrug of PSI-6130) has been reported by Stuyver et al., (114) to be active 
against the HCV NS5B subgenomic replicon with an EC90 of ~4.5 µM but did not affect 
the BVDV NS5B in subgenomic replicons.             
       A 4’ ribose modified nucleoside (4’-azidocytidine (R1479) or the modified version 
of 4’-azidocytidine (R1626)) has also been reported (115), to be able to chain-terminate 
RNA synthesis by HCV NS5B. This analog had a similar IC50 (in the range of 1.12-1.3 
µM) to 2’-C-methyl-cytidine in subgenomic HCV replicon-expressing cells while 
concentrations as high as 2 mM were not toxic to cells (115). S282T mutation apparently 
did not affect the inhibitory effect of R1479. The development of this analog has been 
discontinued due to safety issues (113).  
          3’-deoxy modified nucleoside analogs especially 3’-deoxy-GTP and 3’-deoxy-
CTP are good chain terminators of HCV NS5B RNA elongation in vitro, but they 
suffered from poor activation into their triphosphate forms in cells (116). 
          2’-C-methylcytidine (NM107) was found to inhibit BVDV polymerase with a Ki 
of 160 nM. However, this drug did not have good oral bioavailability but a modification 
at the 3’ OH of ribose (3’-O-valinyl-2’-C-methylcytidine, valopicitabine or NM283) led 
to enhanced pharmacokinetic properties and has showed promise initially in clinical 
studies in HCV infection especially when combined with peg-IFN and ribavirin (113). 
However, due to associated serious side effects FDA has suspended the clinical trials for 
NM283 in the US, but the trials are on in the European union (108). 
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         The resistance mutations to NI include S282T, S96T and N142T (Fig. 9) (111, 
117). The S282T mutation confers resistance to 2’ C-methyl cytidine and 2’ C-methyl-  
adenosine and the presence of this mutation in subgenomic replicons reduces the 
replicative capacity to ~20% to that of WT (111). S96T and N142T mutations confer 
resistance to R1479 (see above) and their presence severely debilitates subgenomic 
replicon capacity (117) and do not confer any cross resistance to 2’ C-methyl cytidine 
suggesting a specific interaction in the binding pocket.  S282 residue is in close 
proximity to the NTPi (initiation nucleotide (78)) binding residues identified in co-
crystal structures of NS5B and GTP (Fig. 9). Mutations involving the NTPi binding 
residues have yielded polymerases that are decreased in de novo initiation but unaffected 
for primer extension activity (118) providing another hint about a different conformation 
of NS5B involved in these two activities. This will also suggest that the NTP binding 
pocket in the active site is more flexible during elongation than during de novo initiation. 
S282 residue therefore should have a very specific interaction with the nucleotide analog 
inhibitors in the NTP binding pocket in order for S282T to confer resistance. None of the 
mutations conferring resistance to NI lie outside the template channel (Fig. 9) suggesting 
that they do not allosterically influence the polymerase function unlike non-nucleoside 
inhibitors (see below). Dinucleotide analogues targeting de novo initiation by NS5B 
have also been reported (119), but no further progress has been reported in their 
development. The purine analog ribavirin (Fig. 10) is an FDA approved drug for 
treatment of HCV in humans and has been in use for more than a decade.  
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Figure 9: The NTPi site and the resistance mutations to NI in HCV NS5B. The top 
image is a front side representation of HCV NS5B (PDB ID 1QUV), while the bottom 
images shows a cut away representation of the top image on a vertical axis (dashed line) 
in order to expose the template channel (an enclosed channel in the polymerase that 
extends from the cavity formed by thumb and fingers domain junctions at the top, to the 
cavity formed between the thumb and palm domain junction. The latter cavity is also 
called as the NTP tunnel). The NTPi site (or initiation GTP binding site) residues D225, 
R48, R158, R386, R394 and S367 are colored in light green. Amino acid S282 is (in red) 
mutated in polymerases which are resistant to 2’-me-C and 2’-me-A to a threonine. 
Amino acids S96 and N142 are in green and blue respectively. S96T and N142T 
mutations confer resistance to compound R1479. T, P and F refer to thumb, palm and 
fingers domains respectively. The ∆1 loop is shown as a ribbon in cyan. The active site 
metal coordinating residues are in yellow.  
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Figure 10: Ribavirin resistance mutation maps to the NTPi binding pocket in NS5B. Cut 
away representation of HCV NS5B (PDB ID 1QUV) as in Fig. 9. ∆1 loop is shown as a 
ribbon in cyan, while the active site GDD residues are colored yellow. The NTPi binding 
residues D225, R48, R158, R386, R394 and S367 are in light green, and Y415 is in 
purple. Y415F has been reported to confer resistance to ribavirin, a purine analog 
(structure is shown). 
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In conjunction with pegylated interferon, ribavirin can clear HCV from patients but in 
only 50% of the cases and also involves many side effects (120). The mechanism of 
action of ribavirin is not clear. It is thought that ribavirin may act by more than one 
mechanism like causing an ‘error catastrophe’ in the virus population and also by 
participating in immune modulation (reviewed in (121)). It may also act by inhibiting the 
host IMP dehydrogenase, which will in turn, lower the GTP levels in the cell. 
Interestingly, Y415F mutation has been mapped in the template channel that can confer 
resistance to this purine analog, providing strong evidence for binding of ribavirin to 
NS5B (122) (Fig. 10).  
 
NON-NUCLEOSIDE INHIBITORS (NNI) 
          While NI act by interfering with the nucleotide addition by the HCV polymerase, 
several NNI have been identified that primarily target the initiation phase of RNA 
synthesis by NS5B, likely by preventing critical conformational adjustments in the 
enzyme in association with RNA binding and initiation. The NNI target different sites 
both on the surface and in the template channel of NS5B. NNI can be broadly classified 
into three different subclasses based on the location of their binding sites: Site 1 involves 
the ∆1 loop and thumb domain interface. Site2 is a pocket in the thumb domain that is 
present beneath Site 1. Site 3 unlike the other two sites is in the template channel and 
involves the ‘primer-grip site’ and the β loop and binds different classes of drugs (Fig. 
11).  
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Figure 11: NNI binding sites in NS5B. The location of the different NNI sites is shown 
on a partial surface and ribbon representation of HCV NS5B ∆55 (PDB ID 1QUV). Site 
1 and Site 2 are on the surface of the thumb domain of NS5B while Site 3 is located 
within the polymerase template channel. In Site 3 the representative drug binding 
residues in the template channel 414, 415 and 556 are colored red while the ‘primer-
grip’ (a region that is thought to help in holding the primer during RNA synthesis) site 
(residues 360-380) is highlighted in pink. The active center of NS5B is shown as two 
yellow spheres representing the metal ions that are coordinated by the conserved GDD 
motif. The table in the right summarizes the three classes of NNI and their mechanism of 
action. 
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Site 1: Benzimidazoles and indole derivatives bind to this site and inhibit the initiation 
stage of RNA synthesis by NS5B. Benzimidazoles were identified by Boehringer 
Ingelheim (Canada) (123) to inhibit NS5B noncompetitively with NTPs with a  
low microomolar IC50 value. The binding site for this compound and the related indole-
N-acetamides is at the binding interface between the ∆1 loop and the thumb domain (62, 
124). This site also overlaps with the allosteric site that putatively binds GTP (38) (Fig. 
12). Inhibitor binding at this site will result in a disruption of the inter-domain 
communication and displacement of the ∆1 loop (62).        
          Biochemical characterization revealed that these compounds did not inhibit NS5B 
during elongative mode of RNA synthesis and also were ineffective on preformed 
NS5B-RNA complexes (125-126). Interestingly, the presence of RNA was required for 
binding of benzimidazoles to NS5B, although prolonged incubation of NS5B and RNA 
abolished inhibitor binding (126). Together with the fact that prolonged incubation of 
NS5B with RNA increases primer extension activity of the enzyme (71, 126), the 
observation that benzimidazoles do not bind to preincubated binary complexes suggests 
a stepwise loss of ∆1 loop-thumb domain interaction as a function of preincubation time. 
Notably, two residues that were identified in this study (see Chapter II) W397 and H428, 
that are critical for de novo initiation by NS5B have side chains that chemically 
resemble the two classes of NNI that act at site 1 (imidazole ring in H428 with 
benzimidazoles and indole ring in W397 with indoles). Resistance mutations for the 
benzimidazole class of NNI include P495A and P495L (126). Plant derived 
phytoestrogens have been shown to be effective against NS5B in biochemical assays  
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Figure 12: NNI site 1. The location of the binding site for benzimidazole and indole 
based NNI (residues P495 and H428 are colored blue) at the interface of the apex of the 
∆1 loop and thumb domain. The ∆1 loop is shown as a ribbon in cyan while ∆2 loop is 
colored magenta and the metal coordinating GDD residues are in yellow (PDB ID 
1QUV) (Left). A representative scaffold of the benzimidazole NNI (Right).   
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(127) and act as non-competitive inhibitors of NTPs and the template RNA. The MOA is 
thought to be similar to that of benzimidazole compounds based on SAR studies.  
 
Site 2: Compounds based on the thiophene scaffold were identified (128) to bind to 
NS5B in the thumb domain and inhibit its activity. Compounds derived from the leads in 
this class are generally hydrophobic due to the nature of their binding site which 
involves residues L419, M423, L474 and W528 (Fig. 13). In the genotype 1b NS5B, no 
gross change in the conformation of the enzyme was observed in presence of the 
inhibitor (61, 128), but genotype 2a NS5B showed a pronounced change with the 
disruption of the helix A in the ∆1 loop that resulted in the formation of a β sheet (60). 
Despite the availability of several crystal structures for the NS5B-inhibitor complex (60-
61, 128-129) a clear MOA has not been elucidated for this class of inhibitors. This site 
may be involved with NS5B oliomerization (60-61, 129), and also inhibitor binding at 
this site may perturb GTP binding at the allosteric site (128). Another report has shown 
that pyranoindoles that putatively bind at Site 3 inhibited the elongation stage of RNA 
synthesis (130). Resistance mutations to Site 2 NNI include L419M and M423T (131). A 
minor population of drug resistant clones carrying M423I and I482L were also observed 
in subgenomic replicons. When the mutations were introduced into WT replicons all of 
them showed resistance to thiophene-2-carboxylic acid derivatives. Although some 
inhibitors that act at Site 2 have shown low nanomolar IC50 values in biochemical assays 
they generally show micromolar IC50 values in cell-based assays. Clinical trials 
involving the NNI binding to this site are currently in progress. 
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Figure 13: NNI Site 2. The location of the binding site for NNI in Site 2. Residues L419, 
M423 that bind to thiophene-carboxylic acids are colored purple. The coloring scheme is 
the same as in Fig.7 (Left). A representative scaffold of thiophene based NNI (Right).  
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Site 3: Different classes of compounds have been described to be binding to this site and 
inhibiting NS5B (Fig. 14). The first consists of derivatives of benzothiadiazines initially 
identified from the GlaxoSmithKline proprietary compound library (132) with 0.5 µm 
IC50 values in subgenomic replicons of genotype 1b. These compounds inhibit the 
initiation phase of RNA synthesis but do not affect elongation or preformed initiation 
complexes of purified NS5B and RNA (42, 133). Benzothiadiazines inhibited de novo 
initiation by WT ∆21 with IC50 values about 5-10 fold lesser than those for primer 
extension (42). Benzothiadiazines appear to act allosterically, as the inhibition is 
noncompetitive with GTP and RNA (42, 132), and may involve disruption of the 
movement of the thumb and palm domains essential for the assembly of the initiation 
complex. Resistance mutations arising in HCV genotype 1b replicons when treated with 
benzothiadiazines include: M414T, C451R, G558R and H95R (Fig. 11) (42). The mutant 
replicons M414T and H95R were not affected for replication efficiency compared to the 
WT replicons. Interestingly, C451R and G558R mutant replicons replicated at very low 
levels in absence of compounds but were increased in replication in the presence of 
compounds (42), in a dose-dependent manner. In biochemical RdRp assays however, 
only M414T showed significant rescue from inhibition of RNA synthesis while H95R, 
C451R and G558R did not.   
      A second class of drugs that bind at this site is the potent inhibitor benzofuran-C3-
carboxamide (HCV796) (IC50 ~9 nM in replicon cells). This compound binds several 
residues in the ‘primer-grip’ site (Fig. 11) apart from L314, C316, C366 and M414 and  
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Figure 14: NNI Site 3. The location of benzothiadiazine binding site in the template 
channel. The NS5B ∆55 structure (PDB ID 1QUV) is split in vertical axis exposing the 
template channel. The drug binding residues 414, 415 and 556 are colored red. The ∆1 
loop is in cyan, active site GDD residues are in yellow (Left). A representative scaffold 
of a benzothiadiazine compound is shown (Right). The structure was drawn using 
ChemDraw. 
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mutations in these residues renders NS5B resistant to HCV796 both in replicons and  
in biochemical enzymatic assays (134). HCV796 showed excellent inhibitory profiles in 
the chimeric mouse model (135) and later on was approved by the FDA to enter phase II 
clinical trials. However, it showed severe hepatocellular toxicity in humans and its 
development has therefore been discontinued (136).  
           A third class consisting of 1,5-benzodiazepines were also reported to bind to Site 
3 and inhibit NS5B in vitro with IC50 values in the range of 3-9 µM (137) and a much 
higher range in HCV replicon cells.  
Several of the NNI binding to all the three sites described above are currently in 
clinical trials (113). Compounds binding to Site 1 (JTK-003 and JTK-009) from Japan 
Tobacco Inc., Japan, are some examples of NNI in clinical trials while the details about 
others are not available.    
 
MISCELLANEOUS NS5B INHIBITORS 
          Other classes of inhibitors based on aminorhodanine scaffold have been reported 
to inhibit NS5B by covalently modifying C366 in the ‘primer-grip’ site (Fig. 11) (138). 
Dicarboxylic and diketo acid derivatives could bind in the active site of NS5B (139-140). 
The MOA of these drugs is by chelating the active site magnesium ions as they act as 
pyrophosphate analogs. These compounds generally have poor cell permeability and 
may involve toxicity hence have not been developed further (113). 
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INHIBITORS THAT ACT INDIRECTLY ON NS5B 
             Cyclosporine A (CsA) was discovered to be effective against HCV replication in 
subgenomic replicon cells (141). CsA has been used as an immunosuppressant in organ 
transplantation patients. Surprisingly, it was also able to inhibit HCV replication. Several 
reports have shown subsequently that CsA acts on HCV replication in part by disrupting 
the association of NS5B with Cyclophilin A (CypA), although NS3 and NS5A may also 
require CypA (142-143). CypA may recruit NS5B to the replication complexes in the 
membranes, and increases RNA binding by NS5B through its prolyl-peptidyl isomerase 
activity (143). Given that the NS5B conformation and oligomerization are intricately 
linked (this study, Chapter IV), CypA may act by assisting the conformational changes 
needed for proper template loading in highly oligomerized states of NS5B in the RC. 
Notably, the CsA resistance mutations include I11V, I432V which are within or in very 
close proximity to the ∆1 loop (144). However mutations like Q438R, E440G which are 
associated with the β loop were also found to confer CsA resistance (144). CsA 
derivatives like NIM-811 and SCY-635 have recently created a lot of interest in this 
novel class of NS5B inhibitors (145-146). A recent report points out an association 
between estrogen receptors and NS5B in HCV replicon carrying cells and the anti-
estrogen drug tamoxifen disrupted this association similar to the role of CsA (147). 
However it is not known if tamoxifen directly associates with NS5B, and it is interesting 
to note here that phytoestrogens were able to inhibit NS5B by a mechanism similar to 
that of Site 1 NNI (127).  
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THE ALLOSTERIC SITE OF NS5B AND NUCLEIC ACID INHIBITORS 
          GTP is known to stimulate RNA synthesis by HCV NS5B at high concentrations 
(55, 64). HCV NS5B has at least two GTP binding sites both identified by X-ray 
crystallography (38) (Fig. 9, 10 and 15A). The NTPi binding site at the active site cleft 
of the enzyme can bind to all four NTPs but the low affinity NTP binding site at the 
surface of the thumb domain (referred as the allosteric site hereafter) adjacent to the 
interacting pocket of the ∆1 loop is specific for GTP. The KD for GTP at this site is 
estimated to be between 200-400 µM (38). GTP is used as the initiating nucleotide for de 
novo initiation at a higher efficiency than ATP (40). In order to examine the importance 
of the allosteric site in NS5B activity, Cai et al., (148) performed a systematic 
mutagenesis analysis of this site, but surprisingly found that none of the point mutations 
at the allosteric site affected de novo initiation activity of NS5B in vitro. However, all of 
the mutations affected the replication of subgenomic replicons to various degrees, 
suggesting that the allosteric site on NS5B is important for HCV replication in cells. The 
site seems to be a ‘hot-spot’ in the NS5B structure for the following reasons: 1) It is 
adjacent to the ∆1 loop binding pocket in the thumb domain (Fig. 12A); 2) It is 
overlapping with the critical residues required for binding the Site 1 NNI (126); 3) It 
overlaps with one of the residues (H502) known to be essential for homomeric 
interactions between NS5B subunits (75); 4) It is needed for replication of HCV 
subgenomic replicons (148); 5) A DNA aptamer inhibitor was identified by SELEX to 
bind NS5B at the allosteric site and inhibit its activity (149).  
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Figure 15: The allosteric site and the exposed ‘basic-patch’ of NS5B. (A) The allosteric 
GTP binding site (38). GTP binding residues in the thumb domain (P495, V499 and 
R503) are colored blue in the crystal structure of ∆35 (PDB ID 1QUV) (Two other 
residues binding to GTP, S29 and R32 are in the helix A of ∆1 loop and not highlighted). 
The ∆1 loop is in ribbon and colored cyan. The active site GDD residues are in yellow 
and the NTPi site that binds to all four NTPs is located within the active site close to the 
GDD residues. (B) The exposed ‘basic-patch’ in the thumb domain of NS5B. Helix-T 
(residues 497-513) has six basic residues and all are surface exposed. The arginines are 
colored red and positions are indicated at the top. The ∆1 loop and GDD residues are as 
in A. 
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          RNA aptamers have also been identified to bind NS5B and inhibit its activity in 
biochemical assays and in HCV infected cells (150). One aptamer, 27v, was competitive 
with RNA for binding to NS5B and prevented both initiation and elongation. A second 
aptamer, 127v, was non-competitive with RNA and inhibited only pre-elongation events 
in RNA synthesis by NS5B. It is likely that 127v also binds to the allosteric site and 
inhibits NS5B in a mechanism similar to Site 1 NNI. 
 
HCV GENOTYPIC VARIATION IN INHIBITOR RESPONSE 
          HCV exists as six known genotypes and a number of subtypes. Within the infected 
individual, significant differences in the viral sequences are commonly encountered, 
demonstrating that each subtype is a quasispecies (151). NI that inhibit NS5B mainly act 
as chain terminators and therefore target elongation stage of RNA synthesis unlike the 
majority of NNI which target the initiation stage. NI are effective to comparable levels 
among all HCV genotypes unlike NNI that have genotypic differences in responses (108, 
151-155). In fact, significant differences in response to NNI have been noted within 
different viral sequences isolated from the same individual patient (151). This may 
suggest either mechanistic differences in the initiation complex assembly process 
between NS5B of different isolates (since most NNI target the initiation stage of RNA 
synthesis), or just variations in binding sites for these NNI. Gu et al., have shown 
differences in oligomeric properties and enzymatic activities in NS5B from genotype 1a 
and 1b (74). It is likely that differences exist in the binding constants for NS5B 
oligomerization across genotypes that may have a role in initiation. But, it is difficult to 
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reconcile major genotypic differences in the events that occur during initiation complex 
assembly in terms of requirement of oligomerization or intramolecular interactions. 
Consistent with this idea, binding site polymorphisms have been proposed to be the 
reason for discrepancies in the response to NNI from NS5B of different genotypes.  
There is evidence in support of differential sensitivities to inhibitors.  Pauwels et 
al., (154) used biochemical assays to show that among the NNI, benzimidazoles did not 
show much variation in IC50 values across genotypes except that they were about 100-
fold higher for genotype 2a and 2b. In comparison, Site 2 and Site 3 inhibitors showed 
significant genotypic variation in responses, consistent with an altered binding site being 
responsible for the observed differences. For example a polar residue at position 414 was 
not tolerated by the 2a NS5B to bind benzothiadiazines while a Q414M mutation 
partially restored the inhibition. In a similar observation 1,5-benzodiazipines were 
effective against only genotype 1a and 1b NS5B while Q414M mutation led to only a 
partial inhibition of the genotype 2a NS5B (137).  In another study the NS5B sequences 
from patient sera were amplified, and cloned into a genotype 1b con1 background 
subgenomic replicon plasmids, and were assessed for sensitivity to different NI and NNI 
(151). While NI affected all the individual replicons equally, differences existed in the 
response to NNI. The response to benzimidazoles showed that within the same 
individual, viruses with NS5B sequences that responded with a difference of almost 20-
fold to the drug were present. This difference was more pronounced with the patients 
with genotype 1b infection than with genotype 1a infection. In the same study 
benzothiadiazines were not effective on isolates from a patient with genotype 1b 
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infection at three times the EC50 value (EC50 was determined for a consensus con1 
NS5B). The response to thiophenes was somewhat uniform among different isolates in 
the same study.         
  Herlihy et al., (153) found a variation of 0-7% at the amino acid level in the 
NS5B sequences from the viral population present in each patient. In this study replicons 
were constructed with a con1 background containing consensus NS5B sequences from 
non-genotype 1 viruses obtained from patient sera to evaluate the response to different 
NI and NNI. While NM107 (2’-C-methylcytidine) and a NS3 protease inhibitor elicited 
an almost similar response from chimeric replicons containing NS5B from different 
genotypes, differences were clear when NNI were tested. Benzimidazoles showed a 
similar response from genotypes 1b, 3a, 4a and 5a but up to a 30- fold reduction in 
response from genotype 2a and 2b. Thiophenes had an 8-fold reduction in response from 
genotype 5a compared to 1b, while genotypes 2b, 3a and 4a did not have any significant 
response. Benzothiadiazines did not show significant response from any of the 
genotypes at concentrations that were inhibitory to genotype 1b replicons. Interestingly, 
HCV796 (Benzofuran) that binds to Site 3 had a comparable response from all genotype 
1 and non-genotype 1 NS5B containing replicons.  
       These results collectively demonstrate the role that the viral quasispecies can play at 
the clinical level in therapeutic failures (Fig. 16). NNI target the initiation complex 
formation in NS5B, and therefore are dependent on strict conservation of their binding 
sites for binding and inhibition. Since NS5B itself does not have a proof reading activity 
and readily incorporates mutations in the genome, polymorphisms are common in the  
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Figure 16: Role of HCV quasispecies in effectiveness of polymerase inhibitors. Presence 
of mutations in the viral genome (black line) in the region encoding NS5B is shown as a 
star, an oval or a filled box. The resulting polymerases (the three domains are in different 
colors and the ∆1 loop is shown as a black line) have different conformations due to 
polymorphisms involving the drug binding sites and also in other regions. NNI act 
during the initiation stage and their effect (denoted by Xs) is less or abolished in 
polymerases that have mutations in their binding sites or are different in their 
conformations. A conformational change occurs after initiation in NS5B and elongation 
ensues. NI that act as chain terminators target the elongating polymerase active site and 
get incorporated in the nascent RNA chain, hence are not affected by the polymorphisms 
in NS5B and therefore equally effective against NS5B of all genotypes. 
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NNI binding sites (154). In contrast, NI are nucleotide analogs and hence compete for 
binding with the NTPs which make them equally effective against all the HCV 
genotypes.          
         Even though a handful of NI and NNI have shown promise in clinical trials, the 
majority of them have suffered from safety issues and have been withdrawn from further 
study (108). Ribavirin-interferon combination therapy remains the only however, 
imperfect choice available against HCV infections. The ‘non-responders’ to this 
combination therapy interestingly have viruses that have about 3-fold more of 
hydrophobic sequences in the viral proteins along with a pattern of covarying networks 
among them (156). Clearly, more genomic analysis as well as studies in chimpanzee, or 
mice transplanted with human livers (157) needs to be carried out in order to improve 
the strategies for antiviral development against HCV. At the same time it is important to 
build and improve on the foundations laid in HCV structural and molecular biology, to 
identify new drug targets and to improve upon the hits to the current ones.  
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CHAPTER III 
THE ∆1 LOOP AND DE NOVO INITIATION IN HCV NS5B* 
 
INTRODUCTION 
          All RNA viruses encode their own RdRps that direct viral RNA replication and 
transcription. Similar to other template-dependent polymerases, the shape of a right hand 
is a useful description of the structures of viral RdRps (59). The finger and the thumb 
subdomains guide the template, whereas the palm contains the active site for nucleotidyl 
transfer. The HCV NS5B provides a useful model system to study viral RNA-dependent 
RNA synthesis. In contrast to a partially open conformation, the HCV RdRp structure 
has extensive interactions between the thumb and finger subdomains, resulting in the 
formation of a closed hand structure with a prominent template channel (56-57). 
          This closed conformation is also found in other viral RdRps (65, 68, 102-103, 
158-161).Modeling studies and analysis of the ternary RdRp complex of the 
bacteriophage Φ6 suggest that the template RNA threads into the channel. Functional 
studies of various template RNAs also reveal a shared requirement for single-stranded 
sequence in RNA-dependent RNA synthesis (50, 78, 162-163). Thus, viral RdRps, 
unlike DNA-dependent DNA polymerases and reverse transcriptases, may use a defined 
channel as part of the mechanism to recognize templates (35). 
* This chapter is reprinted with permission from “A Locking Mechanism Regulates RNA 
Synthesis and Host Protein Interaction by the Hepatitis C Virus Polymerase” by Chinnaswamy, 
S., Yarbrough, I., Palaninathan, S.,  Kumar, C. T.,  Vijayaraghavan, V.,  Demeler, B.,  
Lemon, S. M., Sacchettini, J. C.,  and Kao, C. C. (2008). J. Biol. Chem. 283, 20535-
20546. Copyright [2008] by American Society of Biochemistry and Molecular Biology. 
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In addition, since the channel contains the active site, it must participate in contacting 
the nascent RNA during elongative synthesis.  
          Although the template channel provides an elegant solution for the specific 
recognition of the initiation sequence for RNA synthesis, the diameter of this channel 
within the crystal structure of the HCV RdRp (ranging from 6 to 20 Å, see below) is too 
narrow to accommodate the duplex formed by the template and newly synthesized 
nascent RNA without a significant conformational change. In addition, there is growing 
evidence that the HCV NS5B protein undergoes a transition into an open structure to 
accept the template RNA (60, 130, 164-165). Indeed, the HCV RdRp can initiate de 
novo RNA synthesis from a circular template that cannot possibly be threaded into the 
template channel, functionally demonstrating that a transition between closed and open 
conformation can occur during template recognition (77).  
          Different conformations of the HCV RdRp may also affect its interactions with 
cellular proteins. The retinoblastoma tumor suppressor protein (pRb) is one interesting 
example, since it is targeted by DNA tumor viruses and by HCV as a means to 
deregulate cell cycle progression (166). pRb-binding proteins contain an LXCXE motif. 
In NS5B, this motif overlaps the residues that coordinate divalent metals in the catalytic 
pocket (22). Thus, the NS5B residues that are putatively involved in the interaction with 
pRb are not surface-exposed, suggesting the need for a conformational change in NS5B 
to accommodate the binding of pRb.  
            Cyclophilins are cellular peptidyl isomerases that are required for replication of 
several viruses, including human immunodeficiency virus and HCV (167-169). The 
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peptide drug cyclosporine, which binds cyclophilins, was found to inhibit HCV RNA 
replication (170-173), and some mutations that render resistance to cyclosporine mapped 
to NS5B (172). Cyclophilin A (CypA) and CypB have been shown to co-precipitate with 
the HCV NS5B protein (172), but RNA silencing experiments have yielded conflicting 
results as to whether CypB and/or CypA are required for HCV replication.  
          We have carried out a series of experiments aimed at determining how mutations 
in the template channel of the HCV RdRp affect RNA synthesis and its interactions with 
cellular proteins. Three of the mutations affected an interaction between a surface loop 
and the outer lining of the template channel. Furthermore, the interaction appears to 
regulate the transition between the conformations that are needed for de novo initiation 
and primer extension (PE). Furthermore, we show that RNA synthesis by the PE-
competent and presumably the more open conformation is preferentially inhibited by 
pRb.  
 
MATERIALS AND METHODS 
Reagents, Site-directed Mutagenesis, and Protein Purification. Recombinant pRb was 
purchased from QED Biosciences, Inc. Oligoribonucleotides were chemically 
synthesized by Dharmacon, Inc. Wild-type and mutant versions of the HCV RdRp were 
expressed with a C-terminal His6 tag in Escherichia coli and purified first by metal ion 
affinity chromatography, followed by chromatography with polyuridylate resin (Sigma) 
(163). The purified proteins were stored in 50 mM Tris (pH 7.9), 400 mm NaCl, 1 mm 
dithiothreitol, and 10% (v/v) glycerol at -80 °C. Protein concentrations were determined 
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by staining SDS-PAGE with Coomassie Blue and comparing the bands to those of 
bovine serum albumin at known concentrations. Amino acid substitutions were 
introduced in the plasmid encoding HCV Δ21 using the QuikChange site-directed 
mutagenesis protocol recommended by Stratagene. The entire open reading frame was 
sequenced to confirm the presence of directed mutation and the absence of unintended 
mutations.  
HCV Subgenomic Replicon Assay. All of the mutations except m26-30 were introduced 
into the subgenomic replicon by using the appropriate BglII DNA fragment from the 
pET21B plasmid that can express the mutant protein to replace the comparable fragment 
in the wild-type subgenomic HCV replicon (pFK/I389neo/NS3-3'/5.1). To introduce the 
m26-30 mutation into the replicon, an EcoRI-SpeI fragment from the wild-type 
subgenomic HCV replicon was subcloned into pBSK- plasmid (Stratagene), and 
mutations were introduced by site-directed mutagenesis. The subcloned fragment was 
reintroduced into pFK/I389neo/NS3-3'/5.1, replacing the comparable DNA fragment. The 
presence of the mutation in the HCV subgenomic replicon was confirmed by DNA 
sequencing.  
           Subgenomic HCV replicon RNAs were transcribed using the T7 Ampliscribe kit 
(Epicenter, Madison, WI) from plasmids linearized with ScaI. The subgenomic HCV 
replicon RNAs were transfected into Huh7 cells by electroporation with a GenePulser 
system (Bio-Rad) as described by Krieger et al. (29). Briefly, 1 μg of the in vitro 
transcribed RNAs along with 9 μg of total RNA from naive Huh-7 cells were 
electroporated at 960 microfarads and 270 V into ~1 × 106 Huh7 cells in 0.4 ml of ice-
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cold Cytomix. The cells were immediately transferred to 8 ml of complete Dulbecco's 
modified Eagle's medium containing 1.25% DMSO and seeded in a 10-cm dish. 24 h 
after transfection, the cell culture medium was replaced with complete Dulbecco's 
modified Eagle's medium supplemented with 0.5 mg/ml G418. The medium was 
changed every week for 3 weeks for the colony formation assay. The G418-resistant cell 
colonies were stained with 0.01% Coomassie Brilliant Blue.  
Reverse Transcription-PCR Assay. The reverse transcription reaction used 400 ng of 
total RNA (harvested 72 and 96 h after electroporation with the RNeasy RNA isolation 
kit (Qiagen)). Reverse transcription reactions used the Superscript III reverse 
transcriptase (Invitrogen), incubated at 50 °C for 60 min. 15% of the reaction mixture 
was used directly for PCR with an initial denaturation step at 94 °C for 2 min, followed 
by 30 cycles of 94 °C for 30 °C s, 50 °C for 30 s, and 72 °C for 90 s. The final extension 
was at 72 °C for 5 min. PCR products were separated in a 1% agarose gel. Primers used 
had the sequence 5'-CTCGATGTCCTACACATG-3' (plus-strand primer) and 5'-
ATTGACTGGAGTGTGTCTAG-3' (minus-strand primer).  
RdRp Activity Assays. Standard RdRp assays consisted of 1 pmol of linear template 
RNA and 0.04 μm NS5B (unless stated otherwise) in a 20-μl reaction containing Core 
buffer (20 mm sodium glutamate (pH 8.2), 4 mm MgCl2, 12.5 mm dithiothreitol, 0.5% 
(v/v) Triton X-100) amended with 200 mm GTP, 100 μm each of ATP and UTP, and 
250 nm [α-32P] CTP (Amersham Biosciences). MnCl2, if used, was added to a final 
concentration of 1 mm. The final reaction also contained 20 mm NaCl that came from 
the storage buffer. RNA synthesis reactions were incubated at 25 °C for 60 min and 
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stopped by phenol/chloroform extraction, followed by ethanol precipitation in the 
presence of 5 μg of glycogen and 0.5 m ammonium acetate. Products were usually 
separated by electrophoresis on denaturing (7.5 m urea) polyacrylamide gels. Gels were 
wrapped in plastic, and radiolabel was quantified using a PhosphorImager (Amersham 
Biosciences). Each quantified result shown was from a minimum of three independently 
assayed samples.  
Intrinsic Fluorescence Spectroscopy. Fluorescence measurements were done at 23-25 °C 
with a PerkinElmer Life Sciences LS55 spectrometer. Proteins were in a buffer of 20 
mm Tris (pH 7.9), 1 mm dithiothreitol, 10% glycerol, and 400 mm NaCl. The protein 
concentrations were adjusted to 0.75-1.5 μm. Measurements were performed with 
constant stirring to minimize photobleaching. Five independent measurements were 
recorded per sample with 1-min intervals between scans, and the measurements were 
averaged. Excitation was performed at 295 nm, and the emission spectrum was collected 
at 1-nm intervals from 305 to 400 nm, with an integration time of 1 s and slit width of 5 
nm.  
Electrophoretic Mobility Shift Assays. In vitro transcribed double-stranded RNAs treated 
with alkaline phosphatase were radiolabeled with [32P] ATP, using T4 polynucleotide 
kinase. Labeled RNA (40 fm) was incubated in a 20-μl reaction with a 40 nm final 
concentration of the polymerase in the Core buffer amended with 1 mm MnCl2 and 0.2 
mm GTP. The reactions were incubated at 25 °C for 30 min, after which a 4-μl solution 
containing 10 mm Tris (pH 8.1), 1 mm EDTA, 0.1% bromophenol blue, 0.1% xylene 
cyanol, and 30% glycerol was added. The samples were electrophoresed on a native 10% 
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polyacrylamide gel at 400 V for 1 h, and then the gel was autoradiographed.  
Analytical Ultracentrifugation. Analytical ultracentrifugation experiments were 
performed at the Center for Analytical Ultracentrifugation of Macromolecular 
Assemblies at the University of Texas Health Science Center at San Antonio. Δ21 and 
W397A were analyzed by sedimentation velocity experiments performed in a Beckman 
XLA centrifuge using absorbance optics by measuring intensity scans at 280 nm of a 0.8 
OD loading. The experiments were performed in two-channel epon centerpieces at 
45,000 rpm in an AN50 Ti rotor using a buffer containing 20 mm MOPS, 100 mm NaCl, 
and 0.75% (w/w) glycerol at 10 and 25 °C. Data analysis was performed with the 
UltraScan software suite (174). Data were first analyzed with the two-dimensional 
spectrum analysis (175) with simultaneous time invariant noise subtraction according to 
Schuck and Demeler (176). After noise subtraction, the data were examined for 
heterogeneity with the enhanced van Holde-Weischet analysis (177) and fitted by the 
genetic algorithm Monte Carlo analysis (178) in order to obtain shape information. All 
computations were performed on the TIGRE cluster at the University of Texas Health 
Science Center at San Antonio and the Texas Advanced Computing Center at the 
University of Texas in Austin. Partial specific volume was estimated based on 
PROTEIN sequence according to Durchschlag (179) and was found to be 0.732 cm3/g 
for both Δ21 and W397A.  
Circular Dichroism Analysis. Δ21, W397A, and H428A were subject to thermal 
unfolding using an Aviv 202SF spectropolarimeter with temperature control and stirring 
units. The change in CD signal at 220 nm was measured from 2 to 97 °C with 3-min 
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equilibration intervals, and the data were averaged for 5 s at each interval. The 
concentration of the protein samples was between 4 and 15 μm in 5 mm MOPS at pH 
7.6. The data were analyzed using methods described by Grimsley et al. (180).  
Molecular Modeling. The crystal structure of the wild-type HCV-RdRp (Protein Data 
Bank code 1QUV) was used to construct the W397A mutant model with Modeler 
(Insight II; Accelrys). Residues within a 15-Å radius of the Ala397 were subjected to a 
medium level of simulated annealing optimization with respect to the variable target 
function of Modeler. To mimic the Δ1 loop deletion, we constructed another model by 
mutating the residues L26-S27-N28-S29-L30 into alanines, which were then subjected to 
a medium level of simulated annealing optimization. The mutant models were 
superimposed onto the 1QUV structure using USCF Chimera (available on the World 
Wide Web).  
 
RESULTS 
Mutational Analysis of the Template Channel in the HCV RdRp. An unusual aspect of 
the crystallographic structures of viral RdRps is the presence of a RNA template channel 
that can lead the template RNA to the active site (56-57, 63). The template channel has 
areas that are more constricted, with the narrowest part having a diameter of ~5.5 Å 
when measured from the surfaces of the channel (Fig. 17A). To probe how the template 
channel might regulate RNA synthesis, we mutated many of the polar or aromatic  
residues that line the channel, typically to alanine. The locations of these mutations and 
their relationship to the channel are shown in Fig. 17A.  
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          Template LE19 was used to assess the effects of the mutations on RNA synthesis. 
The 19-nt LE19 can exist either as a hairpin with a single-stranded 3' sequence that 
directs de novo initiation from the 3'-terminal cytidylate or as a partially duplexed dimer 
that can be primer-extended to result in a 32-nt product (Fig. 17B). Higher molecular 
mass bands that are multiples of 19 nt are also produced and have been characterized as 
template switch products (88, 181). Given that these are extended from the nascent 
RNA, they should be considered primer extension products.  
          Compared with the wild-type Δ21 NS5B protein, several mutants demonstrated 
significantly decreased RNA synthesis, including D225A, T389A, and Q436A.  D225 
and T389 are residues that are 6 and 16 Å, respectively, from the active site (the 
measurement was to the center of the respective side chains from the side chain of 
D318), but N436 resides at a distance of 32.4 Å from the active site, at the tip of the 
thumb domain. Unexpectedly, 14 of 33 mutants demonstrated increased RNA synthesis. 
When mapped onto the template channel, these mutations tend to be located at the entry 
and exit portions as well as the constricted region of the channel (Fig. 17A, blue 
residues). Thus, the observed increase in RNA synthesis suggests that these residues 
lining the channel may function to restrict access of inappropriate templates.  
Two substitutions, W397A and H428A, resulted in severely decreased de novo initiation 
but had little impact on PE (Fig. 17C). Both W397 and H428 are more than 20 Å from 
the GDD motif that coordinates divalent metals and therefore should not affect binding 
of the initiation GTP (118). Our reactions contained 1 mm Mn2+, the presence of which 
generally decreases the effects of mutations of the NTPi-binding residues. 
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Figure 17: Mutational analysis of the RNA channel in the HCV RdRp. A, a ribbon diagram 
representation of the structure of the HCV RdRp molecule (Protein Data Bank code 1QUV) and 
a cut away representation of the template channel. The thumb, finger, and palm subdomains are 
identified by the letters T, F, and P, respectively. The amino acids in the template channel 
mutated to alanine are shown with their side chains in different colors. The yellow residues are 
the aspartates that bind the divalent metals and are intended to serve as a landmark in the 
catalytic pocket. The blue residues identify substitutions that increased RNA synthesis. The red 
residues were inactive. The purple residues are defective in de novo initiation but competent for 
extension from a primed template. The mutations that did not significantly affect RNA synthesis 
(Table 1) are not shown in this figure. Distances shown were measured as follows: 18 Å is from 
OE1 of Q446 to OE of K98; 21.5 Å is from CB of S556 to OD1 of D352; 4.5 Å is from NE2 of 
Q446 to OE1 of D143; 16.5 Å is from NE2 of Q355 to CG of K155. B, the sequence and 
predicted secondary structures of LE19, a template for RNA-dependent RNA synthesis. LE19 
exists in two conformations, a stem-loop structure that can direct de novo initiation and a 
partially base-paired dimer that can direct primer extension. C, image of the products of RNA 
synthesis by the mutant RdRps. Mutant proteins tested in each reaction are shown at the top of 
the gel image. The purified proteins used in each reaction, resolved on 4-12% SDS-
polyacrylamide gels and stained with Coomassie Brilliant Blue are shown below the 
autoradiogram images. The protein molecular weight markers are the SeeBlue standards from 
Bio-Rad. The sizes of the RdRp products for de novo initiation (19 nt), PE (32 nt), and the 
purified HCV RdRps (65 kDa) are shown to the left of the gel images. 
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Table 1: A summary of the effects of mutations in or near the template channel of HCV RdRp. 
The mutants are classified according to the five groups distinguished in function. d n, de novo 
initiation. PE- primer extension. Fold synthesis is shown as follows: ++++, >10.0-fold; +++, 5.1-
10.0-fold; ++, 3.1-5.0-fold; +, 1.3-3.0-fold; 0, 0.9-1.2-fold; -, 0.6-0.8-fold; -|-, 0.1-0.5-fold; -|-|-, 
0-0.1-fold. 
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Therefore, these residues are not directly involved in NTPi recognition (118).  
          To further characterize the defects in de novo initiation manifested by H428A and 
W397A mutants, we manipulated the concentration of the initiation GTP. LE19 has a 
cytidylate only at the 3' initiation site; hence, GTP is required for initiation but not PE 
(Fig. 17B). The absence of GTP in the reaction mix did not affect the abundance of the 
32-nt PE product produced by the mutants (Fig. 18A, lanes 7 and 11). In contrast, the 
wild-type Δ21 protein failed to initiate RNA synthesis de novo without GTP (Fig.18A, 
lane 3). To demonstrate that the 32-nt products resulted in PE, we used LE19P, which is 
identical to LE19 but has a puromycin blocking the 3' terminus. H428A and W397A did 
not produce the 32-mer from LE19P (Fig. 18A, lanes 6 and 10), confirming that  
products were made by extension from the 3' terminus of LE19.  
           Next, we used the 115 nt from the 3' end of minus-strand HCV RNA as a 
template to confirm the defect in de novo initiation with W397A and H428A. This RNA, 
designated H115, forms extensive secondary structures (Fig. 18C) but can direct de novo 
RNA synthesis (148). H428A and W397A failed to generate the expected 115-nt 
products from this template (Fig. 18B, compare lane 1 with lanes 2 and 3). However, a 
related template RNA, H115 + PE46, which provides a “looped back” primer allowing 
for PE, restored RNA synthesis by W397A and H428A to 34 and 9%, respectively, of 
the level seen with Δ21. Truncated products from H115 + PE46 were not observed, 
suggesting that the low level of synthesis was not due to premature termination. The 
reduction in PE observed with the H115 + PE46 template suggests that mutants W397A 
and H428A may have additional defects in RNA synthesis that are not as evident with  
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Figure 18: H428 and W397 interact with the Δ1 loop. A, RNA products made by mutant and 
Δ21 using templates and reaction conditions to examine de novo initiation and PE. The proteins, 
templates, and the GTP concentrations used in the reactions are indicated above the gel image. 
LE19P is a version of LE19 that has a covalently attached 3′-puromycin. The lane numbers are 
indicated at the bottom of the gel image. The de novo initiated (19 nt) and primer extension 
products (32 nt) are indicated to the left of the gel image. B, RNA synthesis by the HCV RdRp 
with template derived from HCV. RNA H115 contains the 3′ 115 nt of HCV minus-strand RNA. 
RNA H115 + PE46 contains the PE46 sequence (boxed) fused to the 3′ end of H115. Whereas 
H115 can direct de novo initiation, H115 + PE46 is capable of primer extension. The gel images 
show the reaction products of the enzymes using H115 or H115 + PE46 as template, which were 
run on a 10% urea denaturing polyacrylamide gel. The divalent metal ion manganese was left out 
of the reaction mix in the assays with H115 and H115 + PE46 templates. The lane numbers are 
shown at the bottom, and the enzyme names are shown at the top of the lanes. The lengths of the 
products are shown to the left of the image; the 115 nt band corresponds to a de novo initiation 
product of H115, and the 275 nt band corresponds to the PE product of H115 + PE46. C, 
interaction between H428, W397, and the Δ1 loop. The Δ1 loop is rendered as a blue ribbon with 
the network of primarily hydrophobic interaction residues below, indicated in red, except for 
H428 and W397, which are in purple. The box contains a ribbon representation of the Δ1 loop 
(residues underlined) interacting with the helices in the thumb domain. The apex of the Δ1 loop 
is colored gold. 
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shorter templates.  
Δ1 Loop Participates in the Open and Closed Transition States by the HCV RdRp. W397 
and H428 have their side chains pointing away from the active site and are part of a 
hydrophobic surface overlaid with a structure named the Δ1 loop. In the closed RdRp 
conformation, the Δ1 loop protrudes at the tip of the fingers domain and contacts the 
thumb domain by packing its short α-helix (helix A) against the α-helices O (residues 
388-401) and Q (residues 418-437) (Fig. 19B). H428 contacts the side chains of residues 
S29 and L30 in helix A. The aromatic side chain of W397 stacks against the 
hydrophobic pocket formed by the side chains of residues L21, P22, V37, and A39 
of the Δ1 loop (Fig. 18C) (data not shown). These interactions suggest that the contact 
between the Δ1 loop and the outside surface of the template channel are required for de 
novo initiation. Consistent with this model, inhibitors that bind to a groove in the thumb 
subdomain disrupt interdomain communication mediated by the Δ1 loop and cause 
conformational changes in the 2a and 1b HCV RdRps (60, 62). To determine whether 
the Δ1 loop is required for de novo initiation, we deleted the five residues of helix A 
within the Δ1 loop. The resultant protein, designated m26-30, was capable of PE when 
tested with the LE19 template (Fig. 18A, lanes 13-16). This result confirms that de novo 
initiation requires the interaction between the Δ1 loop and the underlying residues that 
help to form the template channel. Furthermore, the presence of higher levels of the 
template in the reaction increased in preferential accumulation of the primer extension 
products (not shown). Two additional mutants, I432W/H428A and A396W/W397A, 
were made in an attempt to restore this interaction. 
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Figure 19: Molecular modeling of the HCV RdRp, emphasizing the effect of the substitution on 
the Δ1 loop. A, location of Δ1 loop (colored in cyan) with respect to the thumb, palm, and 
fingers is shown in the crystal structure (1QUV) of the HCV NS5B protein. The Δ1 loop 
protrudes at the tip of the fingers domain and contacts the thumb domain by packing its short α-
helix (helix A) against the α-helices O (residues 388-401) and Q (residues 418-437) of the thumb 
domain. The W397 residue is shown in purple. The active site is indicated by green stars. B, 
superposition of the W397 mutant model (red and sky blue) of NS5B and the WT structure 
(yellow and cyan). Only Δ1 loop and its contact regions are shown. The side chain of W397 
stacks into the Δ1 loop. In the W397A mutant model, the key interactions are lost, and the Δ1 
loop moves significantly away from its contact region. The red arrow indicates the movement. 
C, superposing a mutant in helix A of the Δ1 loop (L26A/S27A/N28A/S29A/L30A) and the 
wild-type protein; the Δ1 loop moves away from the thumb domain, and the helix A widens into 
a loop. The arrow indicates the direction of the movement. 
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However, although both of these mutants were found to be competent for PE, they were 
defective for de novo initiation (Table 1), perhaps due to a requirement for additional 
interactions between the outer surface of the template channel and the Δ1 loop that will 
not be addressed in this work.  
W397A, H428A, and the m26-30 and HCV Replication in Cells. We next introduced 
several of these mutations into cDNA encoding a subgenomic HCV replicon in order to 
assess their effects on replication of HCV RNA in cultured human hepatoma cells. In 
vitro transcribed RNAs produced from these mutant plasmids were transfected into 
Huh7 cells, and colonies supporting replication of the viral RNA were selected by 
growth in the presence of G418. The H428A mutant failed to form colonies, whereas the 
wild-type replicon and an unrelated mutant replicon formed a significant number of 
colonies (Fig. 20A). To further examine the functional impact of the NS5B mutations, 
subgenomic replicons containing the H428A and W397A substitutions and the m26-30 
deletion were transfected into Huh7 cells, and the level of replicon RNAs was examined 
semiquantitatively using reverse transcription-PCR. The WT subgenomic replicon RNA 
could be detected at 72 and 96 h after transfection, but an active site GAA mutant and all 
three mutants of interest failed to produce a detectable signal with two independent sets 
of primers specific to HCV cDNA (Fig. 20B and C). These results demonstrated that the 
in vitro competence of NS5B for de novo initiation is correlated to HCV RNA 
replication in cells.  
Molecular Modeling of the Mutant Polymerases. We used molecular modeling to 
examine the effects of the W397A substitution. 
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Figure 20: W397, H428 and the helix A residues are required for HCV subgenomic 
replication in Huh7 cells. A) Formation of G418-resistant colonies in cells electroporated with 
the wild-type and mutant HCV subgenomic replicons. The plates were stained with Coomassie 
Blue three weeks after electroporation.  B) RT-PCR result of the HCV RNAs produced in WT 
and mutant cells.  The DNA bands were visualized by staining the agarose gel with ethidium 
bromide.  The 146-bp fragments were from the GAPDH mRNA that was amplified from the 
same samples.  These bands serve as loading controls.  C) Amplification of a 297-bp fragment 
from the HCV replicon.  This experiment was performed with only the RNAs harvested 96 h 
after electroporation.  The smaller DNA fragment was able to increase the signal from the HCV 
replicon and show that the mutant replicons were unable to replicate.  
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Residues within a 15-Å radius of W397A were subjected to a medium level of simulated 
annealing optimization using the variable target function of Modeler. W397A resulted in 
the Δ1 loop moving away from the thumb domain, with a maximum deviation of 12 Å. 
In fact, helix A unwinds into a loop during the energy optimization and loses contact to 
the neighboring helix Q (Fig. 19A and B). Similar results were obtained when we 
analyzed the structure of an HCV RdRp that had the helix A residues 26-30 in the Δ1 
loop (sequence LSNSL) replaced with alanines (Fig. 19C). These changes in the Δ1 loop 
were predicted to alter the structure of the template channel, making it more accessible 
to solvents. These predicted changes in the structure of the HCV RdRp could account for 
the functional differences we observed between the mutant RdRps and the wild-type Δ21 
polymerase.  
Biophysical Characterizations. We sought biophysical evidence in support of these 
hypothesized differences in the conformations of Δ21 and the mutant RdRps generated 
by computational modeling. The HCV RdRp has been reported to form oligomers (75-
76). Therefore, we examined the masses of Δ21 and W397A in solution at 10 and 25 °C 
using velocity sedimentation analytical centrifugation. Enhanced van Holde-Weischet 
analyses indicated that both protein samples were homogeneous and had S values 
between 4.1 and 4.2 (Fig. 21A). Results from a global genetic algorithm Monte Carlo 
analysis of each sample suggested that the proteins are globular in shape with frictional 
coefficients between 1.1 and 1.25, which correspond to an average molecular mass of 
67.7 kDa, an excellent fit with monomers. Slight differences in the sedimentation of the 
two proteins exist at 25 °C, but it is difficult to assess whether this is due to significant  
 
 
 
77 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 21: Biophysical and biochemical analyses of the mutant RdRps. A, analytical 
ultracentrifugation to examine the oligomerization state of W397A and Δ21 at two temperatures. 
The profiles for the two proteins largely overlap, suggesting that both are homogeneous and 
monomeric in solution. B, intrinsic fluorescence of the Δ21, W397A, H428A, and m26-30. The 
W397A has a spectrum indistinguishable from Δ21. H428A and m26-30 show a pronounced red 
shift in the spectrum between 349 and 363 nm. C, partial rescue of de novo initiation by 
dinucleotide primers. Shown is an autoradiograph of the RdRp products from template LE19 in 
the presence or absence of GTP or the NTPi mimic, GpU, as indicated above the gel image. D, 
PE from template PE46 in the presence of heparin. E, double-stranded RNA binding by Δ21 and 
the mutant RdRps. The gel image is from a 10% nondenaturing gel. The sequence of the probe 
used, RIII46, is shown above the gel image. 
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conformational changes within the monomers. Nonetheless, these results establish that 
the mutation W397A, which renders it unable to initiate de novo, is not through an effect 
on the oligomerization state of the protein.  
          Next, we characterized the intrinsic fluorescence of the wild-type and mutant 
RdRps. The environment of aromatic residues, especially tryptophans, can affect their 
fluorescence (182). The intrinsic fluorescence spectra of several independent 
preparations of the H428A and m26-30 mutants exhibited a pronounced red shift in 
comparison with the wild-type Δ21 protein (Fig. 18B, both panels). Such a red-shifted 
spectrum is indicative of the presence of tryptophan residues in a more polar 
environment (183) and provides evidence for an altered conformation in H428A and 
m26-30. However, this red shift was not seen with the mutant W397A, despite its 
sharing a common defect in de novo initiation. These results suggest that the three 
mutant RdRps are not in identical conformations (Fig. 21B, graph on the left).  
We attempted to examine the relative stabilities of Δ21 and the mutant proteins using 
circular dichroism spectroscopy with increasing temperature. H428A and W397A 
demonstrated smooth two-state transitions, with Tm values of 43 and 46 °C, respectively. 
In contrast, Δ21 demonstrated multiple transitions, probably due to some of the protein 
precipitating during the experiment (Fig. 22). Altogether, these biophysical and 
modeling results show that the mutant proteins have physical properties that differ from 
the wild-type Δ21. Furthermore, the mutant proteins are not in identical conformations.  
Additional Functional Characterizations. We hypothesized that the different 
conformations assumed by the mutant and wild-type HCV RdRps are related to the 
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conformational states required for distinct stages of RNA synthesis by the HCV RdRp. 
The closed conformation with a defined template channel could be responsible for de 
novo initiation, whereas the open conformation would permit elongation. The template 
channel will expand to accommodate the duplex of the nascent and template RNA by 
releasing the interaction with the Δ1 loop. To examine this hypothesis, we characterized 
how Δ21 and the mutant RdRps interacted with RNA. Dinucleotides can replace the 
NTPi and can improve the stability of the ternary complex and rescue some defects in 
RNA synthesis (40). We investigated whether RNA synthesis by the mutants could be 
restored with the dinucleotide (GpU in place of GTP. GpU is complementary to the first 
two nucleotides at the 3' terminus of LE19). The presence of GpU increased de novo 
initiated RNA synthesis by W397A and H428A by 27- and 12-fold, respectively, in 
comparison with GTP (Fig. 21C). However, GpU failed to rescue de novo initiation by 
m26-30.  
          To examine whether template binding by the mutant RdRps was affected, we 
performed RNA synthesis in the presence of heparin, a template mimic (184). RNA 
PE46 was selected for this analysis, because it is capable of directing only PE, thus 
eliminating possible effects on de novo initiation. The enzymes were preincubated with 
PE46 for 5 min to form a binary complex before the addition of heparin and rNTPs. 
Heparin reduced PE by the wild-type protein, Δ21, to ~10%, whereas W397A, H428A, 
and m26-30 were capable of PE at less than 0.5% of the amount seen in the absence of 
heparin (Fig. 21D, lanes 2, 5, 7, and 9). 
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Figure 22: CD spectroscopy to analyze the thermal melts for ∆21 and the PE+ mutant RdRps. 
The complex denaturation pattern of ∆21 suggests that the protein may exist in more than one 
conformation or oligomeric state.  
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However, when heparin and PE46 were added simultaneously to Δ21 before rNTP 
addition, no RNA synthesis was observed (Fig. 21D, lane 3). These results show that 
Δ21 can form a more stable binary complex with RNA than the mutant RdRps and 
suggest that the mutant polymerases might have reduced affinity for single-stranded 
RNA as compared with Δ21 and/or a reduced capacity to form a productive complex as 
compared with Δ21. Together, these results suggest that the interaction between the Δ1 
loop and the thumb subdomain can affect binary complex formation with single-stranded 
RNA, probably accounting for the defect in RNA synthesis.  
          Last, we compared the abilities of Δ21 and the mutant RdRps to bind double-
stranded RNAs in an electrophoretic mobility shift assay. For these experiments, we 
used the RIII46 RNA, which can form a stable 21-nt hairpin (185) (Fig. 21E). Δ21 failed 
to form a shifted band. However, the three mutant enzymes bound detectably to RPIII46, 
in increasing quantities from W397A to H428A and m26-30 (Fig. 21E). These results 
are consistent with the model that the mutant RdRps are in more open conformations 
when compared with Δ21.  
Interaction with Cyclophilins and Retinoblastoma. Several cellular proteins have been 
shown to interact with the HCV NS5B in pull-down and co-immunoprecipitation assays, 
including CypB and CypA and the cell cycle regulator, pRb (22, 141, 170, 172). CypB 
interacts with the C-terminal domain of NS5B and has been reported to increase 
template binding in pull-down assays (141, 172). However, Robida et al. (172) did not 
observe a significant effect on HCV replication with the silencing of CypB, suggesting 
that another cyclophilin, perhaps CypA, has a role. An et al. (167) found that 
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polymorphisms in CypA affected HCV replication.  
          The addition of purified CypA resulted in a concentration-dependent inhibition of 
RNA synthesis by the HCV RdRp from Δ21, m26-30, and I432V, a cyclosporin A-
resistant mutation in NS5B (Fig. 23B) (172). However, both de novo initiation and PE 
were inhibited, indicating that CypA does not preferentially target a particular mode of 
RNA synthesis. The presence of purified CypB resulted in a more pronounced shut-off 
of RNA synthesis than CypA. A molar ratio of three CypA to one RdRp reduced RNA 
product accumulation to approximately half, whereas the same amount of CypB reduced 
product formation 10-fold (Fig. 23C). In addition, the inhibitory effect of CypB was 
slightly stronger on the PE products than the de novo initiation products, although both 
were inhibited at higher CypB concentrations. These results demonstrate that both CypA 
and CypB can affect RNA synthesis by the HCV RdRp in vitro, although the effects are 
distinct. Several other proteins, such as bovine serum albumin and the RNA-binding 
proteins, PusA and App1, that affected brome mosaic virus RNA replication (186) did 
not affect HCV RNA synthesis (not shown). The putative binding site for pRb lies deep 
within the catalytic pocket of the HCV RdRp (Fig. 23A, green residue) (22, 166). This 
location suggests that the closed conformation of the HCV RdRp should be more 
resistant to inhibition by pRb. Purified pRb inhibited RNA synthesis by Δ21 but 
demonstrated a substantially stronger inhibitory effect on the PE products than on the de 
novo initiated products (Fig. 23D, graph). PE by m26-30 and W397A were also 
inhibited by pRb (data not shown). 
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Figure 23: Effects of recombinant cyclophilin A and pRb on RNA synthesis by the HCV RdRp. 
A, model of the HCV RdRp with the locations of residues that affect the activity of CypA or pRb 
in HCV-infected cells. The locations of W397 and H428 are in purple, and the catalytic 
aspartates responsible for coordinating divalent metals are in yellow. I432, which has been 
identified to confer resistance to cyclosporin, the small peptide inhibitor of CypA, is in orange. 
C316, which probably contacts pRb , is in light green. B, CypA can inhibit the HCV RdRp 
products made by de novo initiation and PE. The molar ratios of CypA or CypB to RdRp used in 
the reactions are listed above the gel image. C, quantification of the effects of CypB on de novo 
initiated and PE by Δ21. D, pRb can preferentially inhibit primer extension by Δ21. The gel 
image shows qualitatively the production of the de novo and primer extension products. The 
graph is from a related experiment, where pRb was titrated in increasing concentrations. All 
products made in three independent samples in the absence of pRb were set as 100%. E, effect of 
pRb on Δ21 and the mutant C316A, a part of the pRb binding site in NS5B. Where present, pRb 
was at a molar ratio of 22.5:1 to the RdRps. F, effects of pRb on RNA synthesis by the RdRps 
from JFH-1 2a HCV and BVDV. A 22.5:1 molar ratio of pRb to RdRp was used. 
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A substitution of C316 to an alanine within the putative pRb binding site (Fig. 23A) 
decreased the inhibitory effect of pRb on de novo initiation and also on PE (Fig. 23E, 
lanes 7 and 8). The differential effect of pRb on these two modes of RNA synthesis 
suggests that it preferentially interacts with and inhibits the open conformation of the 
HCV RdRp. Furthermore, mutant C316A was less affected by pRb for primer extension 
compared with Δ21, consistent with the idea that Δ21 exists in dynamic equilibrium 
between open and closed conformations.  
          To determine whether RNA synthesis by other RdRps is also sensitive to pRb, 
NS5B derived from the genotype 2A JFH-1 strain of HCV, named 2a-Δ21, and from the 
pestivirus bovine viral diarrhea virus (BVDV) were tested (49). Both 2a-Δ21 and the 
BVDV RdRp were sensitive to the presence of pRb at levels comparable with that 
exhibited by Δ21 (Fig. 23F). Furthermore, the PE products of both RdRps were 
preferentially inhibited. These results suggest that all three of these related RdRps exist 
in equilibrium between a de novo initiation-competent closed form and a PE-competent 
open form. Consistent with this, the RdRps from BVDV and several other members of 
the Flaviviridae possess loops equivalent to the HCV Δ1 both in location and in 
primarily hydrophobic interactions with the surface of the template channel (Fig. 24).  
 
DISCUSSION 
           Our mutational analysis of the HCV NS5B RdRp template channel identified an 
interaction between the thumb domain and the Δ1 loop that is required for de novo 
initiation of RNA synthesis. Substitutions disrupting this interaction are instructive,  
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Figure 24: Δ1 loop-like structures in other viral RdRps. The space-filling models show the 
locations of the loops that could have a role comparable with that of the HCV Δ1 loop (blue 
ribbon) in the RdRp structures of HCV, Dengue virus, West Nile Virus (WNV), and BVDV. The 
schematic to the left shows the potential interactions that allow the comparable loops to interact 
with the outer surface of the template channels in the RdRps. Residues in the apex of the loop 
are in boldface type, and residues in the ∆2 loop are underlined. The key in the box shows the 
lines used for the different interactions. 
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because they reveal that the HCV RdRp requires distinct conformations for different 
steps in viral RNA synthesis. Furthermore, interactions between NS5B and the cellular 
pRb protein depend on the conformation of the HCV RdRp, suggesting that alternative 
conformations of the HCV RdRp are not only potential drug targets for treatment of 
HCV infection but may also contribute to perturbations of cellular processes.  
Several lines of evidence suggest that mutant proteins W397A, H428A, and m26-30 
exist in a more open, PE-competent conformation. First, molecular dynamic studies 
predict that mutations in either the residues on the outside of the template channel or the 
Δ1 loop decrease contact with helices Q and O and increase access to the catalytic  
pocket of the RdRp (Fig. 19). Second, the mutated RdRp proteins have discernable 
spectroscopic properties when compared with Δ21 and with each other, indicating that 
there are changes in the conformations of these proteins. Third, in comparison with Δ21, 
all three mutants are more sensitive to heparin in the reaction buffer in the presence of a 
primed single-stranded template, suggesting that they are defective in the formation of 
the binary complex (Fig. 21). Fourth, and perhaps the most direct evidence in support of 
the open conformation, the mutants have an increased ability to bind to double-stranded 
RNA relative to Δ21 (Fig. 21E).           
       The interaction between the Δ1 loop and the outer surface of the template channel 
provides an elegant mechanism to regulate the initiation and elongation phases of HCV 
RNA synthesis (Fig. 25).The closed conformation is required for de novo initiation (Fig. 
25, form i). In this conformation, the template channel can orient the singlestranded 
template to the catalytic site (form ii). In fact, since substitutions at the most constricted 
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portion of the template channel increased RNA synthesis, the template channel may 
function to restrict access to more structured or otherwise inappropriate RNAs. The 
addition of the NTPi and a nucleotide complementary to the second template nucleotide 
will stabilize the ternary complex (Fig. 25,  form iii). The nascent RNA will then grow 
with polymerization until the duplex reaches a length where steric constraints force the 
release of the Δ1 loop from the thumb domain (Fig. 25, form iv). The open form of the 
polymerase allows elongation to proceed in a processive manner until the entire template 
is copied. At this point, the Δ1 loop may regain the ability to interact with the thumb  
subdomain.  
           Our model (Fig. 25) is consistent with results from studies of 
benzimidazole/indole-based nonnucleoside inhibitors that have been shown to 
specifically bind to the pocket in the thumb subdomain and inhibit the polymerase at a 
step before the elongation phase of RNA synthesis (42, 124-127, 133, 187). 
Interestingly, pyranoindole small molecule inhibitors that bind to a site different from 
the Δ1 loop-thumb domain interface inhibit elongation but not de novo initiation and 
cause an accumulation of 5-mer products, indicating that elongation might involve 
additional changes in the overall structure of the polymerase (130). There is evidence 
that supports the concept that the HCV RdRp normally exists in equilibrium between 
closed and open conformations. Biswal et al. (60) crystallized two distinct 
conformations of the 2a form of the HCV RdRp, which retains the Δ1 loop, consistent 
with the wild-type RdRp existing in at least two distinct conformations. 
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Figure 25: A model for RNA synthesis by the HCV NS5B. A schematic representation of the 
NS5B in the closed conformation is shown to the left with the thumb (T), fingers (F), and palm 
(P) domains holding a single-stranded RNA (red). The active site residues are shown as red 
asterisks. During elongation, the enzyme undergoes large conformational changes, including the 
displacement of the Δ1 loop to hold the growing nascent RNA-template hybrid (right). 
 
 
 
 
 
 
 
90 
observation that is best explained by the open conformation of the protein wrapping 
itself around the template (77).  
          The closed and open conformations of the HCV RdRp may regulate other 
activities of the NS5B protein that are only indirectly related to RNA synthesis. Viral 
replicases are usually capable of a high level of RNA synthesis despite low amounts of 
RdRp being present, thus making biochemical characterization of the replicase 
challenging (188). This raises the possibility that most of the RdRp molecules and other 
replicase subunits are not involved in RNA synthesis but serve to modulate the activities 
of other viral and also cellular proteins (22, 166, 173, 189-191).  
          In an interaction that is likely to have significant consequences for the association 
of liver cancer with HCV infection, NS5B can bind pRb, inducing its ubiquitination and 
subsequent proteasome-mediated degradation and thereby perturbing regulation of the 
cell cycle (22, 166). In vitro, such a protein-protein interaction resulted in the inhibition 
of RNA synthesis, perhaps by affecting template binding and/or catalysis. Interestingly, 
pRb preferentially inhibited PE by the wild-type HCV RdRp, Δ21, as well as the PE-
competent mutants (Fig. 23 and not shown). pRb is not known to have nucleic acid 
binding domains (192), and our finding that a C316A substitution resulted in escape 
from inhibition by pRb and an increase in the PE product (Fig. 23E) confirms earlier 
observations of Munakata et al. (22), who demonstrated that this substitution near the 
active site of the RdRp inhibits its interaction with pRb. The inhibitory activity of pRb 
contrasts with the effects of CypA, which did not differentially affect the production of 
the de novo initiated versus primer-extended products of the HCV RdRp (Fig. 23B). 
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Given that the recombinant pRb protein made in E. coli was capable of inhibiting the 
RdRp, post-translational modification of pRb is not required for this interaction (193-
194).  
          The differential inhibitory effects of pRb on different steps in RNA synthesis raise 
the interesting possibility that other cellular and/or viral proteins may interact with 
NS5B in a conformation-dependent manner. A screen for such interacting proteins or 
drugs that affect these interactions is now possible with the availability of mutant HCV 
RdRps that exist in different conformations.  
          The HCV RdRp has served as a model for the polymerases of other RNA viruses 
(195-196). Indeed, some common themes are emerging now that the structures of a 
number of RdRps are available. Notably, the RdRp of BVDV can also exist in an open 
conformation, with a displaced loop that regulates access to the active site (65). A 
comparison of the activities of the RdRps from other members of the family Flaviviridae 
revealed that they have generally similar properties with respect to RNA synthesis in 
vitro (39, 88, 99, 163, 197). Consistent with this, we also demonstrated that pRb could 
preferentially inhibit the synthesis of elongation products made by the BVDV RdRp 
(Fig. 23F), suggesting that similar interactions may exist between pRb and RdRps from 
other positive-strand RNA viruses.  
          DNA-dependent RNA polymerases, DNA-dependent DNA polymerases, and 
reverse transcriptases are all known to undergo transitions from open to closed states 
(70, 167, 198-199). Our results indicate that RdRps from positive-strand RNA viruses 
can undergo similar transitions. Whether these changes go in the same order in vivo 
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depends on how the RdRp-replicase complex locates the appropriate viral template 
RNA. In the case of HCV, it is possible that the RdRp first binds an internal sequence 
within the HCV genomic RNA and then scans for the 3' terminus. In this scenario, the 
RdRp will initially bind RNA in the open form. On the other hand, it is also possible that 
the replicase is threaded with the 3' terminus of the HCV RNA. In this case, the RdRp 
will first function in RNA synthesis in its closed conformation, followed by a transition 
to the open conformation during elongation. It is also possible that cellular protein(s), 
such as a cyclophilin, could mediate template loading by manipulating the RdRp 
conformation.  
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CHAPTER IV 
REGULATION OF DE NOVO INITIATED RNA SYNTHESIS IN THE HEPATITIS C 
VIRUS RNA-DEPENDENT RNA POLYMERASE BY INTERMOLECULAR 
INTERACTIONS* 
 
INTRODUCTION 
          Polymerases undergo a series of conformational changes at different stages of 
nucleic acid synthesis (70). Of the template-dependent polymerases, the RNA-dependent 
RNA polymerases (RdRps) are the least understood in terms of their mechanism of 
action. RdRps are of increasing interest due to recent research showing cellular RdRps 
playing important roles in the defense against non-self RNAs (200). In addition, virus-
encoded RdRps are important targets for the development of antivirals. A better 
understanding of RNA-dependent RNA polymerases is thus important for both basic and 
applied science.  
 Several model systems for biochemical study of viral RNA-dependent RNA 
synthesis exist (83, 201-203). Well-characterized RdRps include those from the hepatitis 
C virus (HCV) and poliovirus (56, 158). In the host, the RdRps are complexed with 
other viral and/or cellular proteins that are usually associated with membranous 
intracellular structures.   
 
*This work has been submitted to The Journal of Virology as: “Regulation of De 
Novo Initiated RNA Synthesis in the Hepatitis C Virus RNA Dependent RNA 
Polymerase by Intermolecular Interactions” by Chinnaswamy, S., Ayaluru, A., Li, 
P., and Kao, C. C. 
 
 
 
94 
          The replicases are usually difficult to study biochemically, but the catalytic 
RdRp subunits of several viruses can be purified for functional and structural analyses 
(35). These recombinant proteins can reproduce some of the activities of the replicases 
and can affect the activities of other replicase subunits in vitro (191, 204). Understanding 
how RdRp subunit structure affects function will help us understand the viral RNA 
replication.  
    RdRps form a right-hand like structure with thumb, finger, and palm subdomains. 
The metal-coordinating residues important for nucleotide binding are positioned within 
the palm subdomain (57). An interesting feature of viral RdRps is that they tend to exist 
in a closed conformation, even in the absence of template, in contrast to DNA-dependent 
RNA polymerases that transition from open to closed complexes upon template 
recognition (205). The closed form of the phage φ6 RdRp has been proposed to allow 
specific recognition of the single-stranded viral RNA (68). The template channel formed 
by the closed structure, however, is too narrow to accommodate the partially duplexed 
RNA that forms during RNA synthesis. Hence the closed conformation needs to become 
open in the ternary complex.  
          The HCV RdRp has structural features compatible with a mechanism to initiate 
RNA synthesis by a de novo mechanism (56-57). It can also extend from a primed 
template as well as switch templates without release of the nascent RNA (181). A 
secondary structure that extends from the finger to the thumb subdomains named the ∆1 
loop has been proposed to serve as a gate to cover the template channel and regulate the 
switch from de novo initiation to elongation (56). Mutations that affect the interaction 
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between the ∆1 loop and the mostly hydrophobic residues that it contacts have resulted 
in polymerases that are defective for de novo initiation but can bind to partially duplexed 
RNA and can extend from the 3’ terminus of an RNA primer (see Chapter III).  
          The HCV RdRp likely undergoes a change between the open and closed structure 
in vivo.  The HCV RdRp can bind the master cell cycle regulator, Retinoblastoma (pRb), 
and cause the degradation of Rb (22). The pRb binding motif overlaps with the metal-
coordinating residues of the HCV RdRp in the palm domain (22). It stands to reason that 
only the open RdRp conformation can bind pRb. Biswal et al., (60) have captured an X-
ray crystallographic structure of a partially open conformation of the HCV RdRp.  The 
BVDV RdRp was also shown to exist in a partially open conformation as a result of the 
interaction between two RdRp subunits (65).  
      Two general models for de novo initiation by the HCV RdRp have been proposed 
(Fig. 26). The first shows the HCV RdRp to be functional as a monomer at least during 
de novo initiation because the closed template channel is needed for specific recognition 
of the template ((56, 68) and also see Chapter III). It was presumed that the ∆1 loop and 
thumb domain interaction in the HCV RdRp is stable and mutations that disrupted this 
interaction would render the enzyme catalytically inactive (69). However, a deletion of 
five residues in the tip of the ∆1 loop did not prevent RNA synthesis from a primed 
template by the polymerase (see Chapter III). Furthermore, a genotype 2a RdRp was 
crystallized in a form with altered interaction between the ∆1 loop and thumb domain in 
comparison to the 1b RdRp (60). Interestingly, a low affinity GTP binding site exists on 
the thumb domain close to the base of ∆1 loop binding pocket. GTP binding at this site 
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has been proposed to stabilize the ∆1 loop and thumb domain interactions, favoring the 
closed monomer model (38). A second model for RNA synthesis is based on the reports 
that HCV RdRp can oligomerize and that oligomerization increases its activity (74-76). 
In this model, an RdRp oligomer stabilizes the ∆1 loop and thumb interactions to allow 
formation of the template channel for de novo initiation (Fig. 26). Herein we attempt to 
determine whether monomers or oligomers of the HCV RdRp (from 1b HCV genotype) 
can better perform de novo initiation using biochemical and biophysical analyses.  
 
MATERIALS AND METHODS 
Production of the HCV RdRp. The HCV RdRp we use as a model system, named ∆21, is 
derived from HCV 1b isolate strain BK. Wild-type and mutant versions of the NS5B 
∆21 were expressed in E. coli with the 6X-His tag at the C-terminus of the protein. The 
culture was shaken at 37°C until the OD600 reached 0.8-1.0, and then the temperature 
was changed to 16°C and IPTG was added to 0.5 mM. After a 12-16 h period, the cells 
were pelleted at 8000 g for 15 min., and the pellets were frozen at -70°C until needed.  
          RdRp purification used cells suspended in lysis buffer (20 mM Tris, pH 7.5, 300 
mM NaCl, 10% glycerol, 10 mM imidazole, a protease inhibitor cocktail at the 
concentration suggested by the manufacturer (Sigma Inc.), 5 mM beta-mercaptoethanol 
(BME), and 0.1 mg/ml lysozyme. The suspension was sonicated for 2 min and clarified 
by centrifugation at 16,000 g for 30 min. The supernatant was loaded onto Ni-NTA 
columns equilibrated with 20 mM Tris, pH 7.5, 300 mM NaCl, 10% glycerol, 10 mM 
imidazole, and 5 mM BME. The columns were washed with the same buffer containing  
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Figure 26: Two models for de novo initiation by the HCV RdRp.  Model I is based on 
the central tenant that intramolecular interactions within a RdRp molecule regulate the 
modes of RNA synthesis. The thumb, fingers and palm domain are represented by the 
letters T, F, and P, respectively.The ∆1 loop is shown as a thick black line. The curved 
arrow represents the possible orientation of the template RNA. Model II is an adaptation 
from the dimer model of the norovirus RdRp proposed to require oligomers for de novo 
initiation (206). 
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20 mM imidazole followed by elution of the bound proteins with lysis buffer containing 
500 mM imidazole. ∆21 purified from the NTA column was dialyzed into buffer of 20 
mM Tris, pH 7.5, 100 mM NaCl, 10% glycerol, and 10 mM ΒME using a desalting 
column and then loaded onto a MonoS column (HR 100/10, GE Healthcare) which was 
pre-equilibrated with desalting buffer. ∆21 was eluted with a gradient of 100 to 600 mM 
NaCl in desalting buffer. The proteins generated from these two columns were highly 
pure and did not contain other bands in Coomassie blue stained gels.   
Blue Native PAGE (BN-PAGE). Approximately 250 ng of proteins were mixed with the 
loading dye supplied by the manufacturer (Invitrogen Inc.) and electrophoresed in 3-
12% native-PAGE gels (Invitrogen Inc.) with a Coomassie Blue-containing cathode 
buffer at 4oC for 2 h according to the manufacturer’s instructions. The gel was stained 
with silver stain. 
HCV RdRp assays. LE19 is a template typically used to measure several RNA synthesis 
activities in one reaction (88): de novo initiation, primer extension, template switch and 
nontemplated nucleotide addition. Standard RdRp reactions contained 50 nM RNA, 0.1 
mM ATP and UTP, 33 nM (α-32P) CTP and 0.01 mM GTP (unless stated otherwise) and 
the amount of NS5B as specified. The assays also contain 20 mM sodium glutamate (pH 
8.2), 4 mM MgCl2, 12.5 mM dithiothreitol, 0.5% (v/v) Triton X-100, 20 mM NaCl and 
1 mM MnCl2. The reactions were incubated for 1 hr at 25 oC before extracting the 
products with a 1:1 mixture of phenol-chloroform and precipitated with ethanol in the 
presence of 0.3 M NaOAc. The RNA was electrophoresed on 20% urea denaturing 
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polyacrylamide gels and the gels were wrapped in plastic and exposed to phosphor 
screens prior to scanning by a phosphorimager (Molecular Dynamics). 
Differential scanning fluorimetry (DSF). DSF was carried out in a Stratagene MX3005P 
PCR machine with filter sets for excitation at 492 nm and emission at 610 nm. Each 
sample of 25 µL contained 2 µM final concentration of protein in 300 mM Tris (pH 7.5), 
80 mM NaCl and SYPRO orange (Molecular Probes) at 2.5x final concentration (the 
actual concentration not revealed by MP). The samples were heated at a rate of 
0.5°C/minute, from 25 to 75°C, and the MxPro software (Stratagene) was used to 
calculate the Tmapp by plotting the negative derivative of the observed fluorescence 
change over temperature. 
Dynamic light scatter analysis (DLS). DLS measurements were made with Zetasizer-
NanoS (Malvern Instruments, UK) in a buffer containing 300 mM Tris (pH 7.5) and 1 
µM final protein concentration. The buffer components were filtered through a 0.2 µ 
pore filter (Nalgene, USA) to avoid suspended particles. The measurements were made 
at 10 s intervals with the data points collected after a 1 s scan. At least three 
measurements were made per sample, and the average intensity for the corresponding 
peaks was plotted.      
Electron microscopy and image reconstruction. The protein in a buffer containing 50 
mM Tris pH 7.5, 100 mM NaCl, 5% glycerol and 1 mM ΒΜΕ was adjusted to ~5 ng/µL, 
adsorbed to freshly glow-discharged carbon-coated copper grids (EMS), and stained 
with uranyl acetate (1% w/v aqueous solution). Electron microscopy was performed 
using a transmission electron microscope operated at 80 kV (JEOL 1010). Dimeric 
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particles of the HCV RdRp were selected using the BOXER routine in the EMAN 
program (207), filtered, and centered. Class averages were generated with these filtered 
and centered particles without imposed symmetry. Centered particles (about 4000) were 
subjected to the Multirefine program to sort the particles into an initial model. A 
molecular mass of 130 kDa was used for the surface-rendering threshold of the 3D 
structures of the dimers. 3D reconstructions were visualized using the UCSF Chimera 
software package (208). 
 
RESULTS 
Analysis of ∆21 conformations and oligomerization. Blue-native gel electrophoresis 
(BN-PAGE) was used to examine the oligomeric and conformational state of the HCV 
∆21 protein. In this type of gel electrophoresis, proteins coated with Coomassie blue 
have an overall negative charge and are separated in an acrylamide gel based on a 
combination of size, shapes and/or oligomeric states (209-210). We examined the wild-
type ∆21 (Fig. 27A) along with several mutants that are affected for oligomerization 
(E18R,(75)); de novo initiation (m26-30 and I432V (Chapter III and (144)), and GTP 
binding at the allosteric site (P495/V499A named as PV (38)). While the recombinant 
∆21 migrated at the expected molecular mass of 65 kDa in SDS-PAGE, it existed as 
multiple bands of different intensities in a BN gel (Fig. 27B). m26-30, with a five amino 
acid deletion in the ∆1 loop which renders it defective for de novo initiation (Chapter III) 
had a different banding pattern. E18R and PV mutants deviated significantly from the 
banding pattern of ∆21 and exhibited some poorly resolved high molecular weight 
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complexes (Fig. 27B). I432V had bands in similar position to that of ∆21.  The variety of 
bands exhibited by ∆21 and mutant RdRps in the BN-PAGE suggest that each of the 
RdRps exists in complex arrays of oligomeric states and/or conformations.  
          Dynamic light scatter spectroscopy (DLS) was used to measure the hydrodynamic 
diameter of ∆21 to estimate the dimensions of the protein. In a Tris buffer containing 40 
mM NaCl, ∆21 existed in three peaks (Fig. 27C). The first has a mean diameter of more 
than 8 nm and represents more than 95% of the protein based on volume distribution of 
the peak. This hydrodynamic diameter was higher than expected based on the X-ray 
structure of the monomeric HCV RdRp, indicating polydispersity (25%). The other two 
peaks are likely to be high molecular weight oligomers. Increasing the concentration of 
monovalent salt in the buffer was reported to affect the ∆21 oligomers in solution (211). 
Higher salt concentrations slightly increased the abundance of peak I and altered the 
abundance and positions of the other two peaks in DLS (Fig. 27C). This is consistent 
with the idea that the three peaks are in equilibrium in a manner that can be affected by 
the monovalent salt concentration, as reported previously (211). Finally, ∆21 eluted as 
three distinct peaks in a Superdex-200 gel filtration column when in a buffer containing 
100 mM monovalent salt. However, the most abundant peak eluted at a mass smaller 
than 65 kDa when compared with molecular mass markers (not shown). Similar 
observations were made by Gu et al. (74).             
          Next, we visualized ∆21 by electron microscopy after staining with uranyl acetate. 
∆21 existed in particles of different sizes that are likely monomers (~6 nm average 
diameter), dimers, and higher order complexes with the longest diameters  
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Figure 27: Analysis of the conformations and oligomeric states of the HCV RdRp. A) 
SDS-PAGE demonstrating the mobility of the ∆21 at ~ 65 kDa under denaturing 
conditions. The molecular weight markers are from Invitrogen (Benchmark protein 
ladder).  B) Blue-native gel of ∆21 and its variants that are affected for RNA synthesis.  
The different bands that were distinct in mobility and intensity are labeled from a to e. 
Bands that were common to all proteins are indicated by a filled box; bands common to 
∆21 and I432V are shown with asterisks; whereas bands in m26-30 are shown with filled 
triangles. C) DLS analysis of ∆21 at 40 mM and 400 mM NaCl. D) Polydisperse nature 
of the peak I from C. E) A representative EM image of a 5 ng/µL ∆21 in a Tris buffer 
containing 100 mM NaCl. The particles were stained by uranyl acetate after adsorption 
onto carbon grids. The scale bar shown at bottom left. The arrows point to the likely 
monomers based on the estimated sizes of the particles. Note that some monomeric 
particles may represent different orientations attached on to the grid hence appearing in 
different shapes. One of the oligomer is indicated with an oval. F) Magnified view of 
micrographs showing ∆21 monomers and oligomers. G) A histogram of the dimensions 
of 440 particles of ∆21 picked from different micrographs. The measurements were 
made manually using the image processing software ImageJ (NCBI) at a 2.35 Å/pix ratio 
at specimen level. Two measurements were taken each at the longest and widest 
dimensions of each particle at roughly perpendicular angles and the average of the two 
measurements is plotted as histograms. 
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being up to 20 nm (Fig. 27E, 27F). The diameters of ~450 ∆21 particles distributed in 
several micrographs are plotted in Fig. 27G. The distribution of ∆21 particles on EM 
matched with the polydisperse nature of peak 1 observed in DLS (compare Fig. 27D and 
27G). In Chapter I it is shown by analytical ultracentrifugation that ∆21 is primarily a 
monomer in solution while others have shown by a similar experiment that ∆21 
apoenzyme is a monomer that can form dimers and tetramers in the presence of an RNA 
that can direct de novo initiation (69). The reason for the discrepancy is unclear, but it is 
likely that the oligomeric contacts are weak in the apoenzyme and do not survive 
sedimentation velocity experiments. 
RNA synthesis as a function of enzyme concentration. Since ∆21 can be present as an 
oligomer, we wanted to examine whether oligomerization can affect a particular mode of 
RNA synthesis. For this analysis we used a template LE19 to report on both de novo 
initiation (producing a 19-mer RNA) and primer extension products (producing a 32-mer 
RNA, Fig. 28A). The reactions had 10 µM of the initiating nucleotide GTP, 50 nM 
template RNA, and from 20 to 60 nM of ∆21. Over this concentration range, we 
observed a geometric increase in de novo initiation but a linear increase in primer 
extension and template switch products (Fig. 28B and C).  This suggested that conditions 
that favor higher order RdRp complexes favored de novo initiation. To confirm the 
results without the complex template switch products, we used LE19P, which can direct 
de novo initiation but not primer extension due to a puromycin being attached to the 3’-
most hydroxyl of the template. A second RNA named PE46 that can only direct primer 
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Figure 28: Higher enzyme concentrations selectively stimulated de novo initiation by 
∆21. A) The templates used in the analysis. Template LE19 exists as a monomer and 
directs the synthesis of a 19-nt de novo initiation product from ∆21 while it can also 
form a dimer with another LE19 molecule and directs the synthesis of a primer extension 
product of 32-nt. The capital P represents a puromycin covalently attached to the 3’ 
terminus of the RNA LE19P. PE46 is a stem loop structure that can direct a primer 
extension product of 46-nt. B) A representative gel image of the RdRp assay described 
using different concentrations of ∆21 with a constant concentration of 50 nM LE19 and 
0.1 mM of ATP, UTP; 0.01 mM of GTP and 33 nM of (α - 32P) CTP. PE and Ts denote 
primer extension and template switch, respectively. C) Quantification of products of 
RdRp reaction. The 19-nt product is quantified as de novo initiation product; 32-nt as 
primer extension (PE) product and all other higher molecular weight products as 
template switch (indicated as Ts in the left of the image). The error bars represent 
standard deviations from three reactions. The respective activities at 20 nM were 
normalized to 100% and the relative increase at different concentrations is plotted. D) A 
gel image of the products of the RdRp assay carried out as in B, but with the templates 
LE19P and PE46. PE-primer extension. (A). Each of the RNAs was at a concentration of 
25 nM. The de novo and primer extension activity at different enzyme concentrations 
was normalized and compared to that of 20 nM enzyme concentration and is indicated 
below respective lanes. 
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extension was also present to allow comparative analysis of the two modes of RNA 
synthesis (Fig. 28A). Both RNAs were at 25 nM final concentration. Again, ∆21 
concentrations from 20 to 120 nM yielded a geometric increase in de novo initiated 
RNAs while the primer extension product was inhibited at the highest concentration 
tested (Fig. 28C). These results show that the mode of RNA synthesis by ∆21 is 
dependent on ∆21 concentration. We note that the divalent cation manganese was 
required for the simulation of de novo initiation in all of these reactions while primer 
extension was inhibited at higher enzyme concentrations in a divalent metal independent 
manner (not shown). This is consistent with a previous finding that manganese has a 
selective effect on de novo initiation (88). 
 De novo initiation-defective mutant proteins can stimulate de novo initiation by ∆21. To 
examine the relationship between oligomerization and de novo initiated RNA synthesis, 
we needed a mutant RdRp that was defective for de novo initiation, but could retain 
interaction with ∆21. The ∆1 loop deletion mutant, m26-30 was selected for this activity. 
First, we examined whether highly purified m26-30 (Fig. 29A) was altered in 
conformation/oligomerization when compared to ∆21 using the differntial scanning 
fluorimetry (DSF) assay. The assay uses the dye SYPRO orange that fluoresces when 
bound to hydrophobic regions of the protein. When assayed along over a fixed rate of 
temperature increase, SYPRO orange fluorescence will report on the denaturation profile 
of proteins (212). A clear difference was observed between the melting profiles of ∆21 
and m26-30 (Fig. 29B). ∆21 had a relatively symmetric melting curve with a maximum 
Tmapp of 45.5oC; m26-30 had a more complex melting profile and a maximum Tmapp of  
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Figure 29: Intermolecular interactions in the RdRp can stimulate de novo initiation. A) 
Image of the SDS-PAGE of the ∆21 and the m26-30 proteins used in these studies. m26-
30 has a five-amino acid deletion at the tip of the ∆1 loop (Chapter 3). B) DSF analysis 
of 2 µM of ∆21 or m26-30. The fluorescence increase due to SYPRO-orange dye 
binding to hydrophobic patches in the protein is plotted as a negative derivative on the y-
axis. The plots were generated from the software package MxPro supplied with the real 
time PCR machine (Stratagene). The minimal point on the y-axis for each plot is 
considered the Tmapp. C) Products of RNA synthesis assays as described by ∆21 and 
m26-30 using a equal mix of the LE19P and PE46 templates. The primer extension (PE) 
and de novo initiated products are marked to the left of the gel image. The de novo 
products are quantified and indicated below the lanes. D) Effects of m26-30 on de novo 
initiation by 20 nM of ∆21. This concentration of ∆21 was selected since de novo 
initiation products are at a low level.  The addition of m26-30, which is debilitated for de 
novo initiation, but could retain protein-protein interaction, was able to stimulate de 
novo initiation by ∆21. E) Quantification of the increase in de novo initiation by 20 nM 
of ∆21 in the presence of m26-30 or two unrelated proteins. The unrelated proteins are 
added to test for the effects of molecular crowding. 
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41.5oC. We next compared RNA synthesis by ∆21 and m26-30 over a range of protein 
concentrations. While de novo initiation increased by 69 fold over the range of 
concentrations tested for ∆21, m26-30 produced only a small increase in de novo 
initiated products over the same concentration range tested (Fig. 29C). Finally, we fixed 
∆21 in the RNA synthesis reaction at 20 nM, a concentration that produces only a faint 
amount of de novo initiated products and asked whether the presence of m26-30 could 
stimulate de novo initiated product synthesis. Indeed, there was a concentration-
dependent increase in the de novo products when m26-30 was present with ∆21 (Fig. 
29D). These results suggest that the intermolecular interaction between m26-30 and ∆21 
led to increased de novo initiation by ∆21.  
          Lastly, we wanted to test whether the interaction is specific or could be due to a 
molecular crowding effect.  Hence, recombinant green fluorescent protein (GFP) and E. 
coli TraM proteins were added to ∆21 in the same concentrations as m26-30.  Both had a 
more modest effect on de novo initiation by ∆21 when compared to m26-30 assayed in 
the same reaction (Fig. 29E). These results suggest that molecular crowding did 
contribute to higher de novo initiation by ∆21, but that m26-30 retains the ability to 
interact with a WT ∆21 to increase de novo initiation.    
          We wanted a second de novo initiation-defective mutant to confirm that 
intermolecular interactions could stimulate de novo initiation by ∆21.  A closer 
examination of the ∆1 loop revealed that residue E18 was a good candidate for 
disrupting the interaction of the ∆1-loop with the thumb domain since it formed a salt-
 
 
 
108 
bridge with R401 in the thumb domain (Fig. 30A). E18 was previously claimed to be 
involved in a homomeric pair with H502 (75). However, over 200 sequences from the 1b 
HCV strains revealed that the E18-R401 (or a E18-K401) salt bridge was highly 
conserved (data not shown), suggesting that the interaction with R401 was likely 
important for HCV NS5B function. We produced the E18R mutant protein and subjected 
it to the DSF assay in comparison to ∆21. E18R, like m26-30, has a broader denaturation 
peak and also a lower Tmapp relative to ∆21 (Fig. 30B). When tested for RNA synthesis, 
E18R was also defective for de novo initiation but not primer extension, except at very 
high concentrations of protein (Fig. 30C). Again, when co-incubated with a 20 nM ∆21 
protein, E18R increased de novo initiation by ∆21 (Fig. 30D). Two mutations that are 
defective for producing products by de novo initiation can thus activate de novo 
initiation by ∆21. 
Effect of GTP on conformation and de novo initiation by ∆21. Previous reports have 
shown that GTP stimulates de novo initiation while inhibiting primer extension (41, 55). 
However it is not clear if GTP acts at the NTPi (78), allosteric site on the thumb domain, 
or both (38). The low affinity GTP-binding pocket is at the base where the ∆1 loop 
interacts with the thumb domain, suggesting a relationship with the conformations 
needed for de novo initiation (Fig. 31A). To examine whether the allosteric site has an 
effect on de novo initiation we tested a double mutant, P495/V499A (referred to as PV) 
for RNA synthesis using LE9P and PE46 as templates. Both ∆21 and PV can extend 
from PE46 to similar levels, but the PV mutant synthesized only a fraction of the de  
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Figure 30: E18R can stimulate de novo initiation by ∆21. A) A surface and ribbon 
representation of the X-ray crystal structure of HCV RdRp (PDB ID 1QUV) to highlight 
the location of E18 (red spheres) and its interaction with R401 (blue spheres). The 
complete thumb domain (T); a part of the palm (P) domain and a part of the fingers (F) 
domain are marked. The active site metal coordinating residues in the active site are in 
yellow. The ∆1 loop that connects the fingers and thumb domain is in ribbon 
representation and is colored cyan while the side chains of its residues are in purple. B) 
Proteins used in the reactions shown in this figure and their behavior in a DSF reaction. 
C) Representative image of the products of the RdRp assay with templates LE19P and 
PE46 with increasing concentrations of ∆21 or E18R. The ratio of increase in the de 
novo initiated product has been quantified below the gel image. D) Effects of amending 
a RNA synthesis where ∆21 was kept constant at 20 nM while E18R was at 10 or 60 
nM. The two enzymes were preincubated on ice for 30 minutes before adding the RNAs.   
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Figure 31: The allosteric GTP binding site and de novo initiation of RNA synthesis. A) 
The location of the low-affinity GTP binding site on the surface of the thumb domain of 
HCV RdRp (PDB ID 1QUV) as shown by Bressaneli et al. (38). The ∆1 loop is in cyan 
and the residues P495 and V499that were identified to bind GTP on the thumb domain 
are shown in different colors (residues S29, R32 and H503 which are also part of the 
allosteric site are not shown). B) Gel image of the RdRp reaction products using LE19P 
and PE46 with increasing protein concentrations. The two proteins were at 20, 30, 40, 50 
and 120 nM in the assays. The amount of de novo initiated product at different enzyme 
concentrations was normalized and compared to that of 20 nM of either PV mutant or 
∆21, as indicated below respective lanes. PE-primer extension. C) DSF analysis of ∆21 
and PV mutant as in Fig. 4D to examine conformational differences between the two 
proteins. The inset shows SDS-PAGE of the two proteins used.  
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novo initiated product made by ∆21 while producing more of the primer-extended 
product (Fig. 31B). 
          The DSF assay was used to examine whether PV has a change in 
conformation. PV has a broader melting curve than ∆21 in a manner that was 
reminiscent of m26-30 and E18R and the Tmapp of PV was also 2oC lower than that of 
∆21 (Fig. 31C). However, the changes conferred by the PV mutations are subtler than 
the changes in the ∆1 loop we characterized above (Fig. 29 and 30). The DSF assay can 
measure the effect of ligand binding on the stability of proteins (212). We used it to 
measure the effect of increasing concentrations of GTP on the Tmapp of ∆21. GTP 
increased the thermal stability of ∆21 by ~2.5oC in a concentration-dependent manner 
(Fig. 32A and 32B). A similar increase in stability was observed with UTP (not shown). 
In contrast, the PV protein had a decreased response to GTP and UTP at all 
concentrations tested (Fig. 32B and data not shown). These results suggest that the HCV 
RdRp will undergo a conformational change upon binding NTPs and that the PV 
mutation in the allosteric site did affect the ability of the polymerase to respond to 
nucleotides and undergo a conformational change, but the effect was not specific to 
GTP. 
          Lastly, we examined whether increasing GTP concentration from 10 to 200 µM 
could help to restore de novo initiated RNA synthesis by PV at three enzyme 
concentrations (Fig. 32C). At 20 nM protein, increasing GTP concentrations increased 
de novo initiation by ∆21 
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Figure 32: GTP can stabilize ∆21 conformation and increase de novo initiation. A) Tmapp 
of a 2 µM concentration of ∆21 in absence or presence of increasing concentrations of 
GTP. The Tmapp was 45.5, 46.05, 47.02 and 47.52 oC at 0, 1, 3 and 20 mM GTP 
respectively. B) Increase in Tmapp of PV mutant in comparison to ∆21 at increasing GTP 
concentrations as indicated in the X-axis. The derivative of the Tmapp at different GTP 
concentrations is plotted. C) Gel image of the products of RNA synthesis by ∆21 and PV 
mutant at three enzyme concentrations along with increasing GTP concentrations. 
LE19P was the template and GTP was included at 0.01, 0.05, 0.1, 0.2 and 0.5 mM while 
ATP and UTP were at 0.1 mM along with 33 nM of (α -32P) CTP. Gel image of the 
products of RdRp assay of ∆21 and PV mutant at 120 nM concentration with increasing 
GTP concentrations (0.01, 0.05, 0.1 and 0.2 mM GTP, as represented by the grey 
triangles). The fold increase in de novo initiation activity of different concentrations of 
∆21 and PV mutant when GTP was increased from 0.01 mM to 0.2 mM are shown at the 
bottom of the gel image. 
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significantly, whereas there was no significant rescue of de novo initiation by the PV 
mutant; the de novo initiated product in the reaction with 200 µM GTP was two-fold that 
of the reaction with 10 µM for ∆21, but could not be determined for PV (Fig. 32C, 
leftmost panel).  
The PV mutant did respond to GTP starting at 50 nm and the increase was more 
obvious with 120 nM enzyme (Fig. 32C). Altogether, these results suggest that the 
allosteric GTP binding site is required for optimal de novo initiation while the PV 
mutant retains the ability to respond to GTP, likely through the NTPi substrate binding 
site.  
Reconstruction of RdRp dimers. All of the characterizations so far show that that there 
are complex interactions and conformational changes associated with even RdRps that 
have a single amino acid change and with the mode of RNA synthesis. The dynamic 
nature of the RdRp will make it a challenge to define all of the changes necessary for 
RdRp function, especially by X-ray crystallography. However, 3D reconstruction from 
negative-stained particles obtained by EM can inform us about major changes in protein 
conformation. This approach has already been used to define conformations of larger 
molecules such as ribosomes, GroEL, and innate immune receptors (213-215). With the 
immune receptors, we have determined that ligands can induce dramatically different 
conformations, including oigomerization (214-215).  
    To capture the de novo initiation-competent structure, we first collected over 3000 
individually selected dimers/oligomers of ∆21 from negative-stained electron 
micrographs. However, the final models generated did not yield a good match to the 
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class averages of the data set and the Fourier transform over the eight rounds of 
refinement showed that convergence was suboptimal (data not shown). Therefore, we 
analyzed several other mutant RdRps and found that mutant I432V was a good choice 
for reconstruction. The I432V substitution was originally identified in Huh7 cells in a 
mutant HCV replicon that was resistant to Cyclosporin A and subsequently shown to be 
better at de novo initiation than the WT ∆21 especially at higher enzyme concentrations 
((144) and Fig. 33A, 33B). Finally, the dimensions of the I432V particles were more 
homogenous than that of ∆21 especially measured in absence of GTP (compare Fig. 33C 
and 33D). The I432V mutant was thus selected for single particle reconstruction of a de 
novo initiation-competent HCV RdRp.  
  Over 4000 dimer-like particles of I432V without GTP and with GTP were picked 
and sorted into class averages. The particles selected had a good coverage of the 
potential orientations, as determined by their distributions in the asymmetry triangle 
(Fig. 34A and 34E). The class averages generated are shown in Fig. 34B and 34F. 
Several initial models were selected and used for reconstructions without symmetry and 
with C2 symmetry and the resulting models were congruous but the model generated 
with C2 symmetry had higher resolution. They are shown in Fig. 34D. The final model 
for the complex was at 19 Å resolution without GTP and 16 Å with GTP. The I432V 
molecule has the density set to the mass of 130 kDa (the mass of a ∆21 dimer) and 
reveals a central channel with a width of 16 Å that could accommodate RNA (Fig. 34D).   
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Figure 33. Selection of I432V for reconstruction of dimeric RdRp molecules. A) The 
location of I432 in relation to the ∆1 loop (cyan ribbon) on the thumb domain of HCV 
RdRp (PDB ID 1QUV). The active site residues are in yellow. B) Comparative increase 
in de novo initiation activity by I432V versus ∆21 and E18R at increasing enzyme 
concentrations as indicated. The assays were performed with LE19P and PE46 as 
described in Fig. 3D. Quantification- The activity at different enzyme concentrations 
was normalized and compared to that at 20 nM enzyme concentration and plotted as 
percentage values. I432V shows a higher increase in de novo initiation at 120 nM from 
that at 20 nM compared to other two enzymes. C) Distribution of dimensions for Δ21 
with and without GTP. D) The distribution of dimensions for I432V with and without 
GTP. The dimensions in both C and D were taken from the class averages generated 
with no presumed symmetry. The maximum and minimum dimensions for each of the 
class averages were measured and plotted max vs. min (in top panels in C and D) and the 
maximum dimension against number of particles in each class was plotted in bottom 
panels. 
 
 
 
 
 
 
 
 
 
116 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 34: Single particle analysis and reconstruction of I432V dimers in presence and 
absence of GTP. A) Asymmetry triangle showing distribution of orientation of the 
particles that constitute the model for I432V dimers. B) Class averages as generated for 
I432V dimer complex with no presumed symmetry using EMAN’s refine2d command.  
C) Fourier shell correlation showing the convergence of the final model for I432V to 19 
Å as per 0.5 σ criterion. D) Different orientations of the final model for I432V dimers 
(grey).  The model measures 71 Å x 95 Å with a groove of about 16 Å.  E) Asymmetry 
triangle that shows the particle orientation for the final model of I432V dimers in the 
presence of GTP. F) Class averages for I432V dimers complexed with GTP with no 
presumed symmetry (see materials and methods). G) Fourier shell correlation for I432V 
dimers with GTP showing that the model has converged to 16 Å resolution. H) Different 
views of the final model for I432V dimers + GTP complex (yellow). The model has 
dimensions of 71 Å x 90 Å. 
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However individual monomers were difficult to be delineated in the models due to a 
possible combination of extensive interactions between the monomers and/or a low 
resolution. Interestingly, in the presence of GTP, the densities over the central channel 
closed and the central channel became more constricted (Fig. 34H), showing that a 
conformational change can reconfigure the central channel in the dimeric RdRp.  
 
DISCUSSION 
      Many viral RdRps need to initiate genomic RNA synthesis de novo from the termini 
of their RNA genomes in order to avoid the loss of genomic information. This 
mechanism is fundamentally different than that of DNA-dependent polymerases and 
may ensure the specificity of synthesis from viral templates. In this report, we show that 
factors, such as GTP, and interactions between intermolecular subunits of a higher order 
complex can modulate the conformations of the HCV RdRp and influence the mode of 
RNA synthesis. We demonstrated that highly purified ∆21 is present as a polydisperse 
and heterogeneous protein using multiple spectroscopic, gel-based, and imaging assays. 
Our results further highlight the roles of the ∆1 loop, the thumb domain, and the 
allosteric pocket within this domain in contributing to de novo initiation, although our 
results suggest that the ∆1 loop and thumb interactions may be more important for 
assembling initiation complexes rather than the proposed clamping movement of the 
polymerase on the template during elongation (56, 69). In support of this idea, mutations 
in the ∆1 loop and the associated thumb domains did not adversely affect primer 
extension from short RNA templates.  
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  The conformational changes in viral RdRps are just starting to be defined. 
However, it is important to put this in the context of RNA-dependent RNA synthesis.  
RNA synthesis by an RdRp in vitro can be divided into discrete steps: 1) formation of 
productive initiation complexes (de novo initiation or primer extension complexes), 2) 
formation of the first or first few phosphodiester bonds, and 3) elongation of the stable 
primer along the template. The first two stages are rate limiting and are collectively 
called as initiation events. The Km values for NTPs for initiation nucleotides are 
significantly lower for elongation than initiation (71, 88) consistent with the idea of a 
conformational change in the RdRp between initiation and elongation in RNA synthesis. 
  The template channel in ∆21 seems to be a region whose dimensions can change 
depending on enzyme concentration and the presence of NTPs. This will have a direct 
effect on the initiation events in RNA synthesis. A recent report has shown that the 
degree of ‘closedness’ of the enzyme depends on the amino acid composition in the 
thumb domain (64). This implies that a weak ∆1 loop and thumb domain interaction will 
result in inefficient de novo initiation (64) but efficient primer extension, at least from 
short RNA templates (Chapter III). In this work, we propose that the interactions 
between RdRp subunits can promote the de novo initiation in a manner that involves the 
∆1 loop and the thumb domain. 
          A dimer and/or an oligomer of the HCV RdRp being the state for active RNA 
synthesis was proposed by Qin et al., (75) and Wang et al., (76). Wang et al., (76), 
showed the presence of two broad interacting interfaces in the thumb region of one 
molecule and the finger region of another molecule. However, Cramer et al. (211), 
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reported that a monomeric RdRp is active. This difference may be a matter of the 
sensitivity in detecting the de novo initiated products since we show that the HCV RdRp 
could exist in an array of conformations and/or oligomeric states, even at the nanomolar 
enzyme concentrations used in this study. Proper contacts between RdRp subunits may 
cause the conformational changes that will result in productive de novo initiation 
complex assembly. Our results from the addition of m26-30 and E18R to increase de 
novo initiation by ∆21 (Fig. 29, and 30) provide further support for this hypothesis.  
          The regulation of the HCV RdRp seems to be concentrated at the location where 
the ∆1 loop is interacting with the thumb subdomain. This is an elegant mechanism 
where a flexible loop is used to facilitate changes in polymerase 
structure/oligomerization state. Our results show that E18 and residues 26-30 in the ∆1 
loop are key residues for proper function. Furthermore, the allosteric site in the thumb 
domain and also NTPs (we did not find a specific effect of GTP) could help to maintain 
the proper conformation for de novo initiation. All of these residues are required in vivo 
for replication of HCV subgenomic replicons in hepatoma cells (148, 216).   
          Residue I432 may modulate RdRp conformation through its interaction with the 
∆1 loop. I432V can confer Cyclosporine A resistance to HCV (141, 172), suggesting 
that the role for the cellular Cyclophilins is likely to be to modulate conformational 
changes and possibly the oligomerized states of the RdRp. This role is consistent with 
the need for the active site of Cyclophilin A (protein isomerases) being required for 
HCV replication (142). Therefore, while we have performed biochemical studies, the 
residues that are important in vitro are linked to requirements for HCV infection.  
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           Doubtless, these quasi-stable RdRp conformations could be influenced by the 
sequence of the HCV protein (64, 217), some buffer components, other HCV replicase 
subunits, the membrane environment, and/or the template RNA. The HCV replicase has 
consistently been reported to contain endogenous RNA that cannot be dissociated 
without loss of activity (218-221). Stable binding to the RNA may be of advantage to 
prevent the recognition of HCV replication intermediates by the host innate immunity 
receptors. Contact between the oligomerized polymerase subunits has been reported to 
increase the cooperativity in RNA synthesis in poliovirus 3Dpol (222-223), and more 
recently, for the Norovirus RdRp (206). Another proposal is that the interface contacts 
between poliovirus 3D polymerase monomers (thumb interface) and the poliovirus 3C 
protease could affect RNA synthesis through regulating protein-priming (224). While the 
mechanism needs to be examined further, it is clear that higher order structures of viral 
RdRps and associations with other viral proteins will be a general theme in viral RNA 
synthesis (191, 204, 225). Finally, it is interesting to note a difference between viruses 
that use a polyprotein processing mechanism (including HCV) and viruses that use 
different RNAs to express the replication proteins. The former class of viruses should, 
theoretically, have more comparable stoichiometries of all the viral proteins. In contrast, 
viruses that use distinct RNAs to express the replication proteins could have 
dramatically reduced expression of the RdRp without affecting the overall level of RNA 
synthesis (226-227). These two strategies will certainly allow selection for additional 
activities of the RdRp (such as binding of pRb) as well as distinct ways to deal with the 
host’s innate immunity mechanisms. 
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CHAPTER V 
 
CONFORMATIONS OF THE MONOMERIC NS5B: AN EM APPROACH* 
 
 
 
INTRODUCTION 
 
          The nonstructural proteins required for HCV replication are important therapy 
targets in HCV. The HCV RNA-dependent RNA polymerase, NS5B is also one of the 
best characterized RdRps from positive-strand RNA viruses (35, 78). In vitro, NS5B is 
usually expressed without the C-terminal 21 residues to improve its solubility. The 
majority of the work in the Kao laboratory is with the RdRp from the 1b genotype of 
HCV. The structure of the 2a RdRp has also been recently reported (64). The vast 
majority of the 1b RdRps and the 2a RdRp form a structure that resembles a closed right 
hand, with thumb, palm, and finger subdomains. The metal coordinating residues in the 
RdRp active site are in the palm subdomain that is usually shielded by extensive thumb-
finger interactions (56-57). The closed conformation in absence of template is in contrast 
to the DNA-dependent RNA polymerases, which can transition from an open to a closed 
complex upon template recognition (205).  
          A major influence in the models for viral RNA-dependent RNA synthesis comes 
from the ternary structure of the phage φ6 RdRp (68). 
*This work has been accepted by Virus Adaptation and Treatment as “Conformations of 
the Monomeric Hepatitis C Virus RNA-dependent RNA Polymerase”, by Chinnaswamy, 
S#., Ayaluru, M. #, Cai, H.,  Yi, G.,  Palaninathan, S., and Kao, C. C. (# equal 
contributors) (currently in press). 
 
 
 
 
122 
 Like the HCV RdRp, the φ6 RdRp forms a closed structure with a defined template 
channel. Both template channels are too narrow to accommodate the partially duplexed 
RNA that must form during RNA synthesis, indicating that the RdRp needs to transition 
to a more open conformation after initiation of RNA synthesis (Chapter III). Consistent 
with a need for a change in conformation, a partially open conformation was also solved 
by X-ray crystallography and revealed significant reconfiguration of the secondary 
structure in the region where the finger domain interacts with the thumb domain (60). 
          Mutations that affect the interaction between the ∆1 loop and the hydrophobic 
residues that it contacts have resulted in polymerases that can perform primer extension 
but not de novo initiation from short RNA templates (Chapter III).   
    The open and closed structure transition in vivo may allow or be influenced by 
cellular proteins. The HCV RdRp is reported to interact with the tumor suppressor 
Retinoblastoma (pRb) protein, to manipulate the cell cycle and cause its degradation (22). 
The L-X-C/N-X-D pRb binding motif overlaps with the metal-coordinating residues of 
the HCV RdRp. Therefore unless the RdRp adopts a more open conformation the pRb 
binding motif will remain inaccesible. The cellular protein Cyclophilin, could also 
interact with the HCV RdRp to affect its ability to bind RNA, perhaps through a change 
in NS5B conformation (144). 
          We seek to better understand how the HCV RdRp conformations relate to RNA 
synthesis. This type of analysis will contribute to the mechanism of action of viral 
RdRps and provide new insight into conformation-specific drug targets. X-ray 
crystallography is difficult for the analysis of the flexible conformations.  We used 
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electron microscopy and single particle reconstruction to capture semi-stable states of 
the HCV RdRp. In addition, reconstruction of a mutant version of the HCV RdRp 
lacking the tip of the ∆1 loop resulted in a primarily open conformation. These results 
confirm the role of the ∆1 loop in conformational change in the HCV RdRp. Analysis of 
the residues in the ∆1 loop and the thumb domain identified several conserved 
interacting residues and differences in the interactions that formed the closed 
conformation of the 1b and 2a RdRps. 
 
MATERIALS AND METHODS 
Production of the HCV RdRp. The detailed procedures are described in Chapter IV, 
Materials and Methods. The preparation used for DSF assay was purified through the 
poly-U agarose column (see Chapter III, Material and Methods) after the initial Ni-
column purification step. 
Gel filtration. Analytical gel filtration used a Superdex-200 HR column (GE Healthcare) 
equilibrated with the running buffer (50 mM Tris pH 7.5, 100 mM KCl or 500 mM KCl 
as indicated, 5% Glycerol and 1 mM ΒΜΕ). The fractions obtained were analyzed by 
SDS-PAGE. The column was calibrated with MW standards (BioRad Inc): bovine 
thyroglobulin (670 kDa), bovine γ-globulin (158 kDa), chicken ovalbumin (44 kDa), 
horse myoglobin (17 kDa), and Vitamin B12 (1.35 kDa). 
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HCV RdRp assays. RNA synthesis by the HCV RdRp used a 19-nt template named 
LE19, which measures several RNA synthesis activities in one reaction (88): de novo 
initiation, primer extension, template switch and non-templated nucleotide addition. The 
RdRp reactions are as described in Chapters III and IV, Materials and Methods, except 
that the α-32P-CTP was at 33 nM and NS5B concentrations are as specified in the 
legends. The buffer in the RdRp assays includes 20 mM sodium glutamate (pH 8.2), 
12.5 mM dithiothreitol , 4 mM MgCl2, 0.5% (v/v) Triton X-100, 20 mM NaCl  and 1 
mM MnCl2.  
Differential scanning fluorimetry. Differential scanning fluorimetry utilized a Stratagene 
MX3005P Real-time PCR machine as described reference (144), and in Chapter 4, 
Materials and Methods. 
Electron microscopy and image reconstruction. The proteins were adjusted to ~1 ng/µL 
in buffer containing 50 mM Tris pH 7.5, 100 mM NaCl and 1 mM ΒΜΕ, adsorbed to 
freshly glow-discharged carbon coated copper grids (EMS), and stained with uranyl 
acetate (1% w/v aqueous solution). Electron microscopy was performed using either a 
JEOL 1200 transmission electron microscope operated at 100 kV or the JEOL 1010 at 
80 kV. Micrographs containing the proper spread of the particles taken using the JEOL 
1200 instrument were digitalized using an Epson Projection 3200 scanner at 1200 dpi, 
corresponding to 3.7 Å/pixel at the specimen level. Images from the JEOL 1010 were 
collected with a CCD Camera (4K X 4K) and the micrographs were taken at 50 K 
magnification with an effective 2.35 Å/pixel at specimen level. 3D reconstruction of the 
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single particles used the EMAN software package (213) with a Linux operating system 
as described by Sun et al. (215).  
          Individual particles of the HCV RdRp were selected using the BOXER routine, 
filtered, and centered. Class averages were generated without imposing any symmetry. 
Centered particles (about 38,000) were subjected to the Multirefine program to sort the 
particles among five models. The initial models used for the multirefinement process 
were generated from the HCV RdRp crystal structure (pdb: 1quv) with different noise 
levels to decrease constraints in the conformations. Particles from each of the models 
were collected separately and subjected to additional single model refinement to improve 
the convergence of the data set to the model. The reconstructions were iteratively refined 
until the structure was stable as judged by Fourier shell correlation (FSC). The 
convergence was examined by comparing the projections of the model with 
corresponding class averages. A molecular mass of 65 kDa was used for the surface-
rendering threshold of the 3D structures of the monomers. 3D reconstructions were 
visualized using the UCSF Chimera software package (208). 
Molecular modeling of m26-30.  A crystal structure of the wild-type HCV-RdRp (Protein Data 
Bank code 1QUV) was used to construct a m26-30 model with Modeler (Insight II; Accelrys). In 
this model, residues 26-30 of the ∆1 loop deletion were substituted with glycines since the 
program does not allow deletions. The model was then subjected to a medium to high level of 
simulated annealing optimization with respect to the variable target function of Modeler with an 
effective radius parameter of 10-20 Å. The final model was selected based on visual inspection 
and its best fit to the most open EM map using UCSF chimera. 
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Analysis of HCV sequences. All the sequences in analysis were extracted from HCV 
Sequence Databases (NIH). Then the residues of ∆1loop involving in interaction with ∆2 
loop and thumb subdomain were chosen by PIC webserver (228). 
 
RESULTS 
HCV RdRp exists in multiple conformations or oligomeric states. Several models for 
HCV RNA-dependent RNA synthesis currently exist in the literature. Some researchers 
proposed that a monomer of RdRp is the form that carries out RNA synthesis (68, 211, 
224). Others have shown that oligomers of several viral polymerases can cooperatively 
interact with RNA and that there are two surfaces for RdRp-RdRp interactions that can 
promote the formation of active scaffolds for RNA synthesis (74-76, 206, 222-223, 229). 
It is likely that both forms will contribute to aspects of HCV replication, either directly, 
or through interaction with other viral and cellular factors.  
          A highly purified preparation of HCV RdRp free from contaminating RNAs will 
be necessary to understand HCV RdRp conformation. Our preparation of the HCV ∆21 
protein is highly active for RNA synthesis, more than 98% pure, and soluble at 
concentrations in excess of 10 mg/ml. There is also no contaminating ribonuclease as 
determined by the optical density of the preparations and attempts to stain the 
preparation with silver. When examined by using gel-filtration chromatography using a 
Superdex-200 column (GE healthcare) at a 100 mM monovalent salt concentration, ∆21 
was present in various mass/conformational states (Fig. 35A), with the first peak that 
eluted at a position that corresponded to molecular mass markers of ~40 kDa (∆21 is ~65 
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kDa) and other peaks being less than 30 kDa when compared to the molecular mass 
markers. This is likely due to interactions of the protein with column matrix. SDS-PAGE 
of the different column fractions from the same gel confirmed presence of ∆21 in all 
fractions suggesting that there are likely to be proteins with different masses or 
conformations in the preparation. However, when the same preparation was run under 
similar conditions, with 500 mM monovalent salt in the buffer, ∆21 behaved more like a 
homogenous protein with a single peak eluting at ~50 kDa (Fig. 35A). This further 
confirms that the oligomeric and the conformational state of the protein is dependent on 
the salt conditions in the buffer, in line with DLS results (Chapter IV, Results) and the 
report by Cramer et al. (211). Should the HCV RdRp assume alternative 
conformations/mass states, a DSF assay that measures the denaturaion profile of proteins 
should detect these changes (212) (see Chapter III, Materials and Methods). Since the 
∆21 purified through the Mono-S column showed a single denaturation curve (see 
Chapter IV, Results) a ∆21 that was purified through the poly-U agarose column was 
used at different protein concentrations. At low protein concentrations, ∆21 had a rather 
broad denaturation profile, consistent with the protein existing in multiple 
conformations. With two- or four-fold increases in the concentration of ∆21, at least two 
populations of proteins with distinct Tmapps can be discerned (Fig. 35B). These results 
suggest that the oligomerization states of the HCV RdRp and/or significant changes in 
conformation can be manipulated by its concentration (Fig. 35B).  These results also 
indicate that any analysis of the HCV RdRp will have to take into account the changes in 
the RdRp oligomerization state and conformations. 
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Figure 35: Gel filtration and DSF assay of ∆21. A) About 100 µg of ∆21 purified on Ni-
column and Mono-S column was injected into a Superdex-200 column and 
chromatography was performed at a flow rate of 0.25 ml/min while the elution was 
monitored by absorbance at 280 nm. The ∆21 at 100 mM KCl showed multiple peaks 
hence all the fractions were analyzed by SDS-PAGE to check for the presence of the 
protein (fraction numbers at bottom of gel). B) ∆21 that was purified through Ni-column 
and poly-U agarose column was subjected to DSF assay (see Chapter 4, Materials and 
Methods) at 1, 2 and 4 µM concentrations (indicated as 1X, 2X and 4X respectively). 
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RNA synthesis by the HCV RdRp. RNA synthesis assays which used template named 
LE19 that can report on both de novo initiation and primer-extension in the same 
reaction was used to quantify the 19-nt product of de novo initiated and terminated 
RNA, and the 32-nt product generated by elongation from a primed template. Other 
products in the reaction are ones with terminal additions to the template (20-nt and 21-
nt) that are usually of low abundance, and the more prominent template switch products 
that are multimers of 19-nt in length ((181), Fig. 36A). These last two classes of 
enzymatic activities are likely minor in importance in vivo when compared to de novo 
initiation and primer extension.  
          We examined whether RdRp concentration and the associated changes in 
conformation/oligomerization states will correlate with the mode of RNA synthesis.  
When a range of ∆21 concentrations for RNA synthesis was used, different requirements 
for de novo initiation and elongation were observed (Fig. 36B). The primer extended 
product was more prominent at the lower RdRp concentration and inhibited at the higher 
enzyme concentrations (Fig. 36B). The opposite trend was observed with the de novo 
initiated product. These results suggest that lower ∆21 concentrations favored extension 
from a primed template (akin to elongation) while the higher order structures favored de 
novo initiation. To confirm the effects seen with LE19, we used a 1:1 combination of 
LE19P and PE46. LE19P can direct the synthesis of only the 19-nt de novo initiation 
product but cannot give rise to the 32-nt primer extension product and also cannot be 
efficiently used for template switching. The 3’ terminus of PE46 can be extended to 
form a complete hairpin of 46-nt. In a reaction with a range of ∆21 concentrations, we 
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Figure 36: Concentration dependent RNA synthesis by ∆21. A) Schematic of secondary 
structure and depiction of the two primary modes of RNA synthesis directed by the RNA 
template LE19 by the HCV RdRp: de novo initiation and primer extension. B) RNA 
synthesis from template LE19 RNA by increasing concentrations of ∆21. Final 
concentrations of ∆21 were at 78, 96, 192, 384 and 780 nM in lanes 1-5. The enzyme 
was incubated with LE19 (50 nM) for 5 min. before initiating the RdRp reaction by 
adding NTPs and radiolabeled CTP in a solution containing divalent metal ions as 
described in the Materials and Methods. After incubating the reaction components at 
25oC for 1 h, the RNA was extracted with phenol-chloroform and ethanol precipitated 
before running the products in a 20% urea denaturing polyacrylamide gel. The gel was 
subjected to autoradiography and phosphorimaging (GE Healthcare). The 19-nt de novo 
initiated (De novo) and 32 mer primer-extension products (PE) generated from template 
LE19 are identified to the left of the gel image. C) Effect of increasing concentration of 
∆21 in RNA synthesis with LE19P or PE46. ∆21 was used at 10, 20, 40, 80, and 160 nM 
in reactions 1-5.  In both panels B and C, the de novo initiated and primer-extension 
products are labeled to the left of the gel image to facilitate interpretation of the results.  
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again observed that the primer extension product was produced in larger amounts at the 
lower ∆21 concentrations while de novo initiation increased with ∆21 concentration 
(Fig. 36C).  These results suggest that if the monomer of ∆21 participates in viral RNA 
synthesis, it is in elongation from a nascent template-primer duplex. The oligomerization 
state for de novo initiation will be examined in a separate work. This manuscript will 
focus on the monomeric forms of ∆21.  
Electron microscopy and single particle reconstruction. We seek to visualize the  ∆21 
monomers and determine their shapes and visualize any changes in conformation. A 
method appropriate for this analysis is the single particle reconstruction of proteins 
stained with uranyl acetate. Oligomeric states and conformational changes for innate 
immune receptors in the absence and presence of ligands were captured using this 
method (214, 230). To enrich for the monomers, a concentration of 1 ng/uL was 
empirically determined to give a good spread on the EM grids (Fig. 37A). Over 200 
micrographs were used to collect over 38,000 well-separated particles. We note that the 
particles represent different views of proteins as they land on the grid as well as possible 
oligomers. The particles were then centered and subjected to sorting using the 
Multirefine function of the EMAN suite of programs. We initially designated eight 
subgroups for the sorting of the particles, but inspection of the results showed that three  
of the groups were nearly identical to three others. Therefore, we reduced the number of 
classes to five for 3D model building. To examine whether the sorting was reasonable,  
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Fig. 37. Analysis of single particles of ∆21 by electron microscopy. A) A sample 
image of the micrographs used for the picking of single particles. Some of the particles 
may represent monomers, dimers, and higher order oligomers. However, it is also 
possible that the particles may land in various orientations on the carbon grid.  The scale 
bar used in the imaging is shown at the lower right corner. B) Size distribution of all of 
the single particles for the HCV RdRp used for 3D image reconstruction and the 
distributions for the five models of the ∆21 monomer. More than 40,000 particles were 
individually picked for this analysis; 36,000 represent the five minimal classes of 
monomers as sorted by the multirefine program of EMAN. Each of the five sets of 
monomeric particles was used to generate class averages for image reconstruction. Each 
spot in the scatter plot depicts the longest and shortest dimensions (in angstroms) for 
each of the class averages. The bar graph shows the number of particles present in each 
class average. The total number of the particles used to generate each of the models is 
shown in parentheses.  
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we took measurements of the shortest and longest dimensions for each of the subclasses 
from the five models and plotted the two dimensions in the graphs shown in Fig. 37B. In 
the lower panel, we used   a histogram to show the number of particles within each 
subgroup.  While the entire collection of particles had a wide distribution (left-most 
plot), it is clear that the subgroups within each of the five models are more closely 
clustered, providing some confidence for the sorting of the subclasses.   
          Three dimensional reconstructions without presumed symmetry were performed 
for all five models. After the standard two sets of eight refinements, all five models 
converged to a resolution of 20-23 Å (Fig. 38). The final 3D models match well with the 
projections shown in the class averages, providing some confidence for the models.  
Interestingly, the five models ranged from those that are in a structure which is more 
closed relative to the X-ray structure (models 1 and 3), to ones similar to the X-ray 
structure (model B) and to two forms that appear to be more open (models 4 and 5).  The 
more closed form may explain the elution of ∆21 at a smaller molecular mass in the gel 
filtration column. These models offer a snapshot of the quasi-stable conformations that 
the HCV ∆21 can assume in solution.  
Conformation of m26-30. We hypothesize that the open and closed conformation of ∆21 
is due to the loss of interaction between the ∆1 loop and the hydrophobic residues that it 
contacts. To gain evidence in support of this model, we sought to reconstruct the  
3D structure of the m26-30 mutant protein, which lacks five residues in the tip of the ∆1 
loop. Electron micrographs confirm that the majority of the particles in the m26-30 
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Figure 38. Data used to construct the five models depicting different conformations of 
the ∆21 monomer. Panels A-E all contain the class averages generated for each of the 
five monomer models, the asymmetric triangles that depicts the coverage of all of the 
views in each model, a Fourier shell correlation plots showing the convergence of the 
eight rounds of model refinement. The final calculation of the structures, and two views 
of the model are shown as electron density shells in grey. 
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preparation are also more homogenous than the particles of ∆21 (Fig. 39A).   
          We selected ~4000 particles from over 20 micrographs and used the EMAN 
program to generate a three-dimensional model. The class averages suggest that the vast 
majority of the particles are monomers and belonged to one model (Fig. 39B). The 
reconstruction of m26-30 was achieved in two independent trials using different data 
sets and yielded the same models between 18 and 20 Å resolution (Fig. 39C and data not 
shown). The particles selected were a good representation of the different views of the 
final reconstructed model (Fig. 39E), giving confidence to the validity of the model 
(compare the model in Fig. 39E to the class averages in Fig. 39B).   
          Protein m26-30 was predicted to exist in a predominantly open conformation 
based on preferential binding to dsRNA (Chapter III, Results). Putative thumb, finger, 
and palm subdomains can be appreciated in the model (Fig. 39E), and the exposed 
template channel has a width of 36 Å at the most constricted juncture, a feature 
compatible with the ability to bind dsRNA. To facilitate a comparison, the shape of the 
RdRp determined by X-ray crystallography (pdb: 1QUV) is shown in Fig. 36F. To 
explore further the arrangement of the subdomains, we attempted to fit the electron 
density of m26-30 to the existing atomic resolution structures and found that none 
matched with the extra protrusion observed in the model. 
         However the typical closed form of RdRp can generally fit into the rest of the 
electron density for m26-30. In Chapter III a simulated annealing model of RdRp was 
generated (see Chapter III, Results), which depicted a slightly open conformation with 
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Fig. 39.  3D reconstruction of the m26-30 monomer. A) A sample micrograph of the 
m26-30 protein used for single particle reconstruction. B) Class averages of the ca. 4000 
particles picked for this analysis.  C) Fourier Shell Correlation of the refinement process 
and EOTEST showing that the resolution of the converged m26-30 structure was at 20 
Å. D) An asymmetric triangle showing the distribution of the particles. E) Three views 
of the model of the m26-30 molecule. The EM envelopes of the reconstructions are 
shown. F) Model of a closed form of HCV RdRp intended to illustrate the difference 
between the open conformation of m26-30 and the closed conformation of the HCV 
RdRp. The surface residues that are acidic are shown in red and the basic ones in blue. 
G) Docking of the molecular model generated from the crystal structure of the HCV 
RdRp into the electron density of m26-30.  Two views that differ by 180o are shown. 
The ribbon structure of the HCV RdRp was generated by replacing residues 26-30 of the 
HCV crystal structure (pdb 1quv) with glycines and then calculating the lower energy 
state of the resulting molecule. The altered ∆1 loop is shown in yellow.  
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an unfolded ∆1 loop and flexibility of the nearby helices. To improve the fit, additional 
models were generated by varying the annealing temperature and effective radius for the 
structures of ∆21 using initial manual fitting followed by further refinement using the 
Mapfit option of Chimera (UCSF). Two views of the best fit between the calculated 
structure and the m26-30 3D model are shown in Fig. 39G. The correlation of the final 
fit is ~70 %. Based on the map, it seems that the fingertip region has completely moved 
away from the thumb helices while the simulated model represents an intermediate 
position in this movement of the loop region. There may even be changes in the 
secondary structure(s) as observed by Biswal et al., (2005) (60) that may account for 
some portions of the two molecules not fitting better. These results show that single 
particle reconstruction can be used to identify conformational states of the HCV RdRp 
that are difficult to capture by X-ray crystallography. This is partly confirmed in Fig. 40, 
where we compare the conformations of the five states for the ∆21 monomers and the 
open conformation of m26-30 along with the dimensions of the X-ray structures of a 1b 
RdRp.  
Residues involved in the regulation of the open and closed RdRp conformations. The 
reconstruction of the m26-30 structure is consistent with findings in Chapter III  
showing that the ∆1 loop is involved in the regulation of the open and closed 
conformations. Recently, the crystal structure of the HCV genotype 2a RdRp was solved 
and also shown to be capable of more de novo initiation than the 1b RdRp (64).  The 
increase in de novo initiation is likely due to formation of a more closed conformation. 
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Figure. 40.  A compilation of the conformations of the monomers reconstructed or 
reported in the crystal structure for the HCV RdRp.  The crystal structures are shown 
with higher resolution electron density structures along with their associated pdb 
numbers.  The dimensions for each of the particles were measured using Chimera.  
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The analysis of the RdRp conformations above suggests that changes in the 
interaction between the ∆1 loop and the regions that it contacts could be partially 
responsible for the differences in de novo initiation. To better understand these 
interactions, the sequences of the ∆1 loop of more than 230 1b and 12 2a HCV strains 
were analyzed to determine which residues in the ∆1 loop are conserved for interactions. 
Interestingly, a highly conserved portion included residues 26-35 which involves the 
helix-A in the ∆1 loop (Fig. 41). In addition, the sequences close to where the ∆1 loop 
originated from the finger domain (residues 10-18 and 40-45) were also more conserved 
(residues 12-18 and 40-45).  We also note that the acidic or basic residues, E17, E18, 
R32, H34, and R43, tended to be highly conserved.  With regard to a comparison 
between the 1b and the 2a ∆1 loops, the 2a ∆1 loop contained a Glu at position 19 
(whereas a serine or threonine existed for the 1b RdRp) and a Lys at position 36 where 
Met or Leu normally existed in other HCV strains.  The 2a ∆1 loop thus has two 
additional charged residues when compared to the total HCV isolate.  This analysis 
prompted us to more closely examine how the residues in the ∆1 loop could interact with 
the residues in the thumb domain. We first used the PIC Webserver (228) program to 
predict the locations of potential bond forming partners within the ∆1 loops of the 1b and 
the 2a RdRps (Fig. 42A). As would be expected, a number of interactions are predicted 
in both the ∆1 loops of the 1b and the 2a RdRps.  Both contained a number of 
interactions within the short α-helical  
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Figure 41. Sequence alignment of ∆1-loop region of NS5B found in the different isolates 
in the HCV database (NIH). The program WebLogo, (University of Californaia, at 
Berkeley) (231) was used to generate the alignment. The length of the one-letter name of 
the amino acid indicates the degree of conservation. The number of sequences used for 
each analysis is shown in parenthesis under the HCV genotype.  N-amino terminus, C-
carboxy terminus. 
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region, as well as between the two termini of the loop as they emerged from the finger 
domain.  In addition, a number of additional interactions (highlighted in red, Fig. 42A, 
right panel) are seen with the 2a ∆1 loop. Next, we examined for possible interactions 
between the ∆1 loop and the rest of the RdRp.  The ∆1 loop had interactions with the 
thumb subdomain and with the ∆2 loop. However, the interaction with the thumb 
subdomain was found to be critical in maintaining a closed structure required for de 
novo initiation.  In addition, we observed that there are several new interactions within 
the ∆1 loop of the 2a RdRp with the ∆2 loop. Of special interest is the interaction 
between the Glu19 and Lys154, which adds a sidechain-sidechain hydrogen bond 
interaction that should be of interest for future analysis for the basis of the interactions 
that promote de novo initiation (Fig. 42B).  A detailed summary of the interactions in the 
∆1 loops of the 1b and the 2a RdRps with the thumb subdomain and the ∆2 loop are in 
Table 2.  
          There are several key residues in the interactions between the ∆1 loop and the 
thumb domain.   In the thumb domain, a key sidechain-sidechain interaction between 
E18 and R401 is conserved between the two genotypes of HCV RdRps. Several thumb 
residues also participate in multiple conserved interactions, including W397 (interacting 
with L21, P22, and V37, and A39 in the 1b RdRp), and A396 and L492 that participate 
in multiple, primarily hydrophobic interactions with the residues in the ∆1 loop.  In the 
∆1 loop, I11, L21, P22, L30, L31, Y38 and V37 anchor a set of hydrophobic 
interactions. We note that the 1b RdRp also has M36 involved in hydrophobic 
interactions while this residue was replaced with a K36 in the 2a RdRp. 
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Figure 42. Analysis of the HCV RdRp sequences involved in the formation of the open 
or closed structures. A) Predicted interactions within the ∆1 loops for the 1b and 2a 
HCV RdRps. The key to the interactions are shown at the bottom of the figure.  The 
residues highlighted in yellow are the ones that are at the tip of the ∆1 loop and contain a 
short a-helix.  C) The interactions between the ∆1 loops of the 1b and 2a RdRps with the 
thumb subdomain (residues highlighted in yellow) and the ∆2 loop.  Both the ∆1 and the 
∆2 loops have been splayed to allow the interactions to be shown more clearly.   
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Table 2: Summary of intraloop interactions within the ∆1-loop of HCV NS5B (genotype 
1b) 
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Table 2, Continued: 
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Table 2, Continued: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Altogether, while most of the interactions between the ∆1 loop and the thumb are 
conserved in the two RdRps, there are sufficient differences in the 1b and the 2a HCV 
RdRps that could account for the altered conformational changes that could result in an 
increase in de novo initiation by the 2a RdRp.  
 
DISCUSSION 
          Viral RNA replication and transcription products are recognized by the host innate 
immunity receptors to signal a viral infection (232). Therefore, there should be strong 
selectional pressure to regulate viral RNA synthesis both in terms of timing, and the 
types and amounts of the replication and transcription products. A likely regulatory step 
is the conformations of the polymerase that is required for initiation and elongation. In 
Note: Residues in blue denote mutations to 
similar amino acids 
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this work, we provide evidence to show that ∆21 exists in multiple conformations and 
that the interaction between the ∆1 loop and the residues that it contacts can provide 
regulation for the resulting conformations. This evidence includes low-resolution 
structures of the monomeric HCV RdRps and the open conformation formed by a mutant 
RdRp with a short deletion in the ∆1 loop. These conformations are likely important 
factors for RNA-dependent RNA synthesis and for interaction with cellular proteins, 
such as pRb.  
RdRp conformation and RNA synthesis. The conformation of the HCV RdRp has been 
claimed to distinguish the modes of RNA synthesis (64). We note that the open and 
closed structures observed in the monomers could participate in extension from a primed 
template (which requires lower concentrations of RdRp) but the formation of oligomeric 
structures may be needed to direct de novo initiation. This complex scenario is 
necessitated by our results demonstrating that higher concentrations of the HCV RdRp is 
more competent for de novo initiation, suggesting that monomers may not be sufficient 
for the initiation of RNA synthesis.  In addition, the requirements of an oligomeric HCV 
RdRp complex for the initiation of RNA synthesis have been previously proposed for 
RNA synthesis by the HCV and Poliovirus RdRps (74-76, 206, 222-223, 229). For the 
poliovirus RdRp, contact between the oligomerized polymerase subunits has been 
reported to increase the cooperativity in RNA synthesis (223). Similar results have been 
observed for the Norovirus RdRp (206). The contacts between poliovirus 3D polymerase 
monomers and the poliovirus 3C protease have also been proposed to regulate RNA 
synthesis by regulating protein-priming (224). We propose that the opening of the 
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monomers could be a key state to allow the interaction between HCV RdRp subunits, or 
between the RdRp and cellular proteins, such as pRb which interacts with the exposed 
palm domain of the HCV RdRp (22).  
RdRp conformation and NNI interaction. The open and closed conformations of the 
HCV RdRp will have important implications for the design and efficacy of HCV-
specific NS5B inhibitors. There are three distinct sites for the binding of nonnucleoside 
analog inhibitors (NNI) (Fig. 11, Chapter II). Site 1 involves the ∆1 loop and thumb 
domain interface. Site 2 is a pocket in the thumb domain that is present near Site 1. Site 
3 lies within the template channel and involves the ‘primer-grip site’.  The binding of 
benzimidazole/indoles to Site 1 will affect the interaction between the ∆1 loop and the 
rest of the polymerase (62, 124). The binding of these compounds have led to results 
consistent with the mutational analyses of the HCV RdRp (126); the inhibitors did not 
affect the ability of the HCV RdRp in elongation, but prevented initiation, consistent 
with a closed structure (or one that requires ∆1 loop-thumb interactions between two or 
more RdRp subunits) needed for initiation complex assembly (125).  
          Site 2 binds compounds based on the thiophene scaffold and acts at the base of the 
thumb some distance from the ∆1 loop. The binding of the compounds to the 1b RdRp 
(to residues L419, M423, L474, and W528) did not reveal a dramatic change in RdRp 
conformation (61). However, binding to the 2a RdRp did cause a reconfiguration to the 
tip of the ∆1 loop structure (60), confirming that the 1b and 2a RdRps will have distinct 
interactions that could influence RNA synthesis and binding to inhibitors.   
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          The compounds that bind to Site 3, including those from the benzothiadiazine 
class showed differences in response by the different HCV genotypes (137). We 
speculate that the propensity to form an open RdRp conformation and the strength of the 
interactions between the ∆1 loop, the thumb domain and the ∆2 loop could facilitate the 
entry of the inhibitors. Furthermore, the mutation of one or two key residues in or around 
the ∆1-loop results in polymerases severely affected for de novo initiation but not primer 
extension activity of ∆21 (Chapter IV, Results: E18R and PV mutants for example). 
Since most of the NNI target the initiation stage, the efficiency with which they can act 
on a given virus population may be compromised due to mutations in the key interacting 
residues in the ∆1-loop and thumb regions. How does the virus benefit by having these 
mutations when they fail in de novo initiation is a natural question that arises. 
Interestingly, mutant proteins that cannot themselves de novo initiate can interact with 
and increase de novo initiation from WT ∆21 (Chapter IV, Results).  
          The existing results show that the dynamic conformations of the HCV RdRp could 
pose an important regulatory step in RNA synthesis and, more importantly, can 
potentially be exploited by designing NNI that target the HCV polymerase. In addition, a 
number of predicted interactions, such as ones between the ∆1 loop and the ∆2 loop 
should be examined in detail for effects on RNA synthesis.  
 
 
 
 
 
 
 
 
 
 
149 
CHAPTER VI 
 
PERSPECTIVES AND CONCLUSIONS  
 
 
          In contrast to the host DNA-dependent RNA polymerases that are mostly primer-
dependent enzymes, HCV NS5B initiates RNA synthesis by a de novo mechanism and 
also participates in elongation. Despite the availability of numerous crystal structures 
and several studies involving MOA of inhibitors for the NS5B, a clear model for 
assembly of the initiation complexes has not emerged. Before the present study was 
initiated, it was believed that the closed conformation of NS5B mediated by the finger-
loop interactions (involving mainly the ∆1 loop) is absolutely required for the catalytic 
activity of the enzyme. In the report by Labonte et al., mutations that disrupted the ∆1 
loop and thumb domain interactions and therefore perturbed the closed conformation of 
NS5B, were detrimental for RdRp activity (69). However, there are sequential steps 
involved in RNA synthesis by RdRps and it was not clear which steps were affected by 
the mutations in the ∆1 loop. For instance, if only the assembly of initiation complex 
was adversely affected, all the other steps in the sequence will be affected.  The result 
will be a negative effect on RNA synthesis. Moreover, several inhibitor studies that 
involved benzimidazole/indole scaffolds (which disrupt the ∆1 loop and thumb domain 
interactions) showed that the elongating polymerase was not affected by these inhibitors 
even though they were able to block the initiation events (62, 124-127, 187). This 
suggested that either the ∆1 loop binds to an alternate site elsewhere in the enzyme 
during elongation, or that the closed conformation of the enzyme was no longer retained 
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in the elongation phase of RNA synthesis. Experiments that can differentiate the two 
possibilities were needed to understand this critical piece in the overall mechanism of 
RNA synthesis by RdRps. Importantly, the ∆1 loop like structures are present in RdRps 
from other viruses like West Nile virus, Dengue virus, and poliovirus (Fig. 21, Chapter 
III) suggesting that the mechanism of RNA synthesis may be similar in these viruses too. 
          The requirement of oligomerization in the functioning of RdRps has also been 
unclear as conflicting reports are presented in the literature. For the poliovirus RdRp, 
several reports from the Kirkegaard laboratory (222-223, 229) showed that 
oligomerization is an essential requirement for polymerase function both in vitro and in 
virus infected cells. Pathak et al., (2002) however (224) concluded that the interactions 
of the polymerase with other replicase components were required only for the initiation 
of RNA synthesis by a protein-primed mechanism whereas a monomeric RdRp was 
capable of elongating the 3’ end of a primer. In a similar case, the requirement of HCV 
NS5B oligomerization in RNA synthesis is not clear. Reports from several sources (73-
76), using physical and biochemical methods have shown that HCV NS5B forms 
oligomeric structures and that oligomerization stimulates RNA synthesis. Ma et al., 
(2004) (216) further demonstrated that the residues critical for homomeric interactions 
within NS5B subunits are also required for HCV subgenomic replication. However 
Cramer et al., (2006) (211) showed that NS5B is indeed an oligomer in solution, but did 
not observe an oligomerization-dependent  effect on RNA synthesis. The reason for this 
discrepancy is unclear, but it is likely that the primer-extension templates used in the 
study may have precluded the authors from observing an effect of NS5B oligomerization 
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that is more pronounced on de novo initiation templates as reported in this dissertation 
project. 
           Oligomerization is also a feature of HCV NS3 protein (233). The role of 
oligomerization in NS3 is likely to increase the processivity of the enzyme (233-234). 
Helicases have to work with two strands of nucleic acids of opposite polarity, during 
unwinding. It can be conceived that two subunits can bind to each strand of the RNA and 
unwind cooperatively. From this perspective, an oligomeric helicase must be more active 
than a monomeric helicase (235). In the RdRps however, it is unlikely that more than 
one active site participates in the nucleotidyl transfer; all known DNA and RNA 
polymerases employ a single active site during the catalytic cycle (59, 68).  
          In this context the results presented in this dissertation contribute to the 
mechanism of RNA synthesis by the HCV RdRp by showing that the closed 
conformation of the enzyme is required for de novo initiation RNA synthesis. This 
conclusion is based on the results from several mutations that interfered with the ∆1 loop 
and thumb domain contacts, like W397A, H428A, PV and the deletion mutation m26-30 
(which has five residues in helix A deleted, see Chapters III and IV). These mutants 
were severely debilitated for de novo initiation RNA synthesis while remaining 
competent for primer extension activity from short RNA templates. This suggests that 
the closed conformation stabilizes the initiation complex while the open conformation is 
more suitable for elongation. This finding can also be interpreted to be that the 
interaction between the ∆1 loop and the thumb domain may not be stable and that 
additional factors may play a role in stabilizing this interaction during de novo initiation. 
 
 
 
152 
The results presented in Chapter IV show that oligomeric contacts beween RdRp 
subunits further contribute to de novo initiation, likely by stabilizing the ∆1 loop and 
thumb domain interactions. The HCV RdRp likely depends on both intramolecular and 
intermolecular interactions to stabilize the de novo initiation competent conformation. 
          In summary the work presented in this dissertation project identified different 
states of the HCV RdRp involved in different stages of RNA synthesis (Fig. 43). The 
RdRp exists in at least two conformational states: open and closed as determined by 
whether the ∆1 loop interacts with the thumb domain. The closed conformation is most 
likely the same conformation reported in X-ray diffraction crystal structures for NS5B 
(Fig. 4, Chapter I) with hydrophobic interactions holding the ∆1 loop in its binding 
pocket in the thumb domain, whereas the structural details for the open conformation 
remains to be determined. Since it was observed that the protein stability is affected by 
disrupting the ∆1 loop and thumb domain contacts (Chapter IV, Results, Fig. 29 and 31) 
a dsRNA ligand may be needed to stabilize the open conformation of the protein to make 
it suitable for crystallization. In that sense, an open conformation may actually be more 
suitable to capture the ternary complex of the elongating RdRp.  
        The number of subunits that make up the RdRp oligomer could not be determined 
in this work. There was evidence for NS5B to be present as sizes corresponding to 
dimers as well as higher order oligomers of ~20 nm in average diameter in negatively 
stained samples from EM experiments. This is partly in agreement with the report by 
Wang et al., in which the HCV RdRp was crystallized as an oligomer with two broad 
interacting interfaces (76) (Fig. 43B, Model II). 
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Figure 43: Summary of the major findings in this project. A) HCV NS5B exists in two 
conformational states: closed and open. The conformational states are guided by the 
oligomeric state of the protein which will in turn decide its functional state. At lower 
protein concentrations that favor a monomeric state of the polymerase the enzyme tends 
to be in the open conformation as evidenced by more primer extension and less de novo 
initiation at these concentrations (Chapter IV, Results). B) The two models for de novo 
initiated RNA synthesis by HCV NS5B: the monomer model and the oligomer model. 
The results from this work favor the oligomer model for de novo initiation. It was not 
clear if NS5B was a dimer (I) or a higher order oligomer (II) (six individual monomers 
making contacts with each other are shown). Model II is derived from the oligomeric 
crystal structure of HCV NS5B reported by Wang et al. (76). T, P and F refer to the three 
domains in NS5B and the thick line (black or blue) represents the ∆1 loop. 
De novo initiation Elongation
Closed                                          Open
T
F
P
T
F
P
T F
P
T F
P
T F
P
NS5B Monomer
NS5B Oligomer
I II
B
Primer extension/
ElongationOpen
De novo initiation/
Productive RNA bindingClosedOligomer
Oligomeric state Conformational state
Monomer
Functional state
NS5B
A
 
 
 
154 
On the other hand, Qin et al., saw evidence for an NS5B dimer in glycerol gradient 
fractionation (75) and identified E18 and H502 as the interacting pair in the dimer.  
Consistently, E18R mutation prevented optimal de novo initiation from NS5B (Chapter 
IV, Results) and therefore E18 may be important to maintain the closed conformation of 
NS5B in an oligomeric complex. The ∆1 loop and its interaction with the thumb domain 
could be interacting as part of an interface between two RdRp subunits (Fig. 44A).  This 
would help to explain how mutations in the ∆1 loop, such as m26-30, and even the PV 
mutants were either incapable of, or exhibit only a linear increase in de novo initiation 
activity with increasing enzyme concentrations (Chapter IV, Results). In the study by 
Wang et al., a Hill coefficient of 2.2 was determined for the cooperativity in NS5B 
during RNA synthesis suggesting 2-3 interacting surfaces between monomers which was 
confirmed by crystallization (76). An interesting experiment would be to do a mutational 
analysis of the “basic-patch” on the thumb domain (Fig. 15, Chapter II) near the ∆1 loop 
interaction pocket and analyze the effects on primer extension and de novo initiation. If 
this region is an oligomeric interface as predicted previously (38) it can be identified by 
the RNA synthesis assays and the blue-native PAGE assays described in Chapter IV (Fig. 
27 and Fig. 29). 
           However, another consideration that is likely to be important in determining the 
oligomeric state of NS5B in vivo is how the trans-membrane domain (TMD) at the C-  
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Figure 44: Model showing the interacting surfaces in a putative HCV NS5B dimer. A) 
The closed conformation structure of HCV NS5B monomer (PDB ID 1QUV) was used 
to construct the dimer model (The ribbon structures of the monomers are shown as white 
or grey). A manual docking of two monomers is done without any constraints to get the 
two residues E18 and H502 reported by Qin et al., (75) to be involved in a dimeric pair, 
into close proximity. The thumb domains of each monomer dock into each other with 
minimal steric clashes except at the region involving the apex of the ∆1 loop (shown as 
residues 26-30 in gold). Interestingly a patch of positively charged residues (colored 
cyan) line up along the junction between the thumb domains of each monomer and could 
potentially help to stabilize the RNA that feeds into the template channel leading into the 
active site (GDD residues colored yellow). B) The dimer model shown on the surface of 
a membrane structure. The membrane is shown as two orange horizontal lines connected 
by a set of black vertical lines. The C-terminal tail of NS5B which is the trans-
membrane domain (TMD) is shown as a thick black line emerging out of the active site 
and inserting into the membrane. 
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terminus of the polymerase is arranged within the membrane (Fig. 44B). The C-terminal 
21 amino acids in NS5B are required for viral replication but interestingly can be  
partially or completely replaced by a hydrophobic sequence from the polioviral protein 
3A (236). Polioviral 3A protein as its precursor 3AB binds to the polioviral RdRp, 3D 
pol and anchors it to the membranes. This will suggest that specific interactions between 
the TMD of HCV NS5B and other membrane components may not be important in 
forming the membrane associated HCV replication complex (236). NS5B TMD may be 
responsible only to physically anchor the polymerase on the membranes as no adaptive 
mutations were observed during serial passages of the chimeric HCV subgenomic 
replicons which had the NS5B TMD replaced by the polioviral 3A TMD (236). 
           Since homomeric interactions between viral protein TMDs are common (237) it is 
likely that TMDs of different subunits of NS5B interact with each other and define the 
arrangement of the subunits on the cytosolic side of the protein. In this context it would 
help the oligomerization process if there are more interacting surfaces between the 
subunits. It will be a challenge to determine the arrangement of the NS5B oligomers in 
HCV replication complexes on membranes. In any model, it will be important to take 
into account how the presence of other components of the HCV replicase affects NS5B 
oligomerization. 
            Host Cyclophilins may have key roles in ‘remodeling’ these oligomeric RdRps 
by way of their peptidyl-prolyl isomerase activity (142, 238). The cellular kinases (PRK-
2) phosphorylates NS5B and may affect initiation complex formation (239).  It will be 
interesting to dissect the mechanism by which cyclophilins and PRK-2 kinase affect the 
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function of HCV RdRp. Experiments are underway in the Kao laboratory to understand 
how PRK-2 phosphorylation of NS5B affects its function. Preliminary experiments have 
shown that the mutant polymerases characterized in Chapter III viz. W397A, H428A and 
m26-30 which were all defective for de novo initiation but not primer extension showed 
increased levels of phosphorylation by PRK-2 (data not shown). Phosphorylation is also 
a feature in another replicase protein NS5A, and in preliminary experiments it was seen 
that NS5A inhibits NS5B activity in vitro (not shown). How this inhibition is related to 
the phosphorylation of both proteins is an interesting future area of research. Since 
NS5A also can oligomerize, phosphate groups in both the nonstructural proteins may 
have roles in “remodeling” these oligomeric structures.  Cyclophilins may alter the 
dimensions of the template channel in highly oligomeric RdRp and thereby increase 
RNA binding. In line with this a recent report showed that a baculovirus expressed 
cyclophilin was able to increase RNA synthesis from recombinant HCV RdRp (240). 
Roles for host proteins in HCV RNA synthesis are increasingly being appreciated (141, 
144, 172, 239).  Whole proteome approaches are needed to identify other host proteins 
that associate with HCV RdRp and facilitate NS5B activity.  The information gained 
will surely help to identify additional targets that will lead to new therapies to treat 
hepatitis C. 
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SCREENING OF A NUCLEOSIDE/NUCLEOTIDE MIMIC COMPOUND 
 
 COLLECTION FOR BINDING AND INHIBITION OF NS5B 
 
                
 
          The differential scanning fluorimetry (DSF) assay described in Chapters IV and V 
can be used to determine ligand binding to proteins as shown in those chapters and also 
as reported by Niesen et al. (212) . In order to obtain inhibitors against NS5B we 
purchased a nucleoside/nucleotide compound library from SIGMA (Sigma-Aldrich Inc.). 
A total of ~125 compounds were purchased that were available directly from stocks or 
custom synthesized. Before screening this collection we wanted to determine whether 
the DSF assay can be used to determine NS5B interactions with its ligands/inhibitors 
other than NTPs. The benzothiadiazine compounds described in Dhanak et al., (2002) 
(132) were obtained from GlaxoSmithKline. The two compounds are potent inhibitors of 
in vitro NS5B activity (132). The compounds named as C1 and C2 were included with a 
poly-U column purified ∆21 at different concentrations and subjected to DSF assay (Fig. 
B1A and B1B). As expected the presence of the compounds showed pronounced 
increase in the stability of ∆21 showing compound binding and conformational changes 
in the protein. This further confirmed that the DSF assay can be used to determine the 
ligand-protein interactions. Next we subjected about 45 compounds from the SIGMA 
collection to the DSF assay (Table B1). The remaining compounds had solubility 
problems and had to be dissolved in very harsh acidic or basic solutions and therefore 
were not further analyzed.  
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Figure B1: DSF assay of GSK compounds C1 and C2 with poly-U purified ∆21. 
While ∆21 alone has a Tm of 42.08 oC the presence of the compounds at different 
concentrations showed pronounced right shifts in the Tm as indicated. 
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     Table B1: The compounds that were selected for screening by DSF assay 
   
     
7-Methylguanosine                                    A1        
5-Fluorouridine                                          A2 
8-METHYLXANTHINE                           A3 
4-Thiouridine                                             A4 
Thymidine                                                  B3                 
Xanthine sodium salt                                 B4                 
Adenine 9-beta-D-arabinofuranoside        B5 
5-Methylcytosine hydrochloride               C10 
Uridine                                                       B8 
2-Aminopurine nitrate salt                         B11 
2'-Deoxyuridine                                         C8 
Inosine                                                        B7 
2'-Deoxycytidine                                        D6 
1,3,9-Trimethylxanthine                            D11 
6-Methylpurine                                           E9 
2',3'-Dideoxyadenosine                              G2 
2-Amino-6-chloropurine riboside              G7 
6-(Dimethylamino)purine                          G10 
(+/-)-PD 128,907 hydrochloride                C3 
5-Methoxyuridine                                       A5 
S-(2-HYDROXY-5-NITROBENZYL) 
-6-THIOINOSINE                                     A6 
Isoxanthopterin                                          A7                                           
5-Fluoro-2'-deoxyuridine                           A8 
3-Methyladenine                                        A10 
6-AMINO-1,3-DIMETHYL 
-5-NITROSOURACIL                              B2 
6-ETHOXYPURINE                                 B10 
N6-Benzoyladenine                                   C4 
6-Chloropurine riboside                            C7 
1-Methyladenosine                                    C11 
2'-Deoxyinosine                                         D1 
5-Ethyl-2'-deoxyuridine                             D2 
1,N6-Etheno-2'-deoxyadenosine                D3 
TEGAFUR                                                 D4 
5'-Deoxy-5'-(methylthio)adenosine            D5 
1-Methylthymine                                        D10 
6-Azauridine                                               E1 
5-Carbethoxyuracil                                     E3 
Indoxyl acetate                                            E5 
2',3'-O-Isopropylideneuridine                     E7 
5-Iodo-2'-deoxycytidine                              E8 
6-Methylpurine                                           E9 
IBU-DEOXYCYTIDINE                           F1 
 
 
 
Compound                                  code 
                                                   
(Structures of some of the 
compounds that affected the Tm of 
NS5B in DSF assay) (Code in 
parenthesis) 
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The majority of the tested compounds did not affect the Tm of ∆21 (not shown) while 
compounds B11, C3 and C10 showed a destabilizing effect on ∆21 when included at 10 
mM concentrations (Fig. B2). Intrigued by this result B11, C3 and C10 along with some 
other compounds were tested for effect on the RdRp activity of ∆21. However none of 
the compounds significantly affected RNA synthesis by ∆21 at three different 
concentrations tested (Fig. B3). To understand this better the DSF assay was done for 
∆21 and compound B11 in presence and absence of GTP (Fig. B4). The presence of 
GTP masked the effect of B11 on the stability of ∆21 explaining partially the results of 
the RdRp assay. A few more compounds out of the ones listed in Table B1 showed a 
negative shift in Tm of ∆21 (Fig. B4) or a partial denaturation of ∆21 but none of them 
showed a positive shift in Tm like the C1 and C2 compounds from the GlaxoSmithKline 
collection (133) (Fig. B1). RdRp assays have not yet been performed with ∆21 in 
presence of the compounds shown in Fig. B4. 
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Figure B2: The results of DSF assay of 2 µM ∆21 in absence or presence of 10 mM 
B11, C3 and C10.  
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                A 
 
 
 
 
                B 
 
 
 
 
 
 
 
 
Figure B3: A) RdRp assays of ∆21 in presence of 10, 50 and 100 µM of the compounds 
shown on the top of the gel. Template LE19 and standard RdRp assay conditions (see 
Chapter 3, Materials and Methods) were used. 19-nt is the de novo product and 32-nt is 
the primer extension product. B) DSF assay shows that the effect of compound B11 on 
the stability of ∆21 is masked in presence of GTP. 
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Figure B4: results of DSF assays of ∆21 in absence and presence of 10 mM of each of 
the compound specified. The Tms are indicated in parenthesis. The conditions of the 
assay are described in Chapter 4, Materials and Methods. 
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